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Abstract  
Background: Cannabis is the most commonly used illicit drug in the United 
Kingdom and worldwide. It is associated with a number of negative outcomes, which 
includes developing Cannabis Use Disorder (CUD).  Individuals who meet criteria for 
CUD are at heightened risk for experiencing Major Depressive Disorder (MDD), the 
leading cause of disability worldwide. While this association has frequently been 
reported, the underlying mechanisms remain controversial.  
Aims of thesis: This thesis aims to investigate the degree of co-morbidity between 
lifetime rates of CUD and MDD, test whether this co-morbidity is accounted for by 
shared covariates, and test different twin models to investigate the sources 
(environmental or genetic) of and mechanisms underlying this co-morbidity. 
Methods: Data analysis was conducted on a sample of 3824 Australian twins and 
their non-twin siblings. Epidemiological analyses, using multivariable logistic 
regressions, tested whether CUD and MDD were significantly co-morbid in this 
sample, and to what extent covariates influenced this relationship. Twin models – 
bivariate correlated liabilities, discordant twin and co-morbidity models – examined 
whether the co-morbidity between the disorders could be explained by a) shared 
genetic and environmental factors, b) causal processes, and c) 13 different models 
of co-morbidity.  
Results:  The epidemiological analyses found that MDD and CUD were significantly 
co-morbid in this sample: meeting diagnostic criteria for one disorder more than 
doubled the odds of meeting criteria for the other (odds ratio = 2.23, 95% confidence 
interval = 1.84–2.70). This co-morbidity could not be fully attributed to various 
psychiatric, trauma-related, parental, peer and demographic covariates. Bivariate 
twin analyses found that – when separated into genetic and environmental 
correlations – the only significant correlation between MDD and CUD was genetic (r 
=.41, 95% confidence interval = .24–.60). A possible causal relationship could not be 
excluded, because MDD and CUD were significantly associated (odds ratio = 2.83, 
95% confidence interval = 1.12–7.19) in monozygotic twins discordant for both 
disorders. Co-morbidity model analyses indicated that the direction of influence was 
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from CUD to MDD, and that CUD risk factors may cause MDD symptoms, 
particularly in individuals at high risk of CUD.  
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1.1 Psychiatric co-morbidity: Cannabis Use Disorder and Major 
Depressive Disorder 
The main diagnostic frameworks for mental health problems place disorders into 
clearly separated categories. This principle applies to both the International 
Classification of Diseases (ICD; World Health Organization, 1992) and the 
Diagnostic and Statistical Manual of Mental Disorders (DSM; American Psychiatric 
Association, 2013). Nevertheless, the co-morbidity – or co-occurrence of two or more 
psychiatric disorders within one individual – is highly frequent (Boyd et al., 1984; 
Kessler et al., 1994). The term ‘co-morbidity’ was initially introduced in a paper by 
Feinstein (1970). The definition includes disorders which occur at the same time and 
those which occur at different times throughout an individual’s life. Feinstein (1970) 
recognised the importance of increased awareness of co-occurring conditions in 
clinical practice because individuals with co-occurring disorders differ from 
individuals with single disorders in multiple ways.  
Psychiatric co-morbidity is associated with various negative life outcomes (Compton, 
Thomas, Stinson, & Grant, 2007; Swendsen & Merikangas, 2000). The co-morbidity 
of substance use problems and other mental health disorders has received particular 
attention because it is highly prevalent, and co-morbid individuals exhibit symptoms 
which are often more severe, persistent and difficult to treat (Kessler, 2004; 
Swendsen et al., 2010; Torrens, Mestre-Pintó, & Domingo-Salvany, 2015). 
According to a recent report by the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), individuals with a substance abuse problem co-morbid with an 
additional mental health disorder are at higher risk of suicide, are more likely to be 
unemployed or homeless, engage in behaviours which endanger their personal 
safety, and are more likely to be admitted to a hospital for emergencies (Torrens et 
al., 2015). Co-morbid individuals are also more likely to engage in violent or criminal 
behaviour, when compared to individuals with a single disorder (Torrens et al., 
2015). Aside from the burden on the individual, societal costs related to mental 
health conditions co-morbid with substance use disorders are substantial (see 
Whiteford et al., 2013). 
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Unsurprisingly, identifying the factors which underlie co-morbidity is part of the 
‘Mental Health Research Priorities for Europe’ established in 2015 (Wykes et al., 
2015). This is one of the areas of mental health in which research investment is likely 
to lead to high returns. In 2010, mental disorders were conservatively estimated to 
cost €461 billion a year in Europe alone. However, research investment is 
comparatively low, despite the fact that it has the potential to substantially reduce 
this cost. In the UK, mental health problems were estimated to account for 22.8% of 
the disease burden, 7% more than cancer. However, cancer research receives 4.5 
times more funding. The report concluded that substantially more mental health 
research and research funding should be allocated to the areas of priority they 
identified, co-morbidity being one of them.  
For the abovementioned reasons, various co-morbid mental health disorders warrant 
further research, but the subject of this thesis is the specific relationship between 
Major Depressive Disorder (MDD) and Cannabis Use Disorder (CUD), because 
these disorders co-occur at a rate greater than chance (Degenhardt, Hall, Lynskey, 
Cofey, & Patton, 2012), are both relevant from a public health perspective (Torrens 
et al., 2015), and the mechanisms driving their co-morbidity have not been 
sufficiently explored.  
1.1.1 Major Depressive Disorder 
MDD is characterised by several emotional, cognitive and physiological symptoms, 
including depressed mood and/or the loss of pleasure or interest (American 
Psychiatric Association, 2013). Further symptoms include sleep disturbances, loss of 
energy, feelings of worthlessness or guilt, concentration problems, weight loss or 
gain, psychomotor agitation and suicidal thoughts. According to the DSM-5, five of 
these symptoms lasting for longer than two weeks – and including depressed mood 
and loss of pleasure – would qualify for a diagnosis of MDD (American Psychiatric 
Association, 2013).  
MDD is a highly prevalent and debilitating condition for the individual. Lifetime 
prevalence estimates lie between 6.6% (Japan) and 21.0% (France; Kessler & 
Bromet, 2013). According to the latest Global Burden of Disease study in 2013, MDD 
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was the second leading cause of disability in the world (Ferrari et al., 2013), and the 
World Health Organisation is now citing it as the leading one (WHO, 2017). The 
disorder is associated with a variety of adverse consequences for the individual, 
among which are marital dissatisfaction, financial and educational difficulties 
(Kessler & Bromet, 2013), as well as impairments in cognitive functioning (Snyder, 
2013).  
The disorder is estimated to be a substantial economic burden on society 
(Greenberg, Fournier, Sisitsky, Pike, & Kessler, 2015). Among mental health 
conditions, the financial burden of mood disorders (including MDD) is highest, 
costing European countries €113.4 billion and making up almost a quarter of the 
costs of mental health conditions (Olesen, Gustavsson, Svensson, Wittchen, & 
Jönsson, 2012). 
1.1.2 Cannabis use and Cannabis Use Disorder 
Cannabis is the most commonly used illicit drug (Agrawal & Lynskey, 2014). In a 
survey of 15 to 16 year old American students, cannabis use even exceeded the 
prevalence of tobacco use (EMCDDA, 2017). The most recent EMCDDA drug report 
estimates that 26.3% of 15 to 65 year olds living in the European Union have used 
cannabis in their lifetime, 7% in the past year (EMCDDA, 2017). Clarity about its 
physical and mental health consequences is of particular relevance due to the 
ongoing debate around its legalisation (EMCDDA, 2017). Heavy cannabis use is 
linked to an increased likelihood of road accidents, lower educational attainment, 
financial difficulties, relationship difficulties, physical health complications (e.g. 
respiratory and cardiovascular problems), and various mental health disorders 
(Cerdá et al., 2016; Hall, 2015; Hall & Degenhardt, 2009). In Europe, the number of  
first-time treatment seekers for cannabis problems has almost doubled in the past 
decade (EMCDDA, 2017). 
Some cannabis users will develop clinical levels of drug taking and drug seeking 
behaviour. In the most recent version of the DSM (DSM-5), clinical levels of cannabis 
involvement are defined as Cannabis Use Disorder, which is diagnosed when at 
least two symptoms of drug abuse, dependence or craving (see Table 1) occur 
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within the same 12-month period (American Psychiatric Association, 2013). In the 
previous version of the DSM (DSM-IV; American Psychiatric Association, 2000), 
cannabis dependence and abuse were diagnosed separately, but involved almost 
identical criteria. The estimated number of individuals who transition from use to use 
disorder, abuse or dependence varies by cohort. A recent analysis of the 2007 
National Survey of Mental Health and Wellbeing in Australia found that 22.8% of 
cannabis users developed abuse, and 9.8% developed dependence symptoms 
(Degenhardt et al., 2018). Worldwide an estimated 13.1 million individuals are 
cannabis dependent, which contributes to approximately 2.1 million years of healthy 
life lost due to disability (Degenhardt, Whiteford, & Hall, 2014).  
Table 1. Symptoms of DSM-IV and DSM-5 definitions of clinical cannabis 
involvement. Adapted from Hasin et al. (2013). 
1.1.3 Co-morbidity between Major Depressive Disorder and Cannabis Use Disorder 
The relationship between MDD and CUD is poorly understood. Cross-sectional 
studies of general and clinical populations consistently show that clinical and sub-
clinical symptoms of CUD and MDD co-occur at a rate greater than chance (see 








Hazardous Use X - X 
Social/interpersonal problems 
related to use X - X 
Neglected major roles to use X - X 
Legal problems X - - 
    
Withdrawal - X X 
Tolerance - X X 
Used larger amounts/longer - X X 
Repeated attempts to 
quit/control use - X X 
Much time spent using - X X 
Physical/psychological 
problems related to use - X X 
Activities given up to use - X X 
    
Craving  - - X 
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public health perspective, because of the aforementioned burden of both disorders 
individually, as well as the added burden of co-morbidity. However, research into 
aetiological mechanisms, including longitudinal and genetic studies, has so far not 
succeeded in clarifying the underlying causes of the relationship between MDD and 
CUD. Developing a greater understanding of it is important to help reduce the 
prevalence of both conditions, and associated risks, through the efficient prevention 
and treatment of co-morbid cases.   
This chapter will provide an overview of existing research into the co-morbidity 
between CUD and MDD, introducing cross-sectional studies demonstrating 
significant co-morbidity, then moving on to outline possible mechanisms of co-
occurrence. It will outline the limitations of the studies conducted so far and explain 
how the current thesis will attempt to address gaps in the literature.  
1.2 Reviewing the literature: Definitions of cannabis involvement 
and depression 
The subject of this thesis is psychiatric co-morbidity, as outlined above, so the 
phenotypes of interest are MDD and CUD. However, limiting the literature review to 
only CUD and MDD would severely restrict the number of informative studies that 
can be reviewed. To encompass the various definitions of related phenotypes, this 
introduction will frequently refer to evidence of the association between ‘cannabis 
involvement’ and ‘depression’, and not limit itself to CUD and MDD only.  
The definitions of cannabis involvement and depression used in the literature are 
heterogeneous, so that non-clinical levels of cannabis use encompasses different 
definitions of frequency (e.g. ‘daily’ vs ‘heavy’) and clinical levels of cannabis 
involvement and depression are often not measured as CUD and MDD. Clinical 
levels of cannabis involvement are most frequently defined as cannabis abuse 
and/or dependence, since CUD was only introduced in the latest version of the DSM 
(American Psychiatric Association, 2013). Abuse and dependence criteria are still 
core components of a CUD diagnosis and therefore remain relevant. Studies 
examining clinical levels of depression may include dysthymia or bipolar disorders 
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alongside MDD as a ‘mood disorder’ category, use a subset of MDD symptoms, and 
measure depression using different instruments.  
Overall, studies which have not specifically examined CUD and MDD, but have 
looked at related phenotypes (e.g. frequent cannabis use or dysthymia) can still 
provide information on the likely co-morbidity between CUD and MDD, because they 
are thought to be sufficiently related to the definitions used in this thesis. To capture 
all relevant evidence, a comprehensive literature review on the relationship between 
depression and cannabis involvement was conducted in PubMed, which included the 
following search terms: ‘cannabis’, ‘marijuana’, ‘marihuana’, ‘tetrahydrocan*’, ‘CBD’, 
‘THC’ or ‘cannabinoid*’, and the words ‘MDD’, ‘major depress*’, ‘depress*’, 
‘anhedoni*’, ‘dysthymi*’, ‘low mood*’ or ‘mood disorder*’. Since informing on the 
mechanisms of co-occurrence rests on an exploration of causality, the target of this 
review were primarily twin and longitudinal studies, so the search also included the 
terms ‘longitudinal’ or ‘twin’.  
Because there were few twin studies, and a recent meta-analysis (Lev-Ran et al., 
2014) had been published on the longitudinal relationship between cannabis 
involvement and depression at the time of the first literature search in 2014, a 
systematic literature review has not been conducted. However, the same search 
terms have been used to update the literature throughout the course of this thesis 
(between 2014 and 2018).  
Therefore the following discussion of cross-sectional studies on the extent of the co-
morbidity between MDD and CUD is followed by a discussion of possible 
mechanisms of co-occurrence, which contains a comprehensive and current account 
of twin and longitudinal studies on the causal relationship between cannabis 
involvement and depression.  
1.3 Significant co-morbidity? Evidence from cross-sectional 
studies 
As mentioned above, the co-morbidity between cannabis involvement and 
depression has been consistently observed (see Degenhardt et al. 2012 for a 
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review). For instance, an epidemiological study of 43,093 US citizens showed that 
individuals with mood disorders (MDD, dysthymia, mania, hypomania) had 3.9 (95% 
CI = 2.8 – 5.3) times higher odds of meeting the criteria for lifetime cannabis abuse 
or dependence than individuals without mood disorders (Martins & Gorelick, 2011). 
An epidemiological survey of 25,113 Canadian citizens reported that rates of past-
year cannabis dependence among individuals who met past-year MDD criteria were 
over 7.25 times higher than those of individuals who did not (Patten et al., 2015). 
Rates of past-year cannabis abuse were almost 3.6 times higher (Patten et al., 
2015). Similar results have been found in clinical samples. For example, a recent 
study based on the Norwegian patient registry including 2,659,966 individuals 
reported that levels of ICD-10 depressive illness were almost 3.9 times higher 
among individuals with CUD (12.85%), compared to the general population (3.3%, 
Nesvåg et al. 2015).  
These cross-sectional studies, in conjunction with several others (C.-Y. Chen, 
Wagner, & Anthony, 2002; Cougle, Hakes, Macatee, Chavarria, & Zvolensky, 2015; 
R. R. S. Mathews, Hall, & Gartner, 2011) present convincing evidence that clinical 
levels of depression and cannabis involvement co-occur significantly more frequently 
than expected by chance, which raises questions about the possible mechanisms 
that may underlie this association.  
1.4 Mechanisms underlying co-morbidity 
There are multiple mechanisms which could explain the observed co-morbidity. 
Firstly, some co-morbidity in a sample is expected due to chance: it is the product of 
the prevalence of each disorder separately. Secondly, sampling bias is likely to lead 
to inflated estimates of co-morbidity in clinical samples. Co-morbid individuals are 
likely to have more severe symptoms than individuals with pure disorders and would 
therefore be more likely to enter a clinic (Berkson, 1946). Additionally, clinics in 
which practitioners have a special interest in particular disorders may have an 
increased rate of referrals for clusters of these disorders (Caron & Rutter, 1991). 
Further processes by which such ‘artefactual co-morbidity’ may occur are reviewed 
in Caron and Rutter (1991). Overall, the highest likelihood of observing true co-
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morbidity is in general population samples, which is what most evidence reviewed 
here focuses on. 
Most research on the mechanisms underlying true co-morbidity has examined 
overlapping risk factors and causal processes. Research into overlapping risk factors 
aims to find the source (i.e. biological versus environmental), of the overlap between 
risk factors influencing two disorders (e.g. MDD and CUD). Studies often remain 
agnostic about the process by which this source gives rise to co-morbidity. One 
possibility is that overlapping risk factors simultaneously increase the likelihood of 
developing both disorders. However, these risk factors may also be involved in other 
processes, including, but not limited to, causality. As an example, the 
endocannabinoid system is both involved in mood regulation and is the primary site 
of action for cannabinoids (see Section 1.4.1.1). Any malfunctioning of the 
endocannabinoid system, perhaps due to genetic factors, may increase the risk of 
CUD and MDD simultaneously. However, the endocannabinoid system may also 
provide a plausible site through which mood problems affect cravings for 
cannabinoids, or cannabis consumption alters mood (i.e. causality). Still, causality is 
not the only mechanism via which co-morbidity can arise and there are several 
different categories of causal processes (Caron & Rutter, 1991; Klein & Riso, 1993; 
Neale & Kendler, 1995). An overview of these alternative mechanisms can be found 
in Sections 1.4.3 (Chapter 1), 3.8.2 (Chapter 3) and Chapter 6.  
The following sections will outline potential overlapping risk factors, summarise 
research into causal mechanisms and give an overview of other potential 
explanations of co-morbidity.  
1.4.1 Overlapping risk factors 
Overlapping risk factors may be biological or environmental, and individuals who are 
exposed to or inherit these risk factors may simultaneously be at increased risk for 
MDD and CUD. Alternatively, overlapping risk factors may be a site of action for 
causal or other non-causal aetiological processes.  
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1.4.1.1 Biological overlap between CUD and MDD - the endocannabinoid system  
Research from various fields suggests that the main site of biological – and 
potentially genetic – overlap between cannabis-related problems and symptoms of 
depression is likely to be the endocannabinoid system. It is the primary site of action 
for cannabis and contains two types of G protein-coupled receptors: CB1 and CB2 
(Mechoulam & Parker, 2013). These receptors are activated by cannabinoids 
endogenous to the human organism, mainly anandamide and 2-arachidonoyl 
glycerol (2-AG), as well as synthetic and plant-derived cannabinoids. Delta-9-
tetrahydrocannabinol (THC), the principal psychoactive component of cannabis 
binds to both endocannabinoid receptors. In the central nervous system, 
endocannabinoids act on CB1 receptors to modulate the release of various 
neurotransmitters and other neuromodulators (Gorzalka, Hill, & Hillard, 2008). The 
binding of THC to CB1 receptors is thought to be responsible for the psychological 
effects of cannabis, but the endocannabinoid system can also be linked to MDD 
(Agrawal et al., 2012; Gorzalka et al., 2008; Hill et al., 2008; Mechoulam & Parker, 
2013). The pathophysiology of MDD seems to involve complex interactions between 
monoamine signalling, neurogenesis, inflammation and the human stress response. 
Endocannabinoids interact with or modulate each of these processes, providing a 
possible biological and genetic link between CUD and MDD. The main site of these 
interactions is likely to involve the hypothalamic–pituitary–adrenal axis and limbic 
brain regions in general, which include, but are not limited to the hippocampus, 
amygdala, and nucleus accumbens (Patel & Hillard, 2009).  
1.4.1.2 Environmental overlap between CUD and MDD 
There are also several plausible environmental factors which could predispose an 
individual to both disorders simultaneously. Individuals with both MDD and cannabis-
related problems are likely to have experienced higher levels of childhood adversity 
(Fergusson & Horwood, 1997; Heim & Nemeroff, 2001; Nanni, Uher, & Danese, 
2012; Nelson et al., 2006), which is likely to occur before the onset of either disorder 
and predispose a person to both. Additionally, cannabis users (Fergusson & 
Horwood, 1997; Georgiades & Boyle, 2007) and individuals showing symptoms of 
MDD (E. Chen & Miller, 2013; Gilman, Kawachi, Fitzmaurice, & Buka, 2002; 
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Sadowski, Ugarte, Kolvin, Kaplan, & Barnes, 1999) are more likely to come from a 
disadvantaged social background. Risk factors associated with both are also likely to 
include problematic peer relationships, educational attainment, traumatic life events, 
and marital status (Degenhardt et al., 2012; Manrique-Garcia, Zammit, Dalman, 
Hemmingsson, & Allebeck, 2012).   
Table 2 summarises the covariates that show a significant association with 
depression, cannabis involvement or both, in studies which examine the relationship 
between the two phenotypes. The summary focuses on longitudinal – rather than 
cross-sectional – studies, since they better differentiate between covariates that are 
likely to precede and those that are likely to follow the onset of depression and 
cannabis involvement. Covariates which precede their onset are of primary interest 
because they may provide insight on mechanisms leading to co-morbidity. 
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Table 2. Covariates of depression, cannabis involvement and both, identified from longitudinal studies.  




As a block1: gender, changes of parents (0–15 
years), childhood sexual abuse, IQ age 8, mood 
disorder age 14 
Not reported 
Family social background (mother aged <25 at birth 
of child, mother had no formal educational 
qualification, family of semi-skilled/unskilled SES), 
family functioning (> 2 changes of parents, parental 
conflict, parental history of offending, parental 
history of alcoholism/alcohol problems, parental 
illicit drug use, exposed to childhood sexual abuse), 
individual factors (conduct problems, self-esteem, 
novelty seeking), parent/peer relationships (parental 
attachment, deviant peers), adjustment prior to age 
16 (anxiety disorder, alcohol abuse, other illicit 
substance use, daily smoking, history of property or 
violent offending) 
Bovasso 
(2001) Not reported None of the measured variables Not reported 
Brook et al. 
(2002) None 
Family income, parental 
education level None 
van Laar et 
al. (2007) 
Age, gender, neurotic personality, parental 




Not reported Not reported 
Age, family SES, single parent home, family 
dysfunction, internalising disorders, externalising 
disorders, grade failure 
Pedersen 
(2008) 
As a block1: age, gender, parental educational level, 
parents unemployed or receiving social welfare 
benefits, parental divorce, parental smoking and 
alcohol problems, parental support and monitoring 
measured, early pubertal maturation, school marks, 
conduct problems and daily smoking, alcohol 
intoxication, alcohol problems, impulsivity 
Father unemployment, parental 
divorce, both parents smoking, 
poor parental support, poor 
parental monitoring, early 
pubertal maturation, low school 
marks, conduct problems, daily 
smoking, alcohol problems, no 
full secondary education, living 
on social security 
None reported 
 
Table continues on next page 
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Study Both Depression Cannabis involvement 
Harder et al. 
(2008) Not reported Not reported 
Gender, race, daily tobacco smoking, alcohol abuse 
or dependence, other illegal drug use, 




Educational/occupational failure (not graduating from 
high school/earning GED by age 20, a period of 
unemployment for at least 6 months when wanting to 
work), crime (trouble with police, aside from traffic 
stops) 
Same as ‘both’ Same as ‘both’ 
Brook et al. 
(2011) Not reported Not reported 
Gender, age, violence towards others, 
psychological symptoms, peer deviance, 
association with drug using peers, skipped work, 
violence towards subject in neighbourhood 
Manrique-
Garcia et al. 
(2012) 
As a block1: prior personality disorders at 
conscription, IQ, disturbed behaviour in childhood, 
social adjustment, risky use of alcohol, smoking, 
early adulthood, socioeconomic position, use of other 
drugs, brought up in a city. 
Personality disorders at 
conscription, IQ, smoking, 
disturbed behaviour in childhood 
Not reported 
Degenhardt 
et al. (2013) 
Age, level of education, nationality, parental smoking 
status, tobacco use, symptoms of anxiety, maximum 
qualification achieved (secondary education, 
vocational qualification, degree), ever had a baby, 
currently partnered/married, receiving government 
welfare, in paid employment. 
Not reported Not reported 
Pacek et al. 
(2013) Not significantly diminished  
Gender, age, marital status, 
ethnicity, years of education, 
other drug use disorders 
Gender, age, marital status, ethnicity, years of 
education, income, family history of depression 
Cerdá et al. 
(2013) Ethnicity, family SES Not reported Not reported 
Haug et al. 
(2014) Not reported Not reported 
Means of subsistence, having siblings, belief in God 
and practicing religion, parental divorce before age 
18, higher parental knowledge of peers and 
whereabouts at age 15, peer pressure, nicotine 
dependence, sensation seeking, anxiety 
    
Table continues on next page 
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Study Both Depression Cannabis involvement 
Silins et al. 
(2014) 
As a block1: all 53 covariates included, see reference 
for details 
Alcohol use, father smoking 
status, anxiety symptoms  
Gender, highest maternal education, other illicit 
drug use before age 17 
Feingold et 
al. (2015) Not significantly diminished  Not reported Gender, household income, marital status, age 
Cougle et al. 
(2015) 
As a block1: age, income, marital status, gender, 
ethnicity, education, and psychiatric co-morbidity 
(anxiety disorder, personality disorder, bipolar 
disorder) 
Not reported Not reported 
Gage et al. 
(2015) Cigarette, alcohol or other illicit drug use  Not reported 
Low maternal education, IQ at age 8, conduct 
disorder, cigarette smoking at age 16, illicit drug 
and alcohol use at age 16 
Blanco et al. 
(2016) Non-significant OR and aOR Not reported 
Childhood (family history of alcohol and illicit drug 
use disorders, disturbed family environment, 
childhood parental loss), early adolescence (low 
self-esteem), early-onset anxiety, social deviance), 
late adolescence (past year trauma, Axis I co-
morbidity, Axis II co-morbidity), adulthood (divorce, 
history of alcohol, drug use disorder or nicotine 
dependence, social deviance), socio-demographics 
(age, gender) 
Danielsson 
et al. (2016) 
Age, sex, family tension, alcohol use, other illicit drug 
use  Not reported 
Sex, age, education, place of upbringing, family 
tension, substance use (alcohol and other illicit 
drugs) 
Note. 1. Further information on these studies, including cohort sizes and types of measures used are presented in Tables 5 and 6 for studies since 2013.   
       Earlier studies are presented comprehensively in Lev-Ran et al. (2014).   
          2. Some longitudinal studies do not report any effects of single covariates and are therefore not listed here. Predictors were included if they were 
reported to a) significantly attenuate the relationship between depression and cannabis involvement after being included, b) have a significant 
association with either cannabis involvement or depression. Also, they were included if there was a non-significant association between depression 
and cannabis involvement when predictors were included immediately (only aOR reported). 
1As a block = it is unclear which specific variable significantly attenuated association, but there was an attenuation after controlling for a group of variables
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1.4.1.3 Testing environmental and biological overlap 
Convincing evidence identifying significant biological and environmental risk factors 
for MDD and CUD comes from cross-sectional and longitudinal studies (see Section 
1.4.2.5) which have controlled for potential covariates and observed a significant 
decrease in the strength of association between CUD and MDD, or related 
phenotypes. In a cross-sectional study, Degenhardt, Hall and Lynskey (2001) found 
that the odds ratios (ORs) between cannabis use, abuse and dependence and 
affective disorders (MDD, dysthymia, bipolar I and bipolar II) all become non-
significant after other drug use (tobacco, alcohol and illicit drugs) had been controlled 
for. In a longitudinal study of 85,088 individuals across 17 countries, De Graaf et al. 
(2010) initially found a significant increase in the risk of developing symptoms of 
MDD after early-onset (before age 17) cannabis use, which became non-significant 
when childhood conduct problems were accounted for. In a longitudinal study 
conducted by Fergusson and Horwood (1997), it was found that childhood sexual 
abuse, gender, changes of parents by the age of 15, IQ and mood disorders at 
baseline significantly affect the association between cannabis use frequency and 
MDD in late adolescence (16 to 18 years). When controlling for these and other 
family and childhood factors, the association between cannabis use frequency and 
MDD became non-significant. A recent longitudinal study by Danielsson, Lundin, 
Agardh, Allebeck and Forsell (2016) confirmed the previously identified importance 
of family problems and other drug use. After controlling for family tensions, illicit drug 
and alcohol use, cannabis use at baseline no longer appeared to be significantly 
associated with MDD at follow-up.  
All of the abovementioned factors seem to overlap between cannabis and 
depression-related phenotypes and have the potential to explain some of the co-
morbidity between CUD and MDD. However, cross-sectional and longitudinal studies 
cannot answer whether their influence could occur via environmental or genetic 
pathways. For instance, other drug dependence is likely to have both environmental 
(e.g. smoking cigarettes) and genetic (e.g. innate predisposition toward nicotine 
dependence) components. Additionally, there may be an interaction between 
environmental and genetic components, since nicotine consumption (environmental) 
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may affect the read-out of certain genes via epigenetic mechanisms (Levine et al., 
2011), which in turn affect the development of CUD and MDD.   
Determining whether the covariance between CUD and MDD is primarily explained 
by genetic or environmental factors would require a genetically informative study 
design, such as twin studies. It is an important empirical question, since knowing the 
aetiological mechanisms of the co-morbidity can guide further research, as well as 
prevention and treatment of co-morbid cases. Should the correlated risk factors be 
primarily genetic, family history methods (Milne et al., 2009) and genetic risk scores 
based on molecular genetic studies might be the best way to screen for at-risk 
individuals for preventive interventions before they develop a co-morbidity. If 
overlapping risk factors were primarily environmental, financial resources should be 
allocated toward environmental interventions. Additionally, screening for at-risk 
individuals for potential preventative measures should be primarily conducted in 
high-risk environments.  
1.4.1.4 Twin studies as an avenue to test for genetic versus environmental 
overlapping risk factors for CUD and MDD 
Twin studies are one of the most frequently used methods to decompose individual 
differences – or the variance – within a trait into genetic and environmental 
contributions. In contrast to a population of unrelated individuals, twin data contain 
genetic information: MZ twins share 100% of their DNA, while DZ twins share around 
50% of their segregating genes. Segregating genes are those which contribute to 
individual differences in the population. As there are several reasons to assume that 
environmental influences do not significantly differ for either twin type (discussed in 
Chapter 3, Section 3.7.1; Rijsdijk & Sham, 2002), differences in the concordance of a 
trait between MZ and DZ twins raised together are most likely due to genetics. Using 
structural equation modelling (see Chapter 3, Section 3.5) it is then possible to 
capitalise on the differences in genetic resemblance between the twin types, to 
estimate how far traits, and the relationships between them, are influenced by 
genetic and environmental factors. 
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Twin studies so far have demonstrated considerable evidence that both MDD (e.g. 
Kendler, Gatz, Gardner, & Pedersen, 2006; Sullivan, Neale, & Kendler, 2000) and 
cannabis involvement (Lynskey et al., 2002; Verweij et al., 2010, 2013) are 
influenced by genetic factors (see Table 3). Significant genetic influences have been 
found for cannabis use initiation (Verweij et al., 2010), symptoms of abuse or 
dependence (Lynskey et al., 2002; Verweij et al., 2010), as well as cannabis 
withdrawal (Verweij et al., 2013). Since abuse and dependence are core 
components of CUD, the proportion of CUD variance explained by genetic factors is 
also likely to be around 50%. Environmental factors, which contribute to similarities 
(shared environmental factors; C) and differences (unique environmental factors; E) 
between individuals, are also likely to influence CUD. MDD is likely to be influenced 
primarily by environmental factors that contribute to differences between people (E).  
Table 3. Estimates of genetic and environmental influences on MDD and cannabis 
involvement. 
Phenotype  Study  Gender A (95% CI) C (95% CI) E (95% CI) 





(31 - 42%) 
0% 
(0 - 5%) 
63%  









(53 - 64%) 
Male 29% 





(62 - 81 %) 





(30 - 49%) 
39%  
(29 - 49%) 
21%  
(16 - 27%) 
Male 48%  
(38 - 58%) 
25%  
(11 - 39%) 
27%  





All 45%  
(15 - 72%) 
 
20%  
(0 - 44%) 
 
35%  






Female 59%  
(44 - 73%) 
15%  
(1 - 30%) 
26%  
(23 - 30%) 
Male 51%  
(38 - 65%) 
20%  
(11 - 28%) 
29%  
(22 - 35%) 
Note. A = proportion of phenotypic variance explained by genetic (heritable) factors. C = proportion of 
phenotypic variance explained by environmental factors shared between twins. E = proportion of 
phenotypic variance explained by non-shared environmental factors and measurement error. CI = 
Confidence Interval.    
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However, few twin studies so far have examined to what extent the covariance 
between MDD and CUD may be influenced by genetic and environmental factors. In 
a sample of Australian twins Lynskey et al. (2004) reported a significant genetic 
correlation between lifetime MDD and cannabis dependence (men: r = 0.44, 95% CI 
= 0.17 - 1.00; women: r = 0.69, 95% CI = 0.30 - 1.00). Part of that common genetic 
liability between MDD and cannabis dependence may be explained by genetic 
influences linked to Antisocial Personality Disorder (APD). Fu et al. (2002) conducted 
twin model analyses including multiple variables. Within these models, the genetic 
factors influencing APD were entered into the model first, accounting for a large 
portion of variance in cannabis dependence. This substantially reduced the amount 
of variance that was left to be accounted for by genetic factors related to MDD: while 
the genetic influences of MDD and cannabis dependence overlapped, 62% of this 
genetic correlation could be explained by APD. Once APD was taken into account in 
the genetic model, the genetic correlation between cannabis dependence and MDD 
became no longer significant.  
The author is currently not aware of any other twin study reporting on genetic 
correlations between MDD and clinical cannabis involvement. Conducting such 
research would be important, since neither twin study was primarily investigating the 
bivariate genetic and environmental correlations between cannabis dependence and 
MDD. Lynskey et al. (2004) primarily conducted a discordant twin study and did not 
report on environmental correlations between the phenotypes. Fu et al. (2002) 
focused on the multivariate associations between APD, cannabis dependence, MDD 
and alcohol dependence. Additionally, twin study estimates are known to depend on 
geographical locations and time periods (Neale & Maes, 2004) and need to be 
replicated across these factors in order to be generalisable.  
1.4.1.5 Conclusions and limitations – overlapping risk factors  
Overall, there is evidence suggesting that cannabis involvement and depression may 
overlap neurobiologically and share environmental influences. The importance of 
these overlapping risk factors is unclear to date. Twin studies are capable of 
estimating the degree of genetic and environmental overlap between two traits 
without measuring specific genetic, biological or environmental factors. However, 
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evidence from twin studies on the bivariate relationship between CUD and MDD is 
lacking. While twin studies have identified that MDD and CUD are both likely 
influenced by genetic factors, further bivariate twin studies would be necessary to 
examine to what extent the covariance between MDD and CUD is influenced by 
genetic and environmental factors.  
1.4.1.6 Limitations to be addressed in the current thesis 
Twin studies that have been conducted so far have examined cannabis dependence 
and MDD, leaving uncertainty about the genetic and environmental relationship 
between MDD and clinical cannabis involvement when abuse criteria are included. 
Additionally, no twin study so far has primarily investigated the bivariate genetic and 
environmental correlation between clinical cannabis involvement and MDD. 
Therefore, a bivariate twin study of MDD and CUD will be reported on in Chapter 5. 
1.4.2 Causality  
Given the strong evidence of a significant co-morbidity and several possible sources 
of overlap between CUD and MDD, causality is of primary interest as a possible 
process of co-morbidity. A causal link would be of interest for policy, treatment and 
prevention. Cannabis legalisation is currently highly debated in various countries 
(Pacula & Smart, 2017). If any cannabis-related phenotype, such as CUD should 
causally influence a disorder as prevalent and disabling as MDD, this may influence 
whether and how cannabis would be legalised. From a treatment and prevention 
perspective, this finding could also clarify how to approach co-morbid cases of CUD 
and MDD. If CUD causes MDD, then it may be most efficacious to focus on treating 
the drug problem first. Conversely, finding that MDD causes CUD would suggest that 
co-morbid CUD and MDD cases may be treated best by addressing MDD primarily.  
This causality may be uni- or bi-directional and involve biological or environmental 
mechanisms driving any causal association (Agrawal & Lynskey, 2014). High levels 
of cannabis use in CUD may alter the neural mechanisms the psychoactive 
components bind to, and these alterations may increase the risk for or induce MDD. 
Neurochemical changes occurring during the course of a major depressive episode 
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may make an individual more susceptible to use high levels of cannabis for mood 
elevation, which would be considered ‘self-medication’. High levels of cannabis use 
may also lead to changes in the individual’s environment, such as relationship and 
financial difficulties (Cerdá et al., 2016), which in turn act as a causal factors for 
MDD. Conversely, MDD may cause individuals to withdraw from social activities, 
leading to feelings of loneliness or social exclusion, against which cannabis may be 
used as a buffer (Deckman, DeWall, Way, Gilman, & Richman, 2014).  
1.4.2.1 Causality: Evidence from twin studies 
Twin studies are a powerful tool to examine whether causality is a possible 
explanation for the co-morbidity between two phenotypes. In a discordant twin 
design (see Table 4), the prevalence of an outcome (e.g. MDD) is compared in MZ 
twin pairs where only one twin pair member has been affected by a predictor (e.g. 
CUD). If the MZ twin who is affected by the predictor shows a significantly elevated 
rate of outcome (i.e. OR > 1), the association between MDD and CUD may be 
causal. This is because MZ twins who were raised together overlap 100% in their 
genetic and shared environmental influences. Comparing outcome rates in MZ twins 
discordant for a predictor therefore controls for all genetic and shared environmental 
influences. If the OR between CUD and MDD is elevated despite controlling for 
these influences, two conclusions are possible. Firstly, there may be a causal 
relationship between CUD and MDD. Secondly, a non-causal overlap in unique 
environmental influences, which do differ between MZ twins, may simultaneously 
increase the prevalence of CUD and MDD. Since discordant twin designs do not 
differentiate between these two possibilities, they do not prove causality. 
However, if the OR is not significantly elevated in MZ twins discordant for CUD (i.e. 
OR = 1), this would mean that, after controlling for all genetic and shared 
environmental factors, there has been no causal association detected between MDD 
and CUD. While discordant twin analyses in MZ twins cannot prove causality, they 
can disprove it.  
Unrelated individuals do not share genetic or any environmental influences. 
Consequently, any significant relationship observed in a non-MZ sample, e.g. a 
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sample of unrelated individuals usually enrolled in cross-sectional or longitudinal 
studies, could have occurred due to a non-causal correlation in genetic or shared 
environmental factors between MDD and CUD.  
Discordant twin studies are an efficient way to examine whether causality is a likely 
explanation for the co-morbidity between CUD and MDD which was observed in 
cross-sectional studies of unrelated individuals, since both MDD and CUD have 
shown to be significantly influenced by genetic factors and twin studies have the 
critical advantage of controlling for all genetic and a large portion of environmental 
influences without having to measure them. 
Table 4. Discordant twin design explained, based on rates of CUD and MDD in MZ 
twins, and pairs of unrelated individuals. Individuals are discordant for both predictor 
(e.g. CUD) and outcome (e.g. MDD) measures.  
Relatedness Person CUD MDD (OR > 1) Reason for OR > 1 MDD (OR = 1 in MZ) 
MZ  




B No No1 Yes3 
Unrelated 
A  Yes Yes2 Overlapping genes, shared 
or unique environments and 
causality2  
Yes 
B No No2 No 
Note.  
1MZ twins share 100% of their genetic and shared environmental influences, but 0% of their unique 
environmental influences. Therefore, a significantly increased likelihood of meeting MDD criteria in co-
twins with CUD (OR > 1) must be due to two processes which are not controlled for in pairs of MZ 
twins: overlapping unique environmental influences or causality.  
2Unrelated individuals share no genetic or environmental influences. Any sig. association between 
CUD and MDD could be explained by an overlap in all influences, or causality.  
3If an OR > 1 has been found in unrelated individuals, causality is a possible explanation for co-
morbidity. However, if MZ twins with CUD are not more likely to meet criteria for MDD than their co-
twin without CUD (OR = 1), the MZ result disproves any causality suggested in populations of 
unrelated individuals. The difference in OR between unrelated individuals and MZ twins is likely due 
to overlapping genetic and/or shared environmental influences, which are controlled for in MZ twin 
comparisons. 
1.4.2.2 Cannabis involvement causes depression 
Discordant twin studies have produced mixed evidence with respect to potential 
causal mechanisms between cannabis involvement and depression. One Australian 
twin study examined whether the prevalence of lifetime cannabis dependence in one 
MZ twin increased their risk for subsequent MDD, compared to their co-twin who did 
not have a history of cannabis dependence (Lynskey et al., 2004). Conditional 
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logistic regressions were used to test whether cannabis dependence was associated 
with an increase in MDD in MZ twin pairs. The levels of MDD were not significantly 
increased in MZ twins with cannabis dependence, relative to their non-cannabis 
dependent co-twin (aOR = 1.16, 95% CI = 0.64 – 2.17). However, cannabis 
dependence was associated with elevated rates of MDD in DZ twin pairs discordant 
for cannabis dependence (aOR = 3.40, 95% CI =1.91 – 6.05). The absence of a 
significant association in MZ twin pairs suggests that cannabis dependence is 
unlikely to be a unique causal factor for MDD but that shared genetic influences, 
which are not fully controlled for in DZ twins, explain some component of the 
observed co-morbidity. 
However, the absence of an association in MZ twins may also have been due to the 
relatively small sample size (277 twins discordant for cannabis dependence). A 
subsequent analysis (Agrawal et al., 2017) with a substantially larger sample size, 
including this and two additional Australian twin cohorts, found that MZ twins who 
had used cannabis over 100 times had significantly increased odds of MDD 
compared to their co-twins who were non-users or lighter users (aOR = 1.72, 95% CI 
= 1.05 – 2.82).  
1.4.2.3 Depression causes cannabis involvement 
Lynskey et al. (2004) also examined whether twins meeting the criteria for MDD 
before age 17 were more likely to subsequently report cannabis dependence than 
their co-twins without MDD. Similar to their results on the reverse association, there 
was a significantly elevated prevalence of cannabis dependence among twins with 
MDD in DZ (OR = 9.50, 95% CI = 2.21 – 40.78), but not MZ twins (OR = 1.38, 95% 
CI = 0.55 – 3.42). In other words, MDD was not shown to be causally associated 
with later cannabis dependence. However, Lin et al. (1996) found that the 
prevalence of cannabis abuse/dependence was significantly higher in MZ co-twins 
who met the criteria for MDD (aOR = 2.3; 95% CI = 1.1 – 4.7), relative to their co-
twin who did not meet the criteria for MDD. To the best of the author’s knowledge, no 
other discordant twin studies have been published to date.  
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1.4.2.4 Conclusions and limitation to be addressed in this thesis 
Discordant twin studies so far have produced mixed evidence with respect to a 
possible causal mechanism between depression and cannabis involvement. Causal 
mechanisms cannot be discounted, particularly between CUD and MDD. To date, 
Lin et al (1996) is the only co-twin control study incorporating both cannabis 
dependence and abuse in their definition in a discordant twin analyses. However, 
their assessment was based on DSM-III-R phenotypes, their sample was relatively 
small (234 twin pairs discordant for MDD) and only included male veterans. A 
replication of their results extending to a general population sample of twins, males 
and females, and utilising more recent definitions of both CUD and MDD would be 
beneficial. This thesis will therefore explore the relationship between CUD and MDD 
using a discordant twin design (Chapter 5).  
1.4.2.5 Causality: Evidence from longitudinal studies 
1.1.1.1.1 Cannabis involvement causes depression 
Causality has also been tested in longitudinal studies. Although longitudinal studies 
are more limited than twin studies in their ability to control for genetic and 
environmental factors, or test for biological and environmental processes of 
causality, they provide a strong test of an overall causal relationship. They have 
been conducted in both directions of effect, on a variety of populations, and have 
used different definitions of cannabis involvement and depression.  
Longitudinal studies evaluating whether various forms of cannabis use, abuse or 
dependence are causally linked to symptoms or clinical diagnoses of depression 
have produced mixed results. Among studies which have controlled for symptoms or 
diagnoses of depression at baseline, the majority have found no significant link 
(Blanco et al., 2016; D. W. Brook, Brook, Zhang, Cohen, & Whiteman, 2002; J. S. 
Brook, Rosen, & Brook, 2001; Cougle et al., 2015; Danielsson et al., 2016; 
Degenhardt et al., 2013; Feingold, Weiser, Rehm, & Lev-Ran, 2015; Fergusson & 
Horwood, 1997; Gage et al., 2015; Georgiades & Boyle, 2007; Harder, Stuart, & 
Anthony, 2008; Harder, Morral, & Arkes, 2006; Manrique-Garcia et al., 2012; Paton, 
 36 
Kessler, & Kandel, 1977; Pedersen, 2008; Silins et al., 2014), while some have 
(Bovasso, 2001; J. S. Brook, Zhang, & Brook, 2011; Marmorstein & Iacono, 2011; 
Pacek, Martins, & Crum, 2013; Silins et al., 2014; Van Laar, Van Dorsselaer, 
Monshouwer, & De Graaf, 2007).  
A recent meta-analysis (Lev-Ran et al., 2014) of all but seven (Blanco et al., 2016; 
Cougle et al., 2015; Danielsson et al., 2016; Feingold et al., 2015; Gage et al., 2015; 
Pacek et al., 2013; Silins et al., 2014) of the abovementioned studies, has concluded 
that overall, there is a modest increased risk of developing depression following 
cannabis use (OR = 1.17, 95% CI = 1.05–1.30). This relationship is stronger for 
heavy cannabis use (OR = 1.62, 95% CI = 1.21–2.10). Although the relationship is 
statistically significant, it may be questionable whether these results indicate a true 
causal relationship between cannabis and depression. There was heterogeneity in 
estimates from individual findings (ORs range from 0.68 (95% CI = 0.20–2.33) to 
4.00 (95% CI = 1.23–12.99), and only four out of 18 reported findings were 
statistically significant, which is a cause for concern. Ioannidis (2005) has argued 
that meta-analyses with a ratio of significant to non-significant relationships larger 
than 1:3 are not likely to have found true relationships.  
Among several longitudinal studies which have been published since the meta-
analysis (see Table 5), the author is only aware of two studies finding a significant 
adjusted association (Pacek et al., 2013; Silins et al., 2014), the strongest being 
between clinical levels of cannabis use (CUD) and depression (MDD; Pacek et al., 
2013). This is compatible with findings from studies included in the meta-analysis 
(Lev-Ran et al., 2014): the strongest associations have been found in studies which 
examined the relationship between CUD and MDD (Marmorstein & Iacono, 2011) or 
depressive symptoms (Bovasso, 2001).  
Overall, there is some evidence to support longitudinal causal associations between 
baseline clinical levels of cannabis involvement and later clinical levels of depressive 
symptoms, but it is likely that a significant association only exists among heavy 
users, who may also have clinical symptoms of CUD.
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Table 5. Summary of longitudinal studies investigating the onset of depression (any) following cannabis use (any) since Lev-Ran et al. (2014). 
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Past year cannabis 
use: ‘no use’, ‘some 
but less than 










MDD prevalence at time 2: 
OR = 1.1 (0.9 – 1.2);  
aOR = 0.8 (0.7 – 1.0) 
 
MDD incidence at time 2: 
OR = 0.9 (0.7 – 1.1); 


















aOR = 1.07 (0.84 – 1.36) 







2 years 16 
Frequency of use ‘0 
times’, ‘1–20 times’, 
‘21–60 times’, ‘more 








OR = 1.50 (1.26 – 1.80);  












3 years 18–65+ 
Past year cannabis 
use; frequency from 
‘every day’ to ‘once 
a year’, frequency 
of cannabis on a 











OR (< weekly) = 1.18 (0.77 – 1.82);  
OR (weekly to less than almost daily) 
= 0.83 (0.50 – 1.39);  
aOR (daily to almost daily) = 0.94 
(0.41 – 2.14) 
 
aOR (any) = 1.06 (0.76 – 1.49); 
aOR (< weekly) = 1.04 (0.65 – 1.68);  
aOR (weekly to less than almost 
daily) = 0.67 (0.37 – 1.22);  
aOR (daily to almost daily = 0.58 
(0.22 – 1.51) 
          
Table continues on next page 
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Note. MDD = Major Depressive Disorder, CUD = cannabis use disorder, DSM = Diagnostic and Statistical Manual of Mental Disorders, NESARC = National 
Epidemiological Survey of Alcohol and Related Conditions, ALSPAC = Avon Longitudinal Study of Parents and Children, CHDS = Christchurch Health and 
Development Study, VAHCS = Victorian Adolescent Health Study, ATP = Adolescent Temperament Project, MDI = Major Depressive Inventory, AUDATIS-IV 
= Alcohol Use Disorders and Associated Disabilities Interview Schedule-DSM IV Version, CIDI = Composite International Diagnostic Interview, CIS(-R) = 
Clinical Interview Schedule (Revised), DASS = Depression Anxiety Stress Scale, (a)OR = (adjusted) Odds Ratio, (a)RR = (adjusted) Relative Risk, CI = 
Confidence Interval, RR = Relative risk.  



























Varied Before age 17 
Frequency of 
cannabis use before 
age 17: ‘never’, 
‘less than monthly’, 
‘monthly or more’, 
‘weekly or more’, 
‘daily’ 
17–25 






OR (< monthly) = 1.12 (1.01 – 1.25);   
OR (> monthly) = 1.26 (1.02 – 1.56);  
OR (> weekly) = 1.42 (1.03 – 1.94);  
OR (daily) = 1.56 (1.04 – 2.42) 
 
aOR (< monthly) = 1.01 (0.85 – 1.28);  
aOR (> monthly) = 1.01 (0.72 – 1.42);  
aOR (> weekly) = 1.02 (0.61 – 1.69);  

















OR = 2.02 (1.35 – 3.04); 
aOR = 1.78 (1.17 – 2.71) 
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1.4.2.6 Depression causes cannabis involvement    
There have also been several longitudinal studies investigating whether various 
forms of depression cause cannabis involvement. These studies have shown mixed 
results. Degenhardt et al. (2012) summarised the findings from 11 studies, 10 of 
which did not find a significant relationship. To the author’s knowledge, five 
additional relevant studies have been published within the last six years, which have 
controlled for depression at baseline (see Table 6). As is evident from the table, 
three out of the five recent studies have found significant links between depression 
and cannabis involvement. This is true for the initiation of any cannabis use within 
the past 12 months (Feingold et al., 2015; Haug, López Núñez, Becker, Gmel, & 
Schaub, 2014), as well as the development of CUD (Pacek et al., 2013). However, 
Cerdá et al. (2013) and Danielsson et al. (2016) did not find a significant relationship. 
Overall, the results remain unclear. A recent review of the evidence has argued that 
the longitudinal evidence of mood disorders (including MDD) causing cannabis 
involvement is currently lacking (Lev-Ran & Feingold, 2017).  
 40 
Table 6. Summary of longitudinal studies investigating the onset of cannabis use (any) following depression (any) since 
Degenhardt et al. (2012). 
Note. MDI = Major Depression Inventory, MDD = Major Depressive Disorder, CUD = cannabis use disorder, CD = Cannabis Dependence, CA = Cannabis 
Abuse, DSM = Diagnostic and Statistical Manual of Mental Disorders, MDE = Major depressive episode, SRA = Self-Report Antisocial Behaviour Scale, 
RMFQ = Recent Mood and Feelings Questionnaire, AUDATIS-IV = Alcohol Use Disorders and Associated Disabilities Interview Schedule-DSM IV Version, 
(a)OR = (adjusted) Odds Ratio, (a)RR = (adjusted) Relative Risk, aHR = adjusted Hazard Ratio, CI = Confidence Interval.
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RR = 1.62 (1.28 – 2.03), 
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have MDD but no 
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OR = 2.19 (1.54 – 3.13); 
aOR = 1.72 (1.10 – 2.69 





2774 men (who have 
not used cannabis at 
baseline), 30 
individuals with MDD 
and cannabis use 
15 
months 19–20 
self-report Q: any 12-







MDI aOR = 1.03 (1.01 – 1.05) 




34653; 3320 who 
have MDD but no 
cannabis use   






OR = 2.01 (1.09 – 3.68); 
aOR = 2.28 (1.28 – 4.05) 




499 boys, half 
selected to have high 
antisocial behaviour 
scores  
10 years  9–19 (semi-annually) 
SRA (before age 10), 16- 
item Substance Use Scale 
(after age 10); timing, 
quantity and frequency of 







aHR (recent depression) 
= 0.99 (0.95 – 1.04);  
aHR (cumulative 
depression) = 1.00 (0.95 
– 1.05)  
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1.4.2.7 Longitudinal studies of causality – conclusions and addressed limitations 
Results from longitudinal studies are both mixed and difficult to interpret due to their 
limitations. Firstly, measures of cannabis involvement and depression have been 
used inconsistently. Measures of depression vary from several symptoms assessed 
on a self-administered scale to clinical interviews. Cannabis use varies between any 
lifetime use to clinical cannabis abuse/dependence. Pooling between studies 
becomes difficult in the face of this heterogeneity, since it is unclear to what extent 
the results are comparable (Lev-Ran et al., 2014). Secondly, differences between 
users and non-users do not seem to be sufficiently accounted for. For instance, 
Feingold et al. (2015) found that cannabis users and non-users significantly differed 
in age, gender, household income and marital status. An early study by Fergusson 
and Horwood (1997) also demonstrated differences on a large amount of factors, 
including childhood adversities, social disadvantages, contact with peers who 
engaged in substance use or delinquent behaviours, and psychological adjustment 
problems. Similarly to several other studies reviewed above (Danielsson et al., 2016; 
Gage et al., 2015; Silins et al., 2014), Fergusson and Horwood’s (1997) study first 
showed a significant association between cannabis involvement and later 
depression, but it became non-significant following adjustment for covariates. This 
highlights the importance of controlling for a large variety of confounding factors, 
many of which seem to exert an influence on the association between cannabis and 
depression.  
Furthermore, many longitudinal studies investigating the effect of cannabis 
involvement on later depression have examined low levels cannabis involvement, 
which may not be likely to lead to symptoms of depression. Given the relatively low 
toxicity of cannabis compared to alcohol and tobacco (Nutt, King, & Phillips, 2010), it 
is difficult to explain why having used cannabis a few times during one’s lifetime 
would lead to depressive symptoms, via biological or environmental pathways. 
Longitudinal studies which have examined the relationship between CUD and MDD 
report the highest ORs (Bovasso, 2001; Marmorstein & Iacono, 2011; Pacek et al., 
2013). However, interpreting these results is challenging, because these studies 
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have also controlled for a smaller number of covariates compared to others (e.g. 
Silins et al., 2014).  
The inconsistent controlling for covariates may be explained by data collection for 
several of the cohorts mentioned above since they were not focused specifically on 
cannabis or MDD. For example, Pacek et al.'s (2013) data analysis was conducted 
on a dataset collected for the study of alcohol-related problems. Consequently, such 
cohorts would not be enriched for known covariates of cannabis involvement and 
thus unable to adequately control for them. Further epidemiological analyses of 
cohorts in which data collection was centred around cannabis involvement or 
depression and associated covariates could help to clarify the role such covariates 
are likely to play in the co-morbidity between MDD and CUD.  
Overall, the strongest relationships between depression and cannabis-related 
phenotypes were observed between clinical levels of cannabis involvement and 
depression. It is plausible that there is a causal relationship between these; it is also 
plausible that these strong relationships are due to non-causal overlapping risk 
factors, which were not sufficiently controlled for. Consequently, this thesis examines 
the relationship between MDD and CUD, controlling for a multitude of potential 
covariates. The results are presented in Chapter 4. 
1.4.3 Alternative models of co-morbidity 
Given that longitudinal and discordant twin studies so far have not been able to 
clarify the source of co-morbidity between cannabis involvement and depression in 
general, and CUD and MDD in particular, it is crucial to highlight that causality is only 
one of many aetiological mechanisms that can lead to co-morbidity (Klein & Riso, 
1993; Neale & Kendler, 1995). Twin studies are a powerful method to examine 
mechanisms other than overlapping risk factors. Previous twin studies have 
examined 13 different models of co-morbidity in different phenotypes, of which 
causal and correlated risk factor models are only a subset (Agrawal et al., 2007; 
Agrawal, Neale, Prescott, & Kendler, 2004; Agrawal, Silberg, Lynskey, Maes, & 
Eaves, 2010; Neale & Kendler, 1995; Rhee et al., 2004). The models and the 
questions they investigate are summarised in Table 7.  
 43 
Table 7. Co-morbidity models according to the Neale and Kendler (1995) approach. 
Using structural equation modelling, these models examine whether: 
a) CUD and MDD may be alternate forms of one underlying distribution of risk 
factors. If this was the best-fitting model, CUD and MDD should be regarded 
as one disorder which can manifest as either cluster of symptoms.  
b) CUD and MDD are pure forms of a third, unrelated disorder. This model 
assumes that there are three independent liabilities for CUD, MDD and co-
morbid CUD with MDD.  
c) The liabilities for CUD and MDD are unrelated. CUD discontinuously 
increases the risk of MDD symptoms and vice versa when thresholds are 
crossed. Random multiformity assumes one threshold and extreme 
multiformity assumes two thresholds. For instance, there may not be an 
increased risk of MDD due to CUD risk factors up until some threshold (e.g. a 
certain level of heavy cannabis use), after which the risk of MDD suddenly 
increases. 
Model Question 
1.   Alternate Forms Alternate forms of the same disorder? 
2.   Three Independent Disorders Co-morbid form is an independent disorder? 
3.   Random Multiformity Abruptly increase symptoms of each other? 
4.   RM of MDD MDD abruptly increases CUD symptoms? 
 
5.   RM of CUD   CUD abruptly increases MDD symptoms? 
6.   Extreme Multiformity CUD and MDD abruptly increase symptoms of each       other in extreme cases? 
7.   EM of MDD MDD abruptly increases CUD symptoms in extreme  cases? 
8.   EM of CUD CUD abruptly increases MDD symptoms in extreme  cases? 
9.   Correlated Liabilities Risk factors are correlated? 
10. Reciprocal Causation   CUD and MDD cause each other? 
11. MDD causes CUD MDD causes CUD? 
12. CUD causes MDD CUD causes MDD? 
13. Chance Co-morbid due to chance? 
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d) The liabilities, or risk distributions, are correlated. In other words, this model 
investigates overlapping risk factors – which have been mentioned above. 
e) CUD and MDD are causally related. This test is possible using cross-sectional 
data because different causal directions lead to a different predicted result 
pattern in twins.  
Family, ideally twin, data is necessary to investigate and compare all 13 models. 
Comparison of the different models is possible because different models assume 
different patterns of co-morbidity in twins. The best fitting model will create an 
expected pattern of co-morbidity which most closely matches the pattern of co-
morbidity that was observed.  
Since no previous study has examined all models for MDD and CUD, this thesis will 
aim to address this gap in the literature, and the results of this investigation will be 
presented in Chapter 6. A more thorough explanation of all models can be found in 
Neale and Kendler (1995), and will follow in Chapters 3 (Section 3.8.2) and 6.  
1.5 Conclusion and thesis aims 
Based on the evidence outlined in this chapter, it continues to be important to 
investigate the co-morbidity between MDD and CUD, as previous research, including 
cross-sectional, longitudinal and genetically informative studies, has produced mixed 
evidence with respect to the aetiological mechanisms underlying this relationship. 
The current thesis will analyse data from a sample of 3824 twins and their non-twin 
siblings, born between 1972 and 1979 in Australia. Epidemiological and twin 
analyses will aim to address the gaps in the literature identified in the review above.  
Firstly, epidemiological analyses (Chapter 4) investigating the co-morbidity between 
CUD and MDD will be conducted on a cohort which is enriched for cannabis-related 
covariates, as this was the central aim of data collection. Consequently, the 
association between MDD and CUD will be well-controlled for potential covariates. 
These analyses will identify covariates which are likely to play a particularly 
important role in explaining the co-morbidity of the two disorders. Epidemiological 
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analyses on CUD and MDD are of particular value to the existing literature because 
few studies have used these definitions of cannabis involvement and depression.  
Secondly, bivariate twin models (Chapter 5) will provide an estimate of the heritability 
of CUD and MDD and assess the impact of genetic and environmental factors on the 
covariance between the two disorders. These analyses will be helpful in guiding 
further studies and help understand whether individuals at risk for the co-morbidity, 
and thus who may benefit from early intervention, are best identified based on 
genetic or environmental risk factors.  
Thirdly, discordant twin analyses in Chapter 5 will examine whether a causal 
relationship between CUD and MDD is a plausible explanation of their co-morbidity. 
If the association between MDD and CUD is found to be significant in MZ twins, 
causality can be explored in further twin model analyses. These analyses are also a 
valuable addition to the literature, since there are currently only three discordant twin 
studies on cannabis involvement and MDD, only one of which examined cannabis 
abuse/dependence.  
Lastly, this thesis will examine 13 different models of co-morbidity, including but not 
limited to, causal models (Chapter 6). One of the limitations of cross-sectional and 
longitudinal studies is the lack of genetic information, which can be utilised to 
powerfully examine various aetiological links between two disorders. Examining the 
13 co-morbidity models proposed by Neale and Kendler (1995) will be a valuable 
addition to the literature, since causality and overlapping risk factors so far cannot 
fully explain the co-morbidity between CUD and MDD, and a comprehensive test of 







The methodology for this thesis will be outlined in two chapters: the current chapter, 
on general methods and Chapter 3, on twin methods. The current general methods 
chapter will present a detailed overview of the sample, phenotype and covariate 
measures. Additionally, it will introduce both epidemiology and discordant twin-
related statistical analysis. The statistical analysis section will then be expanded on 
in the subsequent twin methods chapter, which aims to present a thorough 
explanation of twin methods in general and the specific approaches used for this 
thesis. 
2.1 The sample 
The analyses presented are based on a sample of Australian twins from the 
‘Australian Twin Study of Cannabis and other Illicit Drug Misuse’. Data collection was 
centred around cannabis involvement and its correlates, which included measures 
on upbringing, other drug involvement, other mental health conditions, and several 
other factors (Lynskey et al., 2012). 
Participants from this sample were recruited through the Australian Twin Registry 
(ATR), a volunteer registry maintained by the University of Melbourne (Hopper, 
Foley, White, & Pollaers, 2013), currently consisting of around 74,000 members. The 
main responsibilities of the ATR were and are the recruitment of twins into the 
registry, the maintenance of their contact details and baseline questionnaires, and 
the facilitation of research on twins (Hopper, Treloar, de Klerk, & Morley, 2006). 
Recruitment proceeds through a number of avenues, including mass media appeals, 
schools, word of mouth and the Australian Multiple Birth Association (Hopper, 2002), 
and enrolment into the registry is possible for all zygosities and ages, irrespective of 
medical history. Since its establishment, the ATR has been funded by a variety of 
grants, predominantly by the Australian National Health and Medical Research 
Council (Hopper et al., 2006). Further details are available in publications by Hopper 
(2002) and Hopper et al. (2006, 2013).  
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The current sample consists of 3348 individual twins from the ATR, born between 
1972 and 1979, and 476 of their non-twin siblings. At the time of assessment, the 
average age of the sample was 32.1 years. An overview of the recruitment process 
is shown in Figure 1. 
 
Figure 1. An overview of the recruitment process, based on the description in Lynskey 
et al. (2012). 
Recruitment for the study began in 2005 and was conducted by the Queensland 
Institute of Medical Research (QIMR). To comply with ATR ethical standards, mail 
and then telephone contact was established first by the ATR. If individuals were 
interested in participating after receiving information on study goals and procedures, 
and were willing to share their contact details, they were contacted by QIMR 
(Lynskey et al., 2012). QIMR researchers further explained the purpose of the study, 
and proceeded with enrolment and obtaining informed consent. Subjects were 
compensated for completing the assessment with a AUD$50 gift card.    
Due to smaller than expected enrolment rates of twins, their non-twin siblings were 
also contacted for recruitment.  In total, 7850 individual twins and 1218 non-twin 
siblings were contacted, of which 3824 individuals, including twins and non-twin 
siblings completed a full or partial interview. Table 8 summarises the composition of 
the sample by sex and zygosity group.  
 48 
Table 8. Composition of sample by sex and zygosity group. 
  Female   Male  Total  
MZ  976 490 1466 
DZ (same sex) 741 373 1114 
DZ (opposite sex) 308 438 746 
Unknown zygosity 13 9 22 
Non-twin siblings 267 209 476 
 
2.2 Ethical approval and funding 
The data collection was funded by National Institute on Drug Abuse (NIDA) grant: 
DA18267 and facilitated through review by the Australian Twin Registry. Twins 
Research Australia receives support from the National Health and Medical Research 
Council through a Centre of Research Excellence Grant, which is administered by 
the University of Melbourne. Ethical approval for data collection was obtained from 
the Australian Twin Registry, QIMR and Washington University in St Louis. King’s 
College London Research Ethics Subcommittee approved access and storage of the 
data.  
2.3 Measures 
Computer-assisted telephone interviews based on the Australian version of the 
Semi-Structured Assessment of the Genetics of Alcoholism (SSAGA-OZ; Bucholz et 
al. 1994)) were used to assess twins on a number of mental health-related variables. 
Interviews were administered by lay interviewers, who underwent two weeks of 
interview training. With the participant’s permission, interviews were recorded for 
data quality purposes. Members from the same family were assessed by different 
interviewers, to avoid bias.  
2.3.1 The SSAGA-OZ 
The SSAGA-OZ is a semi-structured questionnaire, which has been adapted from 
the original SSAGA (Bucholz et al., 1994) to suit an Australian population and to be 
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administered through the telephone. The SSAGA-OZ has been widely used in family 
studies of alcohol dependence and collects detailed information on patterns of DSM-
IV (American Psychiatric Association, 2000) symptomatology across a range of 
mental health and substance use disorders. In the original SSAGA, assessments of 
these disorders, including DSM-III-R MDD and Cannabis Abuse/Dependence, have 
been shown to have good reliability (Bucholz et al., 1994) and validity (Hesselbrock 
et al., 1999). Inter-rater reliability was tested within and across centres, and had a 
kappa of .82 for Cannabis Abuse/Dependence in both studies (Bucholz et al., 1994). 
Inter-rater reliability for lifetime MDD had a kappa of .65 in the within-centre study 
and .74 in the cross-centre study. Validity was tested by comparing the SSAGA 
instrument to the Schedule of Clinical Assessment in Neuropsychiatry (SCAN), a 
cross-culturally valid instrument (Hesselbrock et al., 1999). The measures showed 
good concordance for MDD, with a kappa of .70. Only cannabis dependence, not 
abuse, was examined here, and, for all positive symptoms assessed on SCAN, had 
a kappa of 0.71.   
The adaptation of the SSAGA interview used for this cohort was enriched for 
variables related to cannabis involvement. Variables assessed in the interview 
included drug abuse and dependence (nicotine, alcohol and other illicit drugs), drug-
related behaviours, mental health problems, socio-demographic and family 
environment factors. Those used for analyses in this thesis are further outlined 
below. 
2.3.1.1 Major Depressive Disorder (MDD) 
Participants were asked whether they had ever felt a) ‘depressed or down’, b) ‘sad, 
blue, low, or discouraged’ and c) ‘a lot less interested in most things or unable to 
enjoy the things [they] usually enjoy’ most of the day and nearly every day, for two 
weeks or more over their lifetime. They were also asked about whether they ‘were a 
lot more irritable than usual, or […] found that people or things seem to get on [their] 
nerves a lot more than usual’ most of the day and nearly every day, for two weeks or 
more before the age of 18. In total, 1823 participants replied ‘yes’ to any of these 
four gateway questions, and they were asked further DSM-IV MDD criteria.  
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For analyses in this thesis, MDD was coded in accordance with the latest DSM, and 
as a binary variable. Although the criteria used in the interview were from the DSM-
IV, there were no significant changes in coding for MDD between DSM-IV and DSM-
5. An individual was coded as affected if they met at least five out of nine DSM-5 
criteria, including ‘depressed mood’ or ‘loss of interest or pleasure’. Individuals were 
only coded as affected if they reported that their MDD symptoms did not occur within 
two months of bereavement and caused a significant impairment in their 
occupational, social and family responsibilities.  
In total, MDD criteria were assessed in five rounds of questions. Out of 1081 
individuals who were asked about DSM-IV criteria for MDD, 930 reported criteria in 
the first round of questions. Individuals were asked about a following episode of 
MDD if they met criteria in the previous round or if individuals recalled an episode 
which occurred in a specific situations which met the DSM-IV exclusion criteria (e.g. 
bereavement). Over five rounds of questions, 968 individuals met the DSM-5 criteria 
for MDD (see Table 9). Data from 35 participants were missing on all questions on 
depression.  
Table 9. Prevalence of MDD among males, females and overall. 
MDD Males Females Total Percentage  
Absent 1122 1699 2821 74.45% 
Present 247 721 968 25.55% 
The higher prevalence of MDD in females (29.79%) than in males (18.04%) is 
compatible with findings from general population surveys reporting gender 
differences in MDD (Kessler et al., 2005, 1994).  
2.3.1.2 Cannabis Use Disorder (CUD) 
Interviewees were first asked whether they ever had the opportunity to use 
marijuana or hashish. Out of all participants, data were missing for 27 and 3399 
(89.54%) reported that they had an opportunity to use cannabis. In addition, 2601 
(68.52%) reported having used cannabis (i.e. marijuana or hashish) at least once in 
their lifetime. Lifetime frequency of cannabis use was also asked about and 
participants who reported having used cannabis at least 11 times in their lifetime 
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were assessed on DSM-IV criteria of lifetime cannabis dependence and abuse. 
Abuse items included ‘hazardous use’, ‘social/interpersonal problems related to use’, 
‘neglecting major roles to use’ and ‘legal problems’. Dependence items included 
‘tolerance’, ‘using larger amounts or using longer’, ‘repeated attempts to quit or 
control use’, ‘much time spent using’, ‘physical or physiological problems related to 
use’, and ‘activities given up to use’. In addition, an assessment of cannabis 
withdrawal was available (see Verweij et al. 2013). However, no assessment of 
‘craving’, a criterion introduced in DSM-5, was available for this sample.  
CUD was coded as a binary phenotype. To approximate DSM-5 criteria, individuals 
were coded as 1 (‘affected’) if they reported at least two symptoms of DSM-5 CUD, 
except for ‘craving’. The remaining participants were coded as 0 (‘unaffected’), 
whether or not they reported a lifetime history of cannabis use. The ‘legal problems’ 
criterion was removed from DSM-5 and therefore was not included in the definition of 
CUD. The prevalence of CUD in the sample was 14.75% (see Table 10).  
Table 10. Prevalence of CUD among males, females and overall.  
CUD Males Females Total Percentage  
Absent 1073 2164 3237 85.25% 
Present 299 261 560 14.75% 
The higher prevalence of CUD in males (21.79 %) than in females (10.76%) is also 
consistent with results from general population surveys (Kessler et al., 2005, 1994).  
These estimates are derived from treating all individuals who report CUD symptoms 
as “affected” and all individuals who do not report symptoms as “unaffected”, 
regardless of their opportunity to use. An alternative approach would have been to 
only include individuals who had the opportunity to use cannabis in the “unaffected” 
category and treat all other cases (10.46% of the sample) as missing for CUD. There 
is no agreed way of deciding between these approaches, either may lead to bias in 
twin estimates. The best way to reduce this bias is to decide on an approach based 
on the genetic structure of the phenotypes involved: if a genetic correlation can be 
expected between opportunity to use and CUD, removing cases which have not had 
the opportunity to use would unduly disregard genetic information (Heath, Martin, 
Lynskey, Todorov, & Madden, 2002). In this twin cohort, age of opportunity to use 
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cannabis and cannabis abuse/dependence have been estimated to overlap 
genetically to a substantial degree: most of the genetic variance in cannabis 
abuse/dependence was explained by genetic factors shared with age of opportunity 
to use (Hines et al., 2018). To reduce bias in genetic and environmental estimates 
and maximise statistical power, individuals who have not had the opportunity to use 
were therefore still included in the sample and treated as “unaffected”.  
2.3.1.3 Covariates 
Since the majority of covariates were only used in epidemiological analyses (Chapter 
4), details on how these were measured and coded as well as descriptive statistics 
will be provided in Chapter 4 (Table 13).  
2.4 Statistical analyses 
This section will focus on the epidemiological analyses (presented in Chapter 4) and 
the discordant twin analyses (presented in Chapter 5), which were both conducted in 
STATA (StataCorp, 2015). Twin model analyses which were not based on logistic 
regression methods will be outlined in Chapter 3.  
2.4.1 Epidemiological analyses 
The first aim of the epidemiological analyses is to provide unadjusted and adjusted 
estimates of the association between CUD and MDD, in order to test whether there 
is a significant co-morbidity in the current sample. Based on previous literature, it 
was assumed that this co-morbidity would be significant but would become 
attenuated after adjustment for covariates. If a diminished association was found, the 
second aim was to examine which covariates may have played a role in this. 
Previous research has identified a number of variables as likely covariates (see 
Table 2), which will be matched with variables in the current dataset. These were 
used as covariates in the epidemiological analyses. 
As a test of an unadjusted and adjusted association between MDD and CUD, as well 
as the effects of covariates, multivariable logistic regression analyses were 
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considered most suitable. These analyses allowed the accommodation of two 
important features of the current data: firstly, that MDD and CUD are binary 
outcomes, as is common in research on psychiatric phenotypes; secondly, that 
observations in this dataset are not independent. Independent standard errors are a 
prerequisite for a logistic regression. Given that the sample consisted of twins, and 
therefore clustered data, the standard errors were not considered independent. 
Huber-White corrections were used to account for this clustering and to allow logistic 
regression to be used. The statistical software used for the current analysis, STATA, 
contains a standardised option for Huber-White corrections (Williams, 2000).   
Additionally, most previous literature examining the association of cannabis 
involvement and depression has used binary phenotypes and reported ORs. ORs 
were also used to express the increase in outcome likelihood due to each predictor. 
Conducting multivariable logistic regressions allowed for a direct comparison 
between current and previous findings.  
A remaining challenge for the epidemiological analyses was to reduce the impact of 
multicollinearity, where two or more predictor variables are highly correlated. 
Multicollinearity can lead to larger standard errors around the regression coefficients 
and confidence intervals around ORs, consequently leading to an incorrect 
assessment of the significance of covariates. Multicollinearity will be checked using 
the Variance Inflation Factor (VIF) criterion. A higher VIF indicates that a variable 
shows more evidence of multicollinearity with other variables.  
The VIF and polychoric correlations (correlations for ordinal variables) were used as 
indicators to decide if variables should be combined or excluded. If correlated 
variables with a high VIF belonged in a similar category (e.g. different variables 
related to parental problems), a composite variable was created. If the correlated 
variables were from different categories (e.g. parental conflict and nicotine 
dependence), the more strongly associated predictor was kept in the model instead 
of the less highly associated predictor. 
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2.4.1.1 Multivariable Logistic Regression in STATA 
Both CUD and MDD were considered as outcome and predictor variables, since 
Chapter 4 will discuss the existence of a relationship in either direction when 
controlling for other variables, rather than presupposing a direction of effect. 
Multivariable logistic regressions were used to determine the probability of the 
outcome variable, for example, being affected by MDD, given the values of the 
predictors, for example age or sex (Cohen, Cohen, West, & Aiken, 2003). 
Mathematically, the formula for such a regression can be expressed as: 
Equation 1. Multivariable logistic regression formula. 
!(#) = 	 11 + )*(+,-+./.0-+1/10-...+3/30) 
where P(Y) is the probability of the outcome variable as a function of the logistic 
transformation of a linear regression equation, which ensures the outcome is 
bounded by 0 and 1 and therefore a valid probability. This equation estimates 
coefficients (bn) for each known value of a variable (Xni), which are a measure of the 
strength and direction of influence for each contextual variable present in the model.  
The coefficients of each predictor variable (bn) are found by maximum-likelihood 
estimation, i.e. optimising the joint set of parameters b, given the data, with respect 
to the specified likelihood function of the model. In the case of logistic regression, the 
likelihood function aims for coefficients which produce the smallest difference 
between the outcome predicted by the fitted model from the data and the outcome 
that was actually observed in the data.   
The fit of the model is assessed as the difference between these predicted and 
observed outcomes, which can be calculated through various statistics. The Wald 
test will be reported, instead of likelihood ratios, since it is recommended when 
working with clustered data (e.g. twin data; Sribney 2005). A statistically significant 
Wald statistic means that at least some of the coefficients in the model are 
significantly different from 0. 
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The selection of covariates was based on a review of longitudinal studies (see Table 
2) reporting on the co-morbidity between depression and cannabis involvement. 
Covariates which were significantly related to depression, cannabis involvement or 
both, were summarized into categories (see Chapter 4) to facilitate the matching 
process with the current dataset. A dataset variable was selected for epidemiological 
analyses if it matched one of these categories and contained age of onset 
information. 
To provide an ‘unadjusted’ estimate of the association between CUD and MDD, a 
multivariable regression between CUD and MDD was computed, which only included 
sex and age. To obtain an ‘adjusted’ estimate of the association, and assess the 
importance of covariates, a multivariable regression was performed first, which 
provided initial estimates of the ORs for each covariate, showing the results found 
with the full model that includes all selected variables based on previous literature. 
Thereafter, backward stepwise regressions were performed to sequentially remove 
variables which did not pass a predetermined threshold of statistical significance (in 
this case 0.10, though other values were explored) and thereby identify a more 
parsimonious model with minimal loss of explanatory power (e.g. pseudo-R2). The 
models were restricted to include CUD or MDD as predictor variables.  
These models were exploratory and not intended to test a particular theory, but 
rather to reveal which predictors may play an important role in the co-morbidity 
between CUD and MDD. Backward, rather than forward regressions were selected 
to avoid suppressor effects. A reduced model also limits the possibility for 
multicollinearity and is therefore less likely to produce inflated standard errors. 
Following standard practice, the p-values of the covariates were adjusted for the total 
number of covariates included in the model (the Bonferroni correction). In other 
words, a p-value of .050 reported in a STATA regression model (see Table 17) with 
10 predictors would have been reported as .005 (.050/10) without correction.  
2.4.2 Discordant twin analyses 
Logistic regression analyses were also employed for discordant twin analyses, in 
which the OR between MDD and CUD was measured in MZ twins discordant for 
 56 
both disorders. This involves within-family comparisons, so a conditional logistic 
regression was used in STATA (StataCorp, 2015). Twins from the same family were 
matched and the likelihood of the outcome variable (MDD), given the predictor 
variable (CUD) within families, was analysed. Only twins discordant for both 
phenotypes could be included in the analysis, since within-pair variation is required. 
Because within-pair comparisons in MZ twins control for all genetic and shared 
environmental (but not unique environmental) influences, and the sample size was 
predicted to be small, no further control variables were included in the model. With 
only MDD and CUD in the model, the OR would have been identical for either MDD 






3 Twin methodology 
The second and fourth aim of the thesis involve applying twin methodology to 
elucidate the mechanisms underlying the co-morbidity between Cannabis Use 
Disorder (CUD) and Major Depressive Disorder (MDD). This objective is founded in 
research, indicating that these phenotypes are co-morbid and both influenced by 
heritable factors (see Chapter 1). Therefore, genetically sensitive statistical methods 
are well placed to enrich our understanding of the relationship between these 
disorders. The following chapter will outline the foundations of the twin methodology, 
discuss its advantages and limitations, and explain how it can be used to break down 
the relationship between CUD and MDD into genetic versus environmental factors. 
3.1 Introduction 
Historically, it has been of great interest to know to what extent human traits are 
influenced by genetic versus environmental factors. For centuries, various prominent 
figures, including philosophers, scientists and politicians, have bitterly debated 
whether differences between humans are best explained by ‘nature’ or ‘nurture’ (e.g. 
Galton, 1874). Recent research has shown that both are equally important (e.g. 
Polderman et al., 2015) with some traits, disorders and behaviours being influenced 
more by genetic factors (e.g. Schizophrenia; Sullivan, Kendler, & Neale, 2003) and 
others more by environmental factors  (e.g. Major Depressive Disorder; Kendler, 
Gatz, Gardner, & Pedersen, 2006). Nowadays, quantitative geneticists often aim to 
explore complex patterns of genetic and environmental effects within and between 
specific traits. This chapter will describe how genetically sensitive data can also be 
used to explore hypotheses of causality and other forms of co-occurrence between 
disorders.   
As mentioned in Chapter 1, twin studies are one of the most popular methods to 
decompose individual differences – or the variance – within a trait into genetic and 
environmental contributions. MZ twins share 100% of their DNA, while DZ twins 
share around 50% of their segregating genes. Therefore, differences in concordance 
for a trait between MZ and DZ are most likely due to genetics. Using structural 
equation modelling (described later in this chapter), it is then possible to capitalise on 
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the differences in genetic resemblance between the twin types, to estimate to what 
degree traits, and the relationships between them, are influenced by genetic and 
environmental factors. While not the only genetically informative study design, twin 
studies have important advantages over family and adoption studies. Compared to 
family studies, it is possible to distinguish between influences stemming from genetic 
factors and those from the family environment (Rijsdijk & Sham, 2002). Adoption 
studies are difficult to conduct, as adopted siblings and other family members can 
often not be traced. Additionally, the factors which lead to adoption may introduce 
biases into a dataset (Rijsdijk & Sham, 2002). 
The following chapter will outline the ideas and assumptions behind twin studies, and 
how twin data is used in structural equation models to answer hypotheses about the 
relative importance of environmental and genetic influences. It will start by explaining 
how the variance within a population is assumed to be caused by such influences. 
Then, it will discuss which specific genetic and environmental effects are present and 
how those may interact. It will outline how the covariance between twin pairs can be 
utilised to estimate such effects in theory and in practice. The application of the twin 
method to binary data will be discussed. Moreover, the assumptions and limitations 
of the twin design will be detailed. Lastly, the chapter will outline types of twin models 




3.2 Causes of individual differences  
Twin studies rest on the assumption that the phenotypic variance within a trait can 
be decomposed into variance due to genetic and environmental factors. Combined, 
‘nature’ and ‘nurture’ are assumed to give rise to the normal distribution of individual 
scores on a measured trait. In support of this assumption, the following section will 
introduce the polygenic theory of inheritance, which suggests that a multitude of 
genes influencing human behaviour are inherited in a manner which gives rise to a 
normal distribution of phenotypic categories. Environmental influences are then 
thought to blur the differences between these categories and lead to a continuous 
distribution. 
3.2.1 Polygenic theory of inheritance  
Many human traits, such as depressed mood, can be described as ‘quantitative’. 
This means that an individual’s score on a trait could be placed along a continuum 
(e.g. a number of days feeling depressed in the past two weeks), which follows a 
normal distribution. On such a continuum, differences between people are of degree 
rather than kind. Clinical disorders, such as MDD, tend to be diagnosed in a binary 
fashion: it is practical for psychiatrists and insurers to keep a binary distinction of 
‘affected’ and ‘unaffected’. However, these categories are created on either side of 
an artificial threshold on a normal distribution. MDD symptoms, such as fatigue or 
depressed mood, can be measured continuously and studies applying taxometric 
procedures suggest that individuals tend to differ in their levels of depression in a 
continuous way, rather than by categories (e.g. Hankin, Fraley, Lahey, & Waldman, 
2005; Slade & Andrews, 2005). Previous research also supports that CUD can be 
conceptualised as a continuous disorder (Baillie & Teesson, 2010).  
According to the polygenic theory of quantitative traits, this continuous distribution 
along which individuals differ on a trait is brought about by the effects of multiple 
genes in addition to environmental influences (Fisher, 1918; Plomin, Haworth, & 
Davis, 2009). Genes create variability in a population, because each individual can 
inherit different combinations of alleles at any genetic locus: each gene can have 
multiple alleles within a population (e.g. Handsaker et al., 2015) and there are 
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several possible allele combinations. Since differences in allele combinations 
correspond to differences in human traits (e.g. Bertolino et al., 2004; Egan et al., 
2001), genetic variation at each locus contributes to a normal distribution within a 
trait (see Figure 2).  
 
Figure 2. Normal distribution of the phenotype influenced by alleles at two loci. 
Different phenotypic categories are marked by shading. Equal allele frequencies are 
implied. 
For simplicity, one could imagine that the type 2 allele (e.g. A2) of each gene 
contributes to an increase in a trait (e.g. depressed mood), while the type 1 allele 
(e.g. A1) contributes to a decrease in this trait. Each combination of alleles gives rise 
to a qualitatively different phenotype. These phenotypic categories are increased as 
genetic loci influencing the trait are added (see Figure 2b).  
In the current example, individuals with an equal amount of type 1 and 2 alleles are 
situated around the mean. When allele frequencies are equal, genetic recombination 
throughout generations gives rise to more heterozygotes (see Figure 2b), i.e. 
individuals, who inherited two different alleles at one genetic locus. Therefore, most 
people will display medium levels of depressive mood. There will be a minority of 
individuals inheriting almost only type 1 or type 2 alleles, and therefore displaying 
very low or very high levels of depression.  
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Each additional gene that contributes to the phenotype exponentially increases the 
amount of possible genotypes in the population. This leads to a quasi-continuous 
normal distribution of phenotypes for quantitative traits, since these traits are 
estimates to be influenced by thousands of genes (Plomin et al., 2013). 
In this example, it is implied that this distribution of phenotypic differences occurs as 
alleles of different genes combine, segregate and recombine over generations. They 
do so according to Mendel’s laws of inheritance (Plomin et al., 2013): each allele 
within an individual has a 50% chance of being passed down to the next generation 
and alleles for different traits assort independently of each other. Although there are 
some violations of these principles, they do not alter the general principles described 
above.  
In a seminal paper, Fisher (1918) formally demonstrated how Mendelian laws of 
inheritance give rise to quantitative traits. He also provides further details on the 
mathematical explanation of this polygenic biometrical model. Fisher (1918) explains 
that the effect of the environment on the variance in a population is overlaid on the 
genetic effects and smooths the genetic categories to create a continuous 
distribution.  
3.2.2 Summary 
Individual differences in a quantitative phenotype arise due to genetic and 
environmental effects. Multiple genetic loci and different combinations of alleles 
create genetic variance. As these alleles are inherited throughout generations, they 
give rise to phenotypic categories, which resemble a normal distribution. The 
addition of environmental effects leads to a smoothing of these categories so that the 
distribution appears continuous.  
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3.3 Genetic and environmental variance components: A, D, C and 
E 
The previous section outlined how continuous phenotypic variance in a trait is 
explained by genetic and environmental effects. However, twin studies further sub-
divide these effects into more specific sources of variation. These are outlined below.  
3.3.1 Environmental and genetic components of phenotypic variance  
Broadly, phenotypic variance (σ2P) is made up of genetic variance (σ2G) and 
environmental variance (σ2E): 
σ2P = σ2G + σ2E 
Some component of phenotypic variance is also influenced by the interaction 
between the two. To be mathematically correct, the equation should therefore be σ2P 
= σ2G + σ2E  + 2Cov(G,E). The interaction term at the end of the equation could 
capture gene-environment correlation (rGE) and/or gene-environment interaction 
(GxE; Falconer and Mackay, 1996), but these are often omitted for simplicity and 
parsimony (Purcell, 2013). The implications of this omission will be further discussed 
below in Section 3.7.   
Both genetic and environmental factors can be partitioned further. In terms of 
environmental variance, we may want to know to what extent a phenotype is 
influenced by the environment that is shared between relatives (e.g. the home 
environment) versus their unique environmental experiences (e.g. trauma which only 
affected one sibling). The shared environment contributes to similarities between 
twins, while the unique environment contributes to differences. Additionally, genetic 
effects can be divided into additive and non-additive effects. While examining 
variance components does not answer which specific environmental and genetic 
factors contribute to the variance in a trait, it may help to understand which types of 
variables are likely to most strongly influence the phenotype (Neale & Maes, 2004).  
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3.3.1.1 Genetic Effects 
Variance due to genetic effects can be sub-divided into variance due to additive and 
non-additive genetic effects. Additive genetic effects are the sum of genotypic effects 
exerted by any allele at each genetic locus which influence the trait in question 
(Rijsdijk & Sham, 2002). A genotypic effect is the influence of a genotype on the 
phenotype. Additive influences account for a large portion of the measurable genetic 
attributes of a population and the resemblance between relatives (Falconer and 
MacKay, 1996; Plomin et al., 2013). Statistically, additive genetic effects are 
expressed by the linear relationship between the number of copies of an allele in a 
genotype (i.e. gene content) and the genotypic effect (see Figure 3a). If this effect is 
of equal magnitude for all alleles of a gene, then their influence on the phenotype is 
said to be ‘additive’. Non-additive genetic effects are ‘dominance’ and ‘epistasis’. 
Dominant genetic effects are present when certain alleles at a locus influence the 
phenotype more strongly than others. In that respect, dominance reflects the 
interaction of alleles at one genetic locus (Evans, Gillespie, & Martin, 2002) and 
would be demonstrated if an increase in the gene content of the dominant allele 
resulted in a non-linear relationship with the genotypic effect (see Figure 3b). While 
dominance is the interaction between alleles at the same locus, epistasis is the 






Figure 3a and b. Linear (additive) relationship and non-linear (dominance) 
relationship between gene content and genotypic effect. 
Note. a  = average genotypic effect of A2A2 (a) and A1A1 (-a) 
         m = midpoint at which genotypic effect is 0 
          d = dominance deviation   
In twin models, additive genetic effects are referred to as A, while dominance effects 
are referred to as D. As epistasis cannot be measured in twin models, it is not 
included in the decomposition of genetic variance (see Section 3.7). The total 
genetic variance contributing to a phenotype is therefore composed of the variance 
due to additive genetic (σ2A) and dominance (σ2D) effects: 
σ2G = σ2A + σ2D 
If the allele frequencies and genotypic effects are known for a particular locus, it is 
possible to calculate these variance components. The formula is as follows (Evans et 
al., 2002): 
σ2A = 2pq[(a + d(q - p)]2 
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σ2D = (2pqd)2 
In this formula p and q stand for the frequency of both alleles at a locus; a stands for 
the additive genotypic effect and d for the effect of dominance. Details on the 
derivation of this formula are provided by Mather and Jinks (1982), but will not be 
demonstrated here, as twin models do not investigate the effects of single genes. 
However, these formula demonstrate several important points (Evans et al., 2002). 
Firstly, the variance due to additive genetic effects takes into account some 
contribution of dominance, while the variance due to dominance does not take into 
account additive genetic effects. Secondly, dominance and additive genetic variance 
are both influenced by the frequency of alleles. It may therefore occur, for example, 
that dominance effects are present for a disorder, but are masked by a low 
frequency of the alleles that exert them (Evans et al., 2002). Lastly, neither formula 
takes into account the level of genetic variance that arises due to the interaction 
between different genetic loci (i.e. epistasis). As mentioned, epistasis cannot be 
assessed in twin studies, but it must be acknowledged as a limitation that a certain 
degree of genetic variation, which is not captured by dominance or additive genetic 
effects, is explained by variance due to epistasis (Neale & Maes, 2004).  
In twin studies, the proportion of variance in the phenotype attributable to additive 
genetic effects (i.e. σ2A / σ2P) is termed ‘narrow sense heritability’ (Plomin et al., 
2013) and abbreviated as h2, a2 or A (henceforth h2). The proportion explained by all 
genetic effects (i.e. σ2G / σ2P) is termed ‘broad-sense heritability’ (Plomin et al., 
2013).  
3.3.1.2 Environmental effects  
Environmental factors are divided into those that make relatives more similar, and 
those that create differences between relatives. They are sometimes also referred to 
as the shared and unique environments. In twin models these are abbreviated as C 
and E, respectively. For instance, the only source of differences between MZ twins 
who were raised together are their unique environments (E) (Neale & Maes, 2004), 
as they share 100% of their DNA (A/D) and, by definition, 100% of the environmental 
influences which contribute to their similarities (C). In contrast to E, C is shared 
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between family members and contributes to within-family similarities and between-
family differences (Neale & Maes, 2004). A study design extending beyond twins, 
and, for instance, including parents, can provide additional information about the 
exact sources of shared environmental variation. However, the studies presented in 
this thesis contain data on twins and non-twin siblings only, and therefore different 
variance components within C cannot be distinguished. These can include the effect 
of parents, the environment shared by all siblings, or that shared by the twins only 
(Neale & Maes, 2004). Environmental variance encompasses both pre-natal and 
post-natal environmental factors (Neale & Maes, 2004).  
Environmental effects are part of the reason why results from different twin studies 
are cohort-specific (Neale & Maes, 2004). Environmental influences specific to a 
region or time period may be particularly salient and have a large influence on the 
phenotype in question, within one cohort, but not another. This may also be more 
important for some phenotypes than for others. For example, the level of MDD in a 
population may be particularly responsive to temporary environmental fluctuations 
(Neale & Maes, 2004). In twin studies, such random effects are included in the 
estimate of unique environmental variance, which also incorporates measurement 
error. 
3.3.1.3 Total variance composition 
Genetic variance is composed of additive and non-additive variance. The latter 
include dominance and epistasis, but only dominance can be measured in twin 
studies. Environmental variance can be broken down into variance due to shared 
and unique environmental influences. The former contribute to similarities within 
families, the latter to differences. In twin studies unique environmental variance 
includes a contribution from measurement error.  
In total, phenotypic variance can therefore be expressed as: 
σ2P = σ2A + σ2D + σ2C + σ2E 
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This decomposition of phenotypic variance is used in twin studies, but involves some 
assumptions. As above, any decomposition of variance into additive components 
mathematically involves interaction terms. The equation above should be as follows:  
σ2P = σ2A + σ2D + σ2C + σ2E + 2Cov(A,D) + 2Cov(A,C) + 2Cov(A,E) + 2Cov(D,C) + 
2Cov(D,E) + 2Cov(C,E)  
However, several assumptions allow us to simplify this equation (Purcell, 2013). 
Firstly, additive and dominance genetic effects are independent of each other by 
default, therefore 2Cov(A,D)  = 0. Similarly, there is no interaction between 
environments which contribute to family resemblance (C) and those which contribute 
to differences (E), so 2Cov(C,E) = 0.  Secondly, and this is a more contested 
assumption, genetic and environmental influences are assumed not to be correlated, 
which equates all covariances involving A or D to 0.  The implications of these 
assumptions will be discussed in Section 3.7.  
3.4 Covariance between relatives  
Monozygotic (MZ) and dizygotic (DZ) twins can be seen as an elegant experimental 
design: both share all environmental influences contributing to their similarity (C), 
while sharing predictably different levels of genetic variance in any trait. MZ twins 
share 100% of their genetic material and consequently 100% of the additive and 
dominance genetic variation in a trait. However, DZ twins share, on average, 50% of 
their segregating genes, 50% of the additive genetic variation in a trait and 25% of 
the variance in dominance effects. Formal proof for these differences between MZ 
and DZ twins can be found in Mather and Jinks (1982) and in Neale and Maes 
(2004). The covariance between twins can be summarised in the following formulae: 
CovMZ(x,y) = σ2A + σ2D + σ2C 
CovDZ(x,y) = 45σ2A + 46σ2D + σ2C 
The fact that MZ and DZ twins are only thought to differ in terms of the genetic 
variance components can be utilised by twin models to estimate these components, 
 68 
as well as σ2C and σ2E. The rationale behind this can be demonstrated using a 
simple calculation, which has been termed Falconer’s formula. Using the formulae 
below, it is possible to approximate the relative importance of different variance 
components. Rather than estimating the unstandardised variance components, they 
are expressed as proportions of phenotypic variance. As discussed in the previous 
section, the proportion of phenotypic variance attributable to additive genetic (i.e. 
σ2A/ σ2P) effects is termed h2. Consequently, other proportions of variance will 
henceforth be called c2 (i.e. σ2C / σ2P), d2 (i.e. σ2D / σ2P) and e2 (i.e. σ2E / σ2P).  For 
instance, h2, c2/d2 and e2 could be estimated by the following formulae (Sham, 1998), 
which are derived by constructing simultaneous equations from MZ and DZ 
covariances. 
h2 = 2(rMZ - rDZ) 
c2 = 2rDZ - rMZ 
e2 = 1 - h2 - c2 
or  
h2 = 4rDZ - rMZ 
d2 = 2(rMZ - 2rDZ) 
e2 = 1 - h2 - d2 
It is important to note that c2 and d2 cannot be estimated at the same time using 
structural equation models (see next section). This is because there are two 
observed statistics (rMZ and rDZ), from which one can estimate two parameters (h2 
and c2; Sham, 1998). Thereafter, e2 can be obtained, because it is known that h2 + 
c2 + e2 equal 1.  
Additionally, twin models can only return reliable estimates if rMZ is not smaller than 
rDZ and never larger than 4 * rDZ (Sham, 1998).  If only σ2C contributes to twin 
correlations and σ2A = σ2D = 0, then both twin correlations should be equal, because 
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both MZ and DZ twins should share all of σ2C. If σ2C = σ2A = 0 and only σ2D contributes 
to the twin similarity, then the MZ twin correlation can be four times higher, because 
they are all of σ2D, while DZ twins share 46σ2D.  
While a crude estimate of the variance components can be obtained with such 
calculations by hand, more exact estimates and more advanced hypotheses are 
examined using structural equation models. For example, it is not possible to use 
Falconer’s formula to examine the genetic relationship between multiple variables, or 
to calculate confidence intervals around estimates. Nevertheless, Falconer’s formula 
and structural equation models have in common that estimates of variance 
components are obtained by using simultaneous equations with MZ and DZ twin 
covariances. The next section describes structural equation models in greater detail.  
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3.5 Structural equation models 
The previous sections have introduced a theoretical account of the sources of 
variance contributing to a phenotype and how these can be estimated from the 
covariance between relatives. To formulate these theoretical assumptions and 
associated hypotheses in a testable way, it is necessary to generate mathematical 
models (Neale and Maes, 2004).  
The path diagram below aims to put the previously introduced theory into a 
mathematical form (see Figure 4). It hypothesises that phenotypic variance (e.g. 
Phenotype twin 1) can be decomposed into A, C, D and E (henceforth used instead 
of σ2A, σ2D, σ2C and σ2E ). It is further assumed that MZ twins share no E, all of A, all 
of D and all of C, while DZ twins share no E, 45 of A, 46 of D and all of C. Only ACE or 
ADE combinations can be modelled at any one time. These variance components 
are unmeasured, or latent factors, and are therefore represented by circles, while the 
squared boxed in the diagram represent observed variables. Each latent variable 
(e.g. A) has a certain magnitude of effect (e.g. a) on the observed variable (e.g. 
Phenotype Twin 1). This causal relationship is indicated by a single-headed arrow, 
and the effect (e.g. a) is a partial regression coefficient. Correlations are expressed 
as double-headed arrows along with a correlation coefficient. By following the path 
tracing rules (see e.g. Rijsdijk & Sham, 2002), one can obtain the estimated 













Figure 4. Path diagrams showing variance components and correlations between twin 
pairs for ACE and ADE models. Partial regression coefficients from latent factors to 
phenotype are displayed on the single-headed arrows, correlations between latent 
factors on double-headed arrows. 
To analyse twin data and to adequately accommodate all these assumptions several 
properties are required of a mathematical model: 1) it must estimate latent (i.e. 
unmeasured) factors, since there is no direct measurement of environmental and 
genetic effects; 2) it must estimate the causal influence (e.g. via regression methods) 
of those factors on a trait and the correlation between these factors across traits; 3) It 
must estimate the conditional relationships of all factors in the model. Structural 
equation modelling (henceforth SEM) is therefore well suited for this task, as it 
combines regression analysis, confirmatory factor analysis and path analysis. 
In SEM, the phenotypic covariance structure of the data is used to extract latent 
genetic and environmental factors and estimate the extent of phenotypic variance 
that is explained by them. MZ and DZ twin covariances can be conveniently 
expressed in variance-covariance matrices (see Table 11), and be decomposed in 
terms of the same parameters: A, C, D and E. These parameters need to be 
estimated in SEM. The aim of the model is to use the minimum number of 
parameters and simultaneously generate parameter values that predict an expected 
variance-covariance matrix resembling the observed data as closely as possible 
(Purcell, 2013).  
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Table 11. Variance-Covariance matrices for univariate twin analyses. 
 MZ Twin 1 Twin 2   DZ Twin 1 Twin 2 
Twin 1 Var   Twin 1 Var  
Twin 2 Cov Var  Twin 2 Cov Var 
  Twin 1 Twin 2    Twin 1 Twin 2 
Twin 1 A + C/D + E   Twin 1 A + C/D + E  
Twin 2 A + C/D A + C/D + E  Twin 2 
45A + C/46D A + C/D + E 
During the model fitting process, the statistical program will sample multiple values of 
A, E and C/D to identify the parameter values which make it most likely to obtain the 
observed variance-covariance matrix given the model. MZ and DZ data are 
considered simultaneously, and the parameters must fit the observed variance-
covariance matrices of both. This optimisation is part of a method called maximum 
likelihood estimation (Neale and Maes, 2003), 
The highest likelihood obtained by the parameters specified under the model is then 
compared to the likelihood obtained under a saturated model, a model with perfect fit 
to the data (Rijsdijk & Sham, 2002). This comparison in goodness-of-fit is achieved 
by computing a ratio between the likelihoods, such as the chi-square statistic 
(Rijsdijk & Sham, 2002). If the difference between the parameterised and 
unparameterised models is not significant, the ACE or ADE (parametrised) model is 
assumed to fit well. Further model comparisons can be conducted. For example, it 
may be worth examining whether a model with fewer parameters (e.g. only A and E) 
may be more parsimonious. Not all specified parameters may explain the data to a 
large enough extent. To this end, it is possible to construct nested models, where 
parameters of one model are fixed to 0 in a sub-model (Purcell, 2013). The best 
fitting and most parsimonious model can be chosen based on the Akaike Information 
Criterion (AIC; Akaike, 1987). According to Burnham and Anderson (2002), an AIC 
difference of three or greater indicates that the model with the lower AIC has 
substantially more support.  
 
 73 
3.5.1 Advantages and limitations of SEM 
SEM has several critical advantages for twin data analysis. Maximum likelihood 
estimation makes it possible to include twin pairs where data is missing, thus 
avoiding the deletion of cases (Evans et al., 2002) and increasing power. SEM also 
allows the assessment of complex models and hypotheses and to compare between 
them (Purcell, 2013). For instance, it is possible to explore the relationship between 
several phenotypes, examine sex differences and include specific measured 
variables (Purcell, 2013). Moreover, relationships between factors can be 
conveniently expressed in the form of path diagrams. 
However, a well-fitting model only implies that the hypothesis is plausible, and not 
necessarily true. There are several models which may have an equally good fit while 
testing different hypotheses (MacCallum, Wegener, Uchino, & Fabrigar, 1993). 
Furthermore, an accurate model may not be testable given the available data. For 
instance, dominance effects are likely to be present but cannot be estimated 
alongside shared environmental factors (Purcell, 2013). Lastly, there are several 
underlying assumptions of the model fitting procedure. It is assumed that the 
components of the model influence each other in a linear fashion, that they additively 
predict the phenotype and that the examined distributions have multivariate normality 
(Purcell, 2013). The extent to which these assumptions can be tested is limited. 
3.5.2 OpenMx 
While structural equation modelling can be performed in various statistical packages, 
most twin models are conducted using OpenMx (Neale et al. 2016), which is a 
package for R statistical software (R Core Team 2014). The advantage of OpenMx 
over other SEM packages includes the fact that it is open source, has been designed 
to handle large datasets and can be used across different computing environments 
(Boker et al., 2011). 
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3.6 Application of twin models to psychiatric phenotypes 
From the previous sections it is evident that the covariance between relatives plays a 
central part in twin models. SEMs take advantage of the covariance structure to 
estimate environmental and genetic effects. When dealing with continuous data, the 
concept of covariance is straightforward. Continuous phenotypes contain a variety of 
values, from which it is possible to generate the exact mean and variance for each 
sample and sub-sample. From these parameters it is then possible to calculate the 
covariance between relatives. However, all psychiatric phenotypes analysed in this 
thesis are defined as binary variables, similarly to previous research reviewed in 
Chapter 4. Calculating covariance is more complicated in these cases, and will be 
described in the following sections. 
3.6.1 Binary data 
Although psychiatric phenotypes (i.e. traits or disorders) are often measured as 
binary variables (0 = affected, 1 = unaffected), this does not necessarily correspond 
to the way in which individuals differ in these phenotypes. For example, an individual 
is considered to be ‘affected’ by MDD if they have experienced five or more 
symptoms of depression (see DSM-5; American Psychiatric Association, 2013) for 
over two weeks, including depressed/irritable mood or loss of pleasure. This disease 
status can be regarded as binary or further sub-divided into three ‘affected’ 
categories depending on the number of displayed symptoms: ‘mild’, ‘moderate’ and 
‘severe’. However, as was mentioned above, individuals tend to differ in their levels 
of depression in a continuous way, rather than by categories (e.g. Hankin, Fraley, 
Lahey, & Waldman, 2005; Slade & Andrews, 2005). Furthermore, it can be assumed 
that psychiatric disorders are polygenic (Wray et al., 2014). In accordance with the 
polygenic theory of inheritance, it is therefore likely that the risk, or liability, to 
develop a psychiatric phenotype is continuously distributed as well.  
To marry the binary nature of the measure and the assumption that the underlying 
liability is continuously distributed, the liability-threshold model was proposed 
(Pearson & Lee, 1901; Sham, 1998). Figure 5 shows a liability-threshold model for 
binary data. While the underlying liability is thought to be continuous, individuals 
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above a certain threshold (t) are labelled as ‘affected’. The area under the curve 
describes the probability of being affected by the disorder, which is influenced by the 
number of risk factors. This is a mathematical expression of the notion that risk 
factors for polygenic disorders do not determine their presence, but they influence 
the likelihood of this (Rutter, Moffitt, & Caspi, 2006) 
 
Figure 5. Liability-threshold model for binary data. 
As the liability distribution underlying the binary phenotype cannot be observed, this 
distribution needs to be estimated. There are three parameters which are used to 
describe such a liability distribution: a mean (7̅), a variance (σ²) and a threshold (t). 
Because binary data only contain one observed statistic – the probability of being 
affected by a disorder – only one of the three parameters can be estimated. 
Identifying restrictions need to be applied to the other two. For twin models, it can be 
most useful to estimate the threshold, while the variance is fixed to 1 and the mean 
is fixed to 0 (Purcell, 2013, Sham, 1998). This has the main advantage that the 
resulting distribution is standard normal, and has well-defined mathematical 
properties, which simplifies calculations during the twin modelling process.  
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3.6.1.1 Tetrachoric correlations  
The distribution of a given phenotype in one population can be described with a 
univariate standard normal distribution containing one threshold (see Figure 5). 
There are only two categories: ‘affected’ (1) and ‘unaffected’ (0). Each population 
has its own distribution and threshold. When examining the correlation between 
twins (e.g. between MZ T1 and MZ T2), two distributions, and two thresholds, need 
to be combined. This results in a joint bivariate normal distribution with four 
categories (T1 = 0, T2 = 0; T1 = 0, T2 = 1; T1 = 1, T2 = 0; and T1 = 1, T2 = 1), which 
represent the different combinations of disorder status (see Figure 6). The areas 
occupied by these four categories within the bivariate normal distribution represent 
the proportions of individuals in those categories.  
 
Figure 6. Tetrachoric correlations between twin pair populations. A slimmer ellipse 
and a stronger correlation are observed on the left, compared to a wide ellipse and a 
weaker correlation on the right. MZ twin correlations are usually expected to be 
higher than DZ correlations. 
The more twins are within the same disorder status category (T1= 1, T2 = 1 or T1= 
0, T2 = 0), the higher the correlation between twins. Visually, the degree of 
resemblance between relatives can be gleaned from the ‘fatness’ of the ellipse 
(Uebersax, 2015): the slimmer the ellipse, the more twin scores correspond to each 
other (T1 = 0, T2 = 0 and T1 = 1, T2 = 1), and the higher the correlation between 
 77 
twin 1 and twin 2 samples.  The ‘fatness’ of this ellipse is the so-called tetrachoric 
correlation (Uebersax, 2015) and is called rho (r*). Tetrachoric correlations were first 
introduced by Pearson (1900). Because the variances are 1 and therefore 
standardised for all twin populations, calculating the correlation is equal to 
calculating the covariance (Purcell, 2013).  
Figure 6 shows visual examples of how ellipses and correlations might be expected 
to differ between MZ and DZ twin pairs. While thresholds are expected to be the 
same, more MZ twins are expected to fall into corresponding categories, show a 
slimmer ellipse and therefore a higher correlation. 
3.6.1.2 SEM with binary data 
In OpenMx, maximum likelihood estimation is used to find values for the twin 1 
threshold, twin 2 threshold and r*. The aim is to estimate the parameters in a way 
that minimises the differences between the expected proportion of twins in the four 
categories, and in the one that is observed. Tetrachoric correlations are estimated 
separately for MZ and DZ twin populations. Once correlations have been obtained 
they are used in simultaneous equations to obtained estimates for h2, c2 and e2.  
One assumption made in calculating tetrachoric correlations using the bivariate 
normal distribution is bivariate normality (Sham, 1998). In other words, it is assumed 
that the underlying distribution is not significantly different from a normal distribution. 
While this assumption cannot be tested using binary data, the additional degrees of 
freedom afforded by adding further thresholds allows for this assumption to be tested 
(Sham, 1998).  
3.7 Assumptions and limitations 
The theoretical and mathematical concepts underlying twin modelling rely on a set of 
assumptions. Some have been mentioned in previous sections and will be outlined 
here in detail. None of the assumptions and accompanying limitations preclude twin 
analyses. However, it is important to be aware of them in order to accurately 
interpret results.  
 78 
3.7.1 The Equal Environments Assumption  
Increased similarity between MZ twins is assigned to genetic factors, because i) MZ 
twins share all of their genetic material, while DZ twins share approximately half, and 
ii) MZ and DZ twins are thought to be influenced equally by environmental factors 
(Rijksdijk & Sham, 2002). The latter statement is frequently referred to as the Equal 
Environments Assumption and states, in more general terms, that the environmental 
influence on similarity within a twin pair on a particular variable is independent of 
zygosity. This has been subject of considerable debate. MZ twins look more 
identical, are more likely to spend more time together, to have the same friends, to 
be treated alike by their parents, to visit the same classes and to dress similarly (e.g. 
Horwitz, Videon, Schmitz, & Davis, 2003; Loehlin & Nichols, 1976; Morris-Yates, 
Andrews, Howie, & Henderson, 1990).  
Critics have argued, therefore, that the environment of MZ twins may contribute 
more to their intra-twin similarity than the environment of DZ twins (Pam, Kemker, 
Ross, & Golden, 1996; Richardson & Norgate, 2005). Nevertheless, increased MZ 
similarity for certain environmental factors does not, in itself, present a violation of 
the EEA, since these may not impact the phenotype in question (Medland & Hatemi, 
2009). Furthermore, it is possible that increased environmental similarity between 
MZ twins may also be driven by increased genetic similarity (Lytton, 1977), in which 
case the variance component would be correctly assigned.  
With respect to psychological traits and disorders, several studies have attempted to 
estimate to what degree the Equal Environments Assumption holds true and twin 
model estimates are accurate. Although evidence is mixed (e.g. Clifford, Hopper, 
Fulker, Murray, & Rao, 1984; Horwitz et al., 2003), most studies do not find that 
evidence contraindicatory to the Equal Environments Assumption (Bouchard, 
Lykken, McGue, Segal, & Tellegen, 1990; Kendler, 1983; Kendler, Neale, Kessler, 
Heath, & Eaves, 1993, 1994; Loehlin & Nichols, 1976; Matheny, Wilson, & Dolan, 
1976; Morris-Yates et al., 1990; Plomin, Willerman, & Loehlin, 1976; Scarr & Carter-
Saltzman, 1979; Xian et al., 2000). In terms of MDD and cannabis dependence, no 
specific violations of the Equal Environments Assumption have been found (Kendler 
et al., 1993, 1994; Lynskey et al., 2002; Xian et al., 2000).  
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3.7.2 Assortative mating 
When individuals make their partner choices non-randomly, this is termed 
assortative mating. Non-random, in this context, means that partners would be found 
to share the same phenotype more often than expected by chance (Falconer & 
Mackay, 1996). This could be due to environmental or genetic influences (Falconer & 
Mackay, 1996), but for twin models it becomes particularly problematic if individuals 
select partners who are genotypically more similar to them. Twins models assume 
that DZ twins share, on average 50% of A. However, increasing the parental 
genotypic similarity means that DZ twins might share a higher amount of their 
segregating genes. This, in turn, would lead to a higher correlation between DZ 
twins, while leaving the MZ correlation unchanged. If this increase in DZ genetic 
similarity is left unaccounted for, the heritability of a phenotype would be 
underestimated (Rijsdijk & Sham, 2002).  
There is evidence for increased partner similarity and therefore assortative mating 
for MDD (e.g. Maes et al., 1998; Mathews & Reus, 2001) as well as CUD (e.g. 
Merikangas et al., 2009). However, it is unclear to what extent this is driven by 
genetic or environmental factors, and there is also the possibility that this similarity 
has developed due to social interaction after partner choice (Neale & Maes, 2004). 
Furthermore, Maes et al. (1998) estimate that the bias in twin studies for psychiatric 
disorders stemming from partner correlations would be minimal.  
3.7.3 Genotype-environment interplay  
In twin models it is usually assumed that individuals experience a random sample of 
environments (Neale & Maes, 2004) and that these are not correlated with genetic 
effects. Therefore, the formula to partition the phenotype σ2P = σ2G + σ2E  + 2Cov(G,E) 
is condensed to σ2P = σ2G + σ2E . However, individuals can create environments for 
themselves and share environments with related individuals, which leads to 
scenarios where genes and environments are correlated. Moreover, particular 
genotypes seem to modify an individual’s response to the environment, and 
therefore lead to genotype-environment interaction. These violations of a 
straightforward partition of σ2P into σ2G + σ2E are outlined below.  
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While the examples will refer to one phenotype at a time, the interplay between 
genotypes and environments can occur both within and between phenotypes 
(McAdams et al., 2014). 
3.7.3.1 Genotype-environment correlation (rGE) 
1.1.1.1.2 Passive genotype-environment correlation  
Passive rGE occurs because individuals share their home environment with people 
they are genetically related to (Neale & Maes, 2004). As an example, an individual’s 
depression levels could be influenced by the genes they inherit from their parents or 
a home environment that is conducive to depression (e.g. Murray & Cooper, 1997). 
This home environment may, in turn, be influenced by the parental genetic 
predisposition to depression (Neale & Maes, 2004). Therefore, the genes and 
environment that children receive from their parents could correlate for this particular 
phenotype (2Cov(G,E)), and seem to do so for mental health problems in general 
(Rutter & Quinton, 1984). Not taking this interaction into account will lead to biased 
estimates for the variance components. A positive correlation between the genotype 
and family environment will overestimate the influence of the family environment 
(Rijsdijk & Sham, 2002), whether it makes twins more alike or different (Rutter et al., 
2006). 
If individuals were adopted randomly, passive rGE related to the parental 
environment does not occur and can therefore be examined in adoption studies. 
Twin studies, which include non-adopted MZ and DZ twins and no further information 
on specific genes or environmental influences, do not control for passive rGE.  
Passive rGE can also be the result of sibling effects, as twins share genetic material, 
as well as their mutually influenced environment. Siblings can create environments 
for each other which can cause resemblance or dissimilarity. Such sibling effects 
may differ between MZ and DZ twins and increase the difference between both twin 
types to non-twins (Neale & Maes, 2004). The latter may affect the generalisability of 
twin data.  
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1.1.1.1.3 Active genotype-environment correlation  
In an active rGE, individuals actively invoke environments based on their genotype 
(McAdams et al., 2014). In other words, individuals will prefer environments based 
on their genotype when given the choice of multiple environments (Neale & Maes, 
2004). The degree of this choice may vary across cultures and circumstances and 
be one reason why heritability estimates vary by cohort.  
Cross-sectional twin studies are unable to differentiate between active rGE and other 
genotypic effects, which is why heritability estimates will be increased by positive 
correlations and decreased by negative correlations (Neale & Maes, 2004). MZ twins 
would be more likely to choose similar environments based on their increased 
genetic similarity if there is a positive active rGE, which would further contribute to an 
increased resemblance between them, and therefore a higher heritability estimate 
than that of DZ twins.  
3.7.3.2 Genotype-environment interaction (GxE) 
A genotype-environment interaction occurs when an individual’s genotype 
determines their response to the environment. This means that individuals can 
experience the same environment but react to it differently depending on their 
genotype. In the case of MDD, several studies have reported that certain genetic 
variants moderate the influence of stressful life events on the development of MDD 
(Caspi et al., 2003; Eley et al., 2004; Kendler, Kuhn, Vittum, Prescott, & Riley, 2005). 
There are also likely to be genotype-environment interactions between cannabis-
related genotypes and environmental factors, at the least because environmental 
exposure to drugs is necessary to develop CUD (Heath, Todorov, et al., 2002). 
However, molecular GxE analyses require cannabis-related genetic targets, and 
those are still in the process of being identified (Stringer et al., 2016).  
In twin studies, one can assess whether specific environments interact with genetic 
liability to a disorder by examining twins discordant for that disorder. If the co-twin of 
an affected twin (e.g. has MDD) is more likely to react (e.g. develop MDD) to an 
environment (e.g. stressful life event) than the co-twin of an unaffected twin, this 
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suggests GxE (see Kendler et al., 1995). One study showed that twins with a high 
genetic risk of developing MDD were more likely to do so following stressful life 
events than those at low risk (Kendler et al., 1995). However, when specific 
environments are not measured, GxE cannot be examined.  
If an interaction between the genotype and non-shared environment is left 
unaccounted for, this will be confounded with and lead to an inflated estimate of E 
(Heath, Todorov, et al., 2002; Rijsdijk & Sham, 2002), since the interaction does not 
contribute to twin co-variance (Heath, Todorov, et al., 2002). Interaction between the 
genotype and shared environment, on the other hand, is confounded with and will 
lead to inflated estimates of A (Heath, Todorov, et al., 2002; Rijsdijk & Sham, 2002), 
because MZ and DZ twins share the same amount of GxC interactions (100% for MZ 
and 50% for DZ twins), as genetic effects (Heath, Todorov, et al., 2002).  
3.7.4 Gene-gene interaction: epistasis and dominance  
In order to exert their effect, genes need to be transformed into proteins. The DNA 
within a gene is transcribed into a particular mRNA sequence, translated into a chain 
of amino acids and folded into proteins. These are the building blocks of the human 
body and can influence behaviour. This sequence of events, between DNA and 
proteins, can be affected by several factors which determine when, where and how it 
takes place. Epistasis is the influence of DNA segments in one location on the 
expression of DNA segments in another location, whether they do or do not code for 
proteins (Rutter et al., 2006). Dominance is such an interaction at the same genetic 
locus. Both are genotype-genotype interaction effects and, when present but not 
taken into account in a twin model, lead to the overestimation of heritability (Mackay, 
2014). This is, because MZ twins share more dominance and more epistasis effects 
than DZ twins, and therefore both are likely to contribute to an increased MZ 
similarity. However, in a standard ACE model, where neither is taken into account, 
this increased similarity will be attributed to A. Disorder-specific (e.g. in MDD; Schott 
et al., 2014) and non-specific epistasis are present and may explain difference 
between MZ and DZ twins, but these cannot be estimated in a twin model. 
Dominance can be estimated, and is included in twin models instead of C when the 
correlation between MZ twins is over twice the correlation between DZ twins. This 
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has the disadvantage that shared environmental effects are not estimated. 
Furthermore, it is likely that dominance contributes to an increased similarity 
between MZ twins even when their correlation is not twice the DZ correlation. Due to 
these limitations, it is important to remember that A in an ACE model is an estimate 
of broad-sense heritability, and includes all genetic effects, not just those inherited 
from the parents.  
3.7.5 Importance of assumptions and limitations 
The aforementioned assumptions and limitations are critical to take into 
consideration when interpreting twin study findings. However, the likelihood of 
violating these assumptions depends on the phenotypes studied. From previous 
literature, there is no reason to assume that applying twin model analses to MDD 
and CUD is likely to violate core assumptions of the twin design.  As reviewed in 
Chapter 1, several twin studies have been conducted on clinical definitions of both 






3.8 Application to MDD and CUD 
As previously stated, the overall objective of the thesis is to gain a clearer 
understanding of the co-morbidity between MDD and CUD by means of twin 
methodologies. This chapter illustrated that this methodology is suitable to the 
phenotypes in question, as it is suitable to psychiatric and quantitative phenotypes in 
general.  
The risk of developing MDD or CUD is likely to be continuous and influenced by 
multiple genes (see Section 3.2.1). Therefore, the variance of MDD and CUD in the 
population, as well as the covariance between them, can be decomposed into 
genetic and environmental factors.  
Having introduced the theoretical background, the following section will give an 
overview of the specific twin models applied to answer the research questions 
explored in this thesis:  
1. Bivariate threshold liability models will be used to obtain a clear picture of 
the extent to which environmental and genetic factors influence the variance 
within and covariance between MDD and CUD.  
2. Co-morbidity models by Neale and Kendler (1995) will be fit to examine 13 
possible aetiological mechanisms through which genetic and environmental 
factors may give rise to the co-morbidity between MDD and CUD.  
3.8.1 Bivariate threshold liability models  
Bivariate twin models aim to decompose the relationship between two variables into 
A, C/D and E, and will be discussed in Chapter 5. Estimates of the partial regression 
coefficients a, c/d and e indicate the relative impact of each latent factor on the 
variance in a single phenotype. Estimates of the correlation between the latent 
factors, rA, rC/rD and rE, indicate the impact of latent factors on the covariance 
between phenotypes.  
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Since models are fit to binary definitions of MDD and CUD, they are bivariate 
threshold liability models. This means that the decomposition of the variance of each 
phenotype into genetic and environmental factors is applied to the estimated 
univariate liability distributions of these phenotypes (illustrated in Figure 5), while the 
covariance decomposition is applied to the estimated bivariate liability distribution 
(illustrated in Figure 6). The path diagram summarising the relationship between two 
phenotypes for the whole study population (rather than by twin types, as shown in 
Figure 4) can be found in Figure 7. 
  
Figure 7. Bivariate threshold liability model for MDD and CUD. Partial regression 
coefficients are marked on single-headed arrows. Latent factor correlations are 
marked on double-headed arrows. The ACE model is used as example. 
As illustrated in Figure 7, bivariate models fit in this thesis are specified according to 
the correlated factors solution, which makes no assumption about the order in which 
individuals experience MDD or CUD. A correlation is estimated between genetic and 
environmental latent factors for both phenotypes (i.e. rA, rC/rD and rE), which can 
then be expressed as a proportion of the total phenotypic correlation, indicating the 
relative importance of those factors in the covariance between disorders. 
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3.8.1.1 Examining sex differences 
Extensions of the bivariate threshold liability model outlined in Neale, Røysamb and 
Jacobson (2006) can be used to examine whether sex differences are likely to be 
present and therefore need to be accounted for in the model. Two types of sex 
differences may present in the data: quantitative and qualitative.  
Quantitative sex differences exist when a phenotype is influenced by the same 
genetic and environmental latent factors in males and females, but to a different 
degree. Allowing separate regression and same-sex correlation paths for males and 
females can test the importance of quantitative sex differences. A model with 
separate paths (see Figure 8) is compared to a model where regression and same-
sex twin correlation paths are equated across sexes (see Figure 7). If model fit 
significantly deteriorates when regression paths and same-sex correlations are 
equated, quantitative sex differences need to be allowed for in the model.  
 
Figure 8. Bivariate threshold liability model with separate paths for males and 
females. The ACE model is used as example. 
Qualitative sex differences are said to be present if males and females are 
influenced by different latent factors. These sex differences can only be estimated 
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using the covariance between opposite-sex DZ (DZos) twins. If different latent 
factors influence a phenotype in each sex, then the correlations of those latent 
factors should be different in DZos twins from those one would usually specify for 
same-sex DZ twins. In other words, between-twin correlations for A, C and D would 
be significantly different from 0.5, 1 and 0.25, respectively. 
This can be tested by leaving latent factor correlations between DZos twins to be 
freely estimated and then comparing this specification to a model where they are 
fixed. If freely estimated DZos correlations significantly differ from those usually 
assumed for DZ same-sex twins, the fixed model should fit significantly worse and 
qualitative differences need to be taken into account in the model. Qualitative sex 
differences are tested separately for A, and C or D, as not enough information is 
present in the model to estimate more than one at a time. Since E does not 
contribute to the covariance, one can only test for qualitative sex differences in A,C 
or D.   
Further details on the rationale to examine sex differences and the results of these 
analyses will be found in Chapter 5.  
3.8.2 The Neale and Kendler co-morbidity models 
Co-morbidity models based on the work of Neale and Kendler (1995) and Klein and 
Riso (1993) examine 13 forms of co-morbidity, which were introduced in Section 
1.4.3 (Chapter 1), are described in detail in Chapter 6 and summarised in Table 12. 
Each model tests different assumptions about aetiological processes which may give 
rise to co-morbidity between two multifactorial disorders (i.e. disorders such as MDD 
and CUD, which are influenced by multiple genetic and environmental factors). They 
also provide information on the importance of A, C/D and E. The description in this 
chapter will focus on the mathematical approach to the co-morbidity models. 
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Table 12. Thirteen Neale and Kendler (1995) co-morbidity models and the questions 
these models aim to address. 
 
3.8.2.1 Co-morbidity model mathematical approach 
To illustrate the logic of the Neale and Kendler (1995) co-morbidity models, two 
models will be used: The alternate-forms model and the random multiformity model. 
The alternate-forms model assumes that two disorders (Disorders A and B in Figure 
9) are alternative expressions of the same liability distribution. After crossing a 
common threshold on this shared liability distribution (the probability of crossing the 
threshold is U), a proportion of individuals will experience disorder A (with the 
probability of p), others will experience disorder B (with the probability of r) and some 
will be co-morbid for both (with the probability p*r). The probabilities of an individual 
Model Question 
Single liability model  
1. Alternate Forms Alternate forms of the same disorder? 
Independent liability model  
2. Three Independent Disorders Co-morbid form is an independent  disorder? 
Multiformity models  
3.   Random Multiformity Abruptly increase symptoms of each other? 
4.       Random Multiformity of MDD MDD abruptly increases CUD symptoms? 
5.       Random Multiformity of CUD CUD abruptly increases MDD symptoms? 
6.   Extreme Multiformity CUD and MDD abruptly increase symptoms of each other in extreme cases? 
7.       Extreme Multiformity of MDD MDD abruptly increases CUD symptoms in extreme cases? 
8.       Extreme Multiformity of CUD CUD abruptly increases MDD symptoms in extreme cases? 
Correlated liabilities models  
9.     Correlated Liabilities Liabilities are correlated? 
10.    Reciprocal Causation CUD and MDD cause each other? 
11.    MDD causes CUD MDD causes CUD? 
12.    CUD causes MDD CUD causes MDD? 
13.    Chance Co-morbid due to chance? 
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not experiencing disorders A and/or B are 1 – p and 1 – r, respectively, when the 
threshold has been crossed. The probability of not having both disorders is 1 if the 
threshold has not been crossed (the probability of not crossing the threshold is L). 
 
Figure 9. Alternate-forms model schematic from Neale and Kendler (1995). The 
figure describes the probabilities of a single individual to have various disease 
statuses. The probability of having disorder A and B are expressed as p and r, 
respectively. R stands for the latent genetic and environmental risk factors affecting 
the shared liability of both disorders. Dashes above the letters denote being 
unaffected by a disorder. 
The likelihood of any disease status for an individual under the assumptions of the 
model can therefore be given in four equations, where P(A,B) is the likelihood of 
being affected by both disorders: 
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P(A,B) = L + (1 – p) (1 – r) U  
P(A,B) = r (1 – p) U 
P(A,B) = (1 – r)pU  
P(A,B) = prU 
In twin models, these equations are expanded to include the probability of disease 
statuses for two individuals (e.g. P(A1,B1,A2,B2)). Actual rates of individuals within 
twin disease categories are compared to the ones estimated given the assumptions 
of the model to determine model fit.  
Models can be compared with each other, because the calculations for disease 
status combinations between twins differ. If, for instance, the random multiformity 
model were a better fit to the data, the disease status likelihoods for an individual 
would be better expressed as: 
P(A,B) = LA* LB 
P(A,B) = (1 – r) LA* UB 
P(A,B) = UA *(1 – p) LB 
P(A,B) = UA * (UB + pLB) + rLA * UB 
This would mean that two separate liabilities for each disorder better account for the 
co-morbidity status of an individual (see Figure 10). All individuals who cross the 
threshold on the disorder-specific liability develop the disorder and a proportion of 
those also develop a co-morbidity. Here, p and r stand for the probability of 
developing Disorders A and B, respectively, when crossing the threshold on the 
liability of the other disorder. Under the Random Multiformity model, liabilities for 
both disorders are unrelated, but developing one disorder abruptly increases the 




Figure 10. Random Multiformity model schematic from Neale and Kendler (1995). 
The figure describes a single individual’s probabilities of having various disease 
statuses. The probability of having Disorder A and B are expressed as p and r, 
respectively. RA and RB stand for the latent genetic and environmental risk factors 
affecting the separate liabilities of both disorders. Dashes above letters denote being 
unaffected by a disorder.  
All models have differing formula for all possible co-morbidity statuses of twins. The 
assumptions of the best fitting model about the number of liabilities, thresholds and 
directions of causation allow the researcher to make inferences about the aetiology 
of the co-morbidity between Disorder A and B when model fits are compared.  
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3.9 Summary 
Individual differences on quantitative traits are influences by genetic (A and D) and 
environmental (C and E) factors. Twin model analyses – using structural equation 
models – decompose the variance of a trait into these factors. Twin model 
assumptions and limitations need to be taken into consideration when interpreting 
results.  MDD and CUD are quantitative phenotypes, i.e. influenced by large number 
of genes, and twin models can be used to estimate in how far their variances and 
covariance are influenced by genetic and environmental factors. Since both 
disorders are measured as binary variables, threshold liability models are the 
foundation for both bivariate and co-morbidity models, which will be presented in 
Chapters 5 and 6, respectively. 
  
 93 
4 Epidemiological Analyses 
 
4.1 Introduction 
The literature reviewed in Chapter 1 presents convincing evidence that cannabis 
involvement and depression co-occur. Most cross-sectional studies have found a 
significant association between various measures of cannabis involvement and 
depression (Degenhardt et al., 2012), while longitudinal studies observed the 
strongest links (aORs ranging from 1.78 (95% CI = 1.17 – 2.71) to 4.00 (95% CI = 
1.23–12.99)) between clinical levels of both (e.g. Bovasso, 2001; Marmorstein & 
Iacono, 2011; Pacek, Martins, & Crum, 2013).  
However, few cross-sectional and longitudinal studies so far have been conducted 
on MDD and CUD specifically, and many analyses on clinical levels of cannabis 
involvement and depression have not examined an extensive range of potential 
covariates. This may be explained by analyses being conducted with existing data 
which had not been collected to examine cannabis-related or depression-related 
variables originally. Incidentally, the longitudinal studies finding the strongest ORs 
between clinical levels of cannabis involvement and depression are among those 
that control for the fewest covariates (see study summaries in meta-analysis by  Lev-
Ran et al., 2014 and Pacek et al., 2013). Consequently, some large ORs reported 
may be an overestimation of the genuine co-morbidity.  
To address the limitations of previous studies, the aim of the current chapter is to 
establish whether CUD and MDD are co-morbid in a cohort of 3824 Australian twins 
and their non-twin siblings (see Section 2.1) and to what extent this co-morbidity is 
influenced by covariates. The influence of covariates will be demonstrated by the 
extent to which the overall association between MDD and CUD diminishes when 
covariates are accounted for. Additionally, the influence of individual covariates will 
be analysed and interpreted. Data analysed in this thesis has been collected for the 
purpose of examining cannabis-related research questions (Lynskey et al., 2012). 
Consequently, it is enriched for known covariates and is well-positioned to provide 
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an estimate of co-morbidity which is less likely to be confounded by unexamined 
covariates.   
The main aim of the current chapter is to report epidemiological analyses, which 
address two main questions: 
1. Is there a significant association between CUD and MDD in the twin 
sample examined in this thesis? 
2. What role do covariates play in this relationship? 
a. Which covariates influence CUD and MDD uniquely, which 
influence both disorders? 
For the first research question, a logistic regression model will be used to estimate 
the odds ratio between binary measures of DSM-5 CUD and MDD, controlling for 
age and sex only. Addressing the second aim will involve fitting a series of logistic 
regression analyses, again focused on CUD and MDD, but in which covariates 
significantly associated with cannabis involvement and/or depression in previous 
literature will be controlled for. These covariates include age, sex, family SES, other 
substance dependence (nicotine, alcohol and illicit drugs), conduct disorder, panic 
disorder, social phobia, childhood sexual abuse, death of a parent, having been 
raised by both parents, the excessive drinking of parents, disagreements with 
parents, parental problems, and peer drug use. The adjusted odds ratio (aOR) will 
be an indicator of the extent to which the relationship between CUD and MDD 
changes when known covariates are taken into account.  
Testing whether the association between CUD and MDD is significant in this cohort 
is not only a contribution to previous literature, but also plays a central role for 
subsequent twin model analyses in this thesis. Twin model analyses decompose the 
covariance between two phenotypes into genetic and environmental factors. 
Therefore, establishing whether there is a significant covariance between two 




This chapter outlines analyses on the Australian twin cohort which was 
comprehensively described in Section 2.1. The analysis sample consisted of 3824 
MZ and DZ twins, as well as their non-twin siblings, who were born between 1972 
and 1979.  
4.2.2 Measures 
4.2.2.1 Main variables  
Details on the definition and coding of the main variables of interest – CUD and MDD 
– can be found in Chapter 2. Briefly, MDD and CUD were coded as binary variables 
and according to DSM-V criteria as far as the information included in the SSAGA-OZ 
interview allowed.  
4.2.2.2 Covariates 
1.1.1.1.4 Choice of covariates  
To assemble a list of covariates for inclusion in the epidemiological analyses, studies 
reviewed in Chapter 1 were examined, in particular those which explored a variety of 
covariates in their analyses and reported adjusted and unadjusted ORs (see Table 
2). These ORs indicate to what extent the included covariates may mediate the 
relationship between CUD and MDD. Due to the heterogeneity of covariates tested 
in the literature, they were grouped into categories.  
The following categories were identified: 
- Demographic factors 
- Family or parental factors 
- Childhood behavioural problems (e.g. conduct problems) 
- Childhood trauma 
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- Other psychiatric/psychological problems 
- Other drug use/use disorders 
- Romantic relationships 
- Peer factors  
- Neighbourhood factors 
- Educational/work factors 
- Adolescent conduct problems and drug use 
- Personality/intelligence factors 
- General health and life satisfaction 
These categories were then mapped as closely as possible onto the covariate 
measures available in the current dataset. Only those items with information on the 
age of onset or items which likely occurred before the onset of CUD and MDD, i.e. in 
childhood or adolescence, were further considered. This was done to avoid over 
controlling for variables which may have been caused by rather than the cause of 
CUD or MDD, and which thus may lead to an underestimation of the true co-
morbidity. 
The selected covariates are summarised in Table 13. Not all categories identified in 
the literature could be matched with items present in the interview. This was either 
because items were unavailable, age of onset was not measured, or the variable 
was not likely to have occurred before the CUD and MDD ages of onset.  
For instance, none of the items assessed under the ‘romantic relationships’ category, 
such as marriage, divorce and separation were likely to, on average, occur before 
the age of onset of CUD. Therefore, no covariates pertaining to romantic 
relationships were assessed. Other examples are general health and work (e.g. 
employment status) factors. While questions on both were available in the interview 
and matched the categories identified from the literature, none asked about ages of 
onset in this dataset. If changes in physical health or employment status were 
consequences, rather than causes of depressive symptoms or cannabis 
involvement, including these in the model would have overcontrolled for covariates 
and possibly masked the relationship between CUD and MDD.  
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In addition to the variables presented in Table 13, ADHD and Agoraphobia were also 
initially considered. However, they were excluded, because the number of ADHD 
cases was low (N = 24) and Agoraphobia showed high collinearity with Panic 
Disorder.  
Similar to many other studies investigating the relationship between cannabis 
involvement and depression (e.g. Brook, Zhang, & Brook, 2011; Degenhardt et al., 
2013; Marmorstein & Iacono, 2011), most covariates were measured as either binary 
or ordinal variables. 
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Table 13. Covariates examined in the epidemiological analyses. 
Variable Question Age of Onset Type Sample Characteristics 
Demographics     
Age ‘How old are you now?’ 
 
- Continuous Min = 21 
Max= 46 
Gender ‘Male/Female’ - Binary Female = 2435 
Male = 1389 
Family SES  ‘Compared with the average family in 
your community when you were 6 to 
13, was your family financially better 
off, about average, or worse off during 
most of that time?’ 
 
6–13 Ordinal Better off = 618 
Average = 2687 
Worse off = 511 
Family/Parental     
Raised by both parents 
until age 16?  
‘Were you raised by both of your 
biological parents until age 16?’ 
 
<16 Binary Yes = 3149 
No = 674 
Disagreements with 
mother 
‘How often did you have an unpleasant 
disagreement or conflict with your 
mother (mother figure) between the 
ages of 6 to 13?’ 
 
6–13 Ordinal Often = 258 
Sometimes = 1155 
Rarely = 2005 
Never = 387 
Disagreements with 
father 
‘How often did you have an unpleasant 
disagreement or conflict with your 
father (father figure) between the 
ages of 6 to 13?’ 
 
6–13 Ordinal Often = 405 
Sometimes = 860 
Rarely = 1478 
Never = 861 
Parental fighting 
 
‘Between the ages of 6 to 13, how 
often did your parents (parent figures) 
fight or argue in front of you? 
 
6–13 Ordinal Never = 862 
Rarely = 1478 
Sometimes = 860 
Often = 405 
 99 




‘How much conflict and tension was 
there between your parents (parent 
figures) when you were 6 to 13?’ 
 
6–13 Ordinal A lot = 385  
Some = 641 
A little = 1384 
None = 1192  
Mother excessive 
drinking  
‘Do you now think your mother (mother 
figure) drank too much when you were 
6 to 13?’ 
 
6–13 Binary Yes = 138 
No = 2618 
Father excessive 
drinking  
‘Do you now think your father (father 
figure) drank too much when you were 
6 to 13?’ 
6–13 Binary Yes = 2581 
No = 623 
Mother strictness ‘In your opinion, when you were 6 to 
13, was your mother (mother figure) 
more strict than most mothers?’ 
 
6–13 Binary  No = 2577 
Yes = 1215 
Father strictness  ‘In your opinion, when you were 6 to 
13, was your father (father figure) 
more strict than most fathers?’ 
 
6–13 Binary No = 2337 








‘Was your mother (mother figure)/ 
father (father figure) pretty consistent 
about the rules, or was she more 
inconsistent, where she would make 
you follow a rule one day 
and forget about it the next?’ 
6–13 Binary No = 3456 
Yes = 339 
 
Father 6–13 Binary No = 3113 
Yes = 496 
Trauma     
Death of father  ‘Is your biological father still alive?’ 
 
‘How old were you when 
he died?’ 
 
Binary Before CUD or MDD onset 
No = 3571 
Yes = 195 
 
Lifetime 
No = 3456 
Yes = 322 
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Variable Question Age of Onset Type Sample Characteristics 
Death of mother   ‘Is your biological mother still alive?’ 
 
‘How old were you when 
she died?’ 
 
Binary Before CUD or MDD onset 
No = 3703 
Yes = 98 
 
Lifetime 
No = 3639 




‘Before age 18, were you ever forced 
into sexual intercourse or any other 
form of sexual activity?’ 
 
‘How old were you the 
first time you were forced 
into sexual activity?’ 
 
Binary Before CUD or MDD onset 
No = 3476 
Yes = 292 
 
Lifetime 
No = 3457 
Yes = 324 
Neighbourhood Factors    
School Safety ‘How safe was the school that you last 
attended?’ 
 
High school Ordinal Very unsafe = 69 
Somewhat unsafe = 188 
Pretty safe = 1337 
Very safe = 2224 
 
Peer factors     
Peer illegal drug use  ‘In your opinion, how many of the 
students who were in the same grade 
as you at the last high school you 
attended ever used illegal drugs such 
as marijuana while of high school age? 
 
High school Ordinal None = 185 
Just one or two = 444 
Just a few = 1545 
A quarter = 948 
Half = 413 
Three-quarters = 195 
Almost all = 49 
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Variable Question Age of Onset Type Sample Characteristics 
Peer alcohol use ‘In your opinion, how many of the 
students who were in the same grade 
as you ever used alcohol while of high 
school age?’ 
 
High school Ordinal None = 46 
Just one or two = 129 
Just a few = 569 
A quarter = 733 
Half = 857 
Three-quarters = 839  
Almost all = 638 
Peer cigarette use ‘How many of the students who were 
in the same grade as you ever smoked 
cigarettes while of high school age? 
 
High school Ordinal None = 33 
Just one or two = 195  
Just a few = 1311 
A quarter = 1274 
Half = 693 
Three-quarters = 241  
Almost all = 62 
Other drug use     
Nicotine Dependence  All individuals who reported smoking 
at least 100 times in their lifetime, 
were assessed on DSM-IV criteria of 
nicotine dependence. The binary 
response to the clustering question (3+ 
symptoms in a 12-month period) was 
used as the indicator of nicotine 
dependence in the analyses.  
Onset of any nicotine 
dependence symptom in 
DSM-IV questionnaire 
(SSAGA-OZ) 
Binary Before CUD or MDD onset 
No = 3059 
Yes = 749 
 
Lifetime 
No = 2845 
Yes = 976 
 
Alcohol Dependence  All individuals who reported drinking at 
least five drinks in a single day at least 
once, were assessed on DSM-IV 
criteria of alcohol dependence. Those 
reporting three or more symptoms 
occurring within a 12-month period 
were classified as meeting criteria for 
DSM-IV alcohol dependence. 
Onset of any alcohol 
dependence symptom in 
DSM-IV questionnaire 
(SSAGA-OZ) 
Binary Before CUD or MDD onset 
No = 3091 
Yes = 707 
 
Lifetime 
No = 2862 
Yes = 949 
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Variable Question Age of Onset Type Sample Characteristics 
Other illicit drug 
dependence 
All individuals who reported using any 
illicit drug (cocaine, stimulants, 
opiates, sedatives, hallucinogens, 
PCP, solvents, inhalants) at least 10 
times over their lifetime, were 
assessed on DSM-IV criteria of illicit 
drug dependence. Those reporting 3+ 
symptoms in a 12-month period were 
classified as meeting DSM-IC criteria 
for illicit drug dependence.  
Onset of any illicit drug 
dependence symptom in 
DSM-IV questionnaire 
(SSAGA-OZ) 
Binary Before CUD or MDD onset 
No = 3717 
Yes = 68 
 
Lifetime 
No = 3618 
Yes = 180 
Other psychiatric problems/childhood behavioural problems    
Social Phobia Social phobia was coded as present if 
participant met DSM-IV criteria 
(SSAGA-OZ) of social phobia (except 
for criterion F, which was not 





‘How old were you when 
you first began to: 
Avoid this situation or do 
it feeling very 
uncomfortable? 
[…] Feel 
extremely nervous or 
panicky right away in any 
of these situations?’ 
Binary  Before CUD or MDD onset 
No = 3266 
Yes = 505 
 
Lifetime 
No = 3198 
Yes = 586 
Panic Disorder Panic disorder was coded as present if 
participants met DSM-IV criteria 
(SSAGA-OZ) of panic disorder. 
Exclusion criteria were applied, except 
that not sufficient information was 
available to exclude cases that would 
be better accounted for by other 
psychiatric disorders.  
 
 
‘How old were you the 
first time you had one of 
these sudden 
attacks/sudden 
periods of physical 
discomfort along with four 




Binary  Before CUD or MDD onset 
No = 3707 
Yes = 64 
 
Lifetime 
No = 3642 
Yes = 142 
 
Conduct Disorder Individuals were assessed on DSM-IV 
Conduct Disorder criteria (SSAGA-OZ) 
before age 18 
‘How old were you the 
first time you did at least 
three of these things 
within the same 12-month 
period?’ 
 
Binary  Before CUD or MDD onset 
No = 3502 
Yes = 264 
 
Lifetime 
No = 3459 
Yes = 325 
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4.2.3 Statistical analyses 
4.2.3.1 Logistic regression analyses 
To assess the co-morbidity between MDD and CUD, and the influence of covariates 
on this relationship, several logistic regression models were conducted (see Chapter 
2 for a detailed description). The first model examined the OR between CUD and 
MDD and controlled for sex and age only. The second is a full model, controlling for 
all measured covariates. The third model only includes predictors at α <  0.1 
measured by backward selection. As outlined in Chapter 2, reducing the model also 
reduces the effect of multicollinearity, leading to more accurate estimates of standard 
errors. The second and third model were fit with CUD and MDD as outcome 
variables, to a) remain agnostic with regard to the direction of causation, and b) 
assess shared and unique influences of covariates. Statistical analyses were 
conducted in STATA (StataCorp, 2015) and the Huber-White correction was applied 
to account for family clustering. 
4.2.3.2 Controlling for age of onset 
As mentioned above, the regression models only aimed to control for factors which 
were likely to contribute to the onset of CUD and MDD and thereby explain their co-
occurrence. Since the average age of onset for CUD was 19.9 and for MDD 23.8, 
only childhood and adolescent factors or those variables which had a measured age 
of onset were controlled for. 
Variables which included age of onset information were only coded as ‘present’ if 
they occurred before the age of onset of CUD and MDD symptoms. As an example, 
if a participant met the criteria for nicotine dependence over their lifetime, they were 
coded as 1 (‘present’) only if the age of onset of their nicotine dependence was 
before the age of onset of their CUD and MDD. Cases where CUD or MDD criteria 
were met, but either age of onset was missing, were deleted from the analyses. 
Factors which did not have a defined age of onset were judged as to their likelihood 
of occurring before or after any onset of a CUD or MDD episode. Where a covariate 
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spanned a wider range of time, the variable was included to provide a conservative 
estimate of the adjusted OR between CUD and MDD. For instance, some individuals 
may have had a CUD onset as early as high school, which would overlap with the 
peer drug intake measures. However, observing peer drug use most likely happened 
before any CUD symptoms and certainly before the average age of CUD onset. 
The age of onset variable chosen for MDD was the onset of the most severe period 
of depression that did not start within two months of bereavement. It was also the 
age of onset variable that had the least missing data among individuals who met 
criteria for MDD (missing N = 1). The mean age of onset for this most severe period 
of depression was 23.82 years. A question about the age of onset alongside each 
MDD symptom check list would have been the preferred way to measure MDD 
onset, but was unavailable in the dataset.  
For CUD, the age of onset was available for each dependence criterion measured in 
the symptom checklist.  However, no age of onset was available for abuse criteria. 
Since there were 12 cases where the age of onset was unavailable, those may have 




4.3.1 The association between CUD and MDD adjusted for age and sex 
The results of a logistic regression with MDD as the outcome variable and CUD as 
the predictor are shown in Table 14. Age and sex are controlled for. The same OR 
would be estimated with CUD as the outcome and MDD as the predictor.  
Table 14. Prevalence of and odds ratios (95% confidence intervals) between MDD 
and CUD, controlled for age and sex. 




No CUD 88.19% 77.04% 
CUD 11.81% 22.96% 
4.3.2 Covariates associated with CUD or MDD 
After examining odds ratios between the variables of interest and all variables in the 
dataset that matched the categories extracted from previous studies, only those 
variables with a significant relationship with either variable of interest were kept for 
the logistic regression analyses. Table 15 shows the ORs between the covariates 
and both MDD and CUD. Note that not all variables presented in Table 13 are 
presented here. Firstly, only factors significantly associated with at least one variable 
of interest are shown. Secondly, several related variables were combined due to 
high and significant polychoric correlations between them, or to increase cell counts: 
a) ‘peer illegal drug’, ‘alcohol’ and ‘cigarette use’ were combined into a binary 
variable indicating ‘any peer drug use’; b) ‘death of father’ and ‘death of mother’ were 
combined into a binary ‘death of parent’ variable; c) ‘disagreements with mother’ and 
‘disagreements with father’ were also combined into ‘disagreements with parents’, 
with the same response options of ‘never’, ‘rarely’, ‘sometimes’ and ‘often’ as the 
original variables; d) ‘inconsistent parenting’ and ‘strict parenting’ were combined 
from binary variables specific to each parent, and the same response categories 
were kept. A ‘parental problems’ count variable was created from four binary 




Table 15. Unadjusted odds ratios (95% confidence intervals) between CUD, MDD 
and selected measures of demographic variables, family factors, childhood trauma, 


















Note. 1) “Better off” vs “Average”; 2) “Better off” vs “Worse off”; 3) “Never” vs “Rarely”; 4) “Never” vs 
“Sometimes”; 5) “Never” vs “Often”; 6-8) 0 vs 1-3; 9) “Very safe” vs “Pretty safe”, 10) “Very safe” vs 
“Somewhat/very unsafe” 
Variable OR MDD (95% CI) OR CUD (95% CI) 
Demographics     
Age 1.01 (0.99–1.04) 0.94 (0.91–0.98) 
Gender (male = 0, 
female = 1) 1.93 (1.62–2.29) 0.43 (0.36–0.53) 
Family SES   
0.94 (0.76–1.17)1  0.81 (0.63–1.05)1 
1.73 (1.32–2.27)2 0.86 (0.61–1.21)2 
Family/Parental     
Raised by both parents 




















drinking  1.64 (1.36–1.98) 1.20 (0.95–1.52) 
Trauma     
Death of parent  0.85 (0.62–1.17) 0.63 (0.40–0.98)    
Childhood Sexual Abuse 3.01 (2.35–3.85) 1.97 (1.46–2.65) 
Neighbourhood Factors     





Peer factors     
Any peer drug use  1.15 (0.92–1.44) 2.59 (1.80–3.73)    
Other drug use     
Nicotine Dependence  1.56 (1.31–1.87) 2.94 (2.42–3.57) 
Alcohol Dependence  1.24 (1.03–1.49) 1.34 (1.07–1.67) 
Other illicit drug 
dependence 2.01 (1.21–3.35) 3.55 (2.13–5.90) 
Other psychiatric problems     
Social Phobia 3.68 (3.03–4.47)  1.23 (0.94–1.61) 
Panic Disorder 5.42 (3.19–9.23) 1.85 (0.99–3.46) 
Conduct Disorder 2.22 (1.70–2.90) 6.22 (4.77–8.11) 
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4.3.2.1 Covariates associated with CUD and MDD 
Most covariates were independently associated with both phenotypes. Between the 
ages of 6 and 13, individuals with MDD and participants with CUD were more likely 
to have been raised by a single parent, to have had disagreements with both 
parents, and to have experienced higher levels of parental problems, which include 
parental fighting, conflict or tension, and above average strict or inconsistent 
parenting. Any drug dependence – nicotine, alcohol and illicit drugs – was more 
likely to occur in both groups, as was conduct disorder, childhood sexual abuse, and 
attending a school that was not self-rated as ‘very safe’. Finally, there are significant 
gender differences for both CUD and MDD. While men were more likely to 
experience CUD, women were more likely to meet criteria for MDD. 
4.3.2.2 Covariates associated only with MDD 
In addition to the above factors, individuals with MDD were also more likely to report 
being from a family that was ‘worse off’ financially and more likely to believe that 
their parents drank excessively when they were 6 to 13 years old. They also had 
higher odds of meeting criteria for social phobia and panic disorder. 
4.3.2.3 Covariates associated only with CUD  
Individuals with CUD were younger, and were more likely to report that their peers 
consumed illegal drugs, alcohol or cigarettes. Finally, participants who lost either 
parent before the onset of MDD and CUD were also significantly less likely to report 
CUD.  
4.3.3 Associations between CUD and MDD adjusted for covariates 
Given that multiple variables were associated with both phenotypes of interest, the 
aim of the following analyses is to assess, firstly, whether the co-morbidity between 
MDD and CUD stays statistically significant once covariates are considered. 
Secondly, the analyses examine which covariates play a particularly important role 
when all variables are assessed simultaneously.  
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4.3.3.1 Predictors of MDD 
4.3.3.2 Full Model 
The full model with MDD as an outcome shows that the OR between CUD and MDD 
remains statistically significant even after controlling for all covariates (see Table 16). 
Each level of an ordinal variable (e.g. parental problems) was treated as a separate 
variable by the model. Individuals with CUD have almost twice the odds of meeting 
the criteria for MDD (OR = 1.92 (95% CI = 1.52–2.42)). The Wald statistic indicates 
that the predictors significantly contribute to the model (Wald χ2(24) = 429.32, p = 
<.001), and they explain 12% of the variance of MDD (pseudo-R2 = .12). The mean 
VIF is 3.64. This is mainly driven by the large VIF for age (VIF = 27.01), which is 
highly correlated with many other variables in the model. No other variable had a VIF 
above 10. There are no clear cut-offs for VIFs which indicate problematic 
multicollinearity, but VIFs below 10 are often cited as acceptable (Field, Miles, & 
Field, 2012). 
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Table 16. Full multivariable regression model with odds ratios (95% confidence 
intervals) between selected predictors and Major Depressive Disorder (MDD).  
MDD Odds Ratio (95% CI) Robust SE p-value*  
Cannabis Use Disorder 1.92 (1.52–2.42) 0.12 <.001 
Age 1.02 (0.99–1.05) 0.01 .215 
Sex 1.92 (1.58–2.34) 0.10 <.001 
Family SES    
Average 1.01 (0.81–1.27) 0.12 .925 
Worse off 1.45 (1.08–1.95) 0.15 .014 
Nicotine Dependence 1.09 (0.89–1.35) 0.11 .402 
Alcohol Dependence 1.17 (0.94–1.45) 0.11 .152 
Illicit Drug Dependence 1.15 (0.64–2.08) 0.30 .645 
Conduct Disorder 1.47 (1.06–2.04) 0.17 .020 
Panic Disorder 3.03 (1.66–5.51) 0.31 <.001 
Social Phobia 2.86 (2.31–3.53) 0.11 <.001 
Raised by both parents 1.01 (0.80–1.26) 0.12 .966 
Excessive drinking parents 0.99 (0.80–1.23) 0.11 .945 
Childhood Sexual Abuse 1.70 (1.27–2.27) 0.15 <.001 
Death of parent 0.76 (0.54–1.08) 0.18 .131 
Disagreement with parents    
Rarely 1.01 (0.71–1.42) 0.18 .967 
Sometimes 1.24 (0.88–1.77) 0.18 .221 
Often 1.85 (1.24–2.76) 0.20 .002 
Parental Problems    
1 1.51 (1.20–1.90) 0.12 <.001 
2 2.19 (1.70–2.82) 0.13 <.001 
3 2.60 (1.84–3.66) 0.18 <.001 
School Safety    
Pretty safe 1.03 (0.86–1.22) 0.09 .776 
Very/somewhat unsafe 1.28 (0.92–1.77) 0.17 .138 
Peer drug use 1.02 (0.81–1.30) 0.12 .828 
Note. pseudo-R2 = .12, Wald χ2(24) = 429.32; *Bonferroni adjusted  
4.3.3.3 Backward regression 
The results of a backward regression with an inclusion p-value of .100 are presented 
in Table 17. The number of variables in the model was reduced from 24 to 12 and 
the Wald χ2 was statistically significant at p <.001. Approximately 12% of the 
variation in MDD was explained by the predictors in the model. The average VIF 
within this model was 1.45, with the maximum VIF being 2.16 for sex. This indicates 
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that standard errors are, on average, 1.45 times larger than if the predictors were not 
correlated.  
All predictors included in this model were significant at a Bonferroni-corrected 
theshold of 0.05. Bearing in mind the full list of possible predictors, demographic, 
family problems, and other psychopathologies were particularly strong predictors of 
MDD, as was childhood sexual abuse.  
Table 17. Odds ratios (95% confidence intervals) for significant predictors of Major 
Depressive Disorder (MDD) after backward regression. 
MDD Odds Ratio (95% CI) Robust SE p-value*  
Cannabis Use Disorder 1.96 (1.57–2.45) 0.12 <.001 
Sex 1.86 (1.53–2.26) 0.10 <.001 
Family SES    
Worse off 1.44 (1.15–1.80) 0.11 <.001 
Conduct Disorder 1.55 (1.13- 2.12) 0.16 .006 
Panic Disorder 3.12 (1.71–5.67) 0.30 <.001 
Social Phobia 2.87 (2.32–3.54) 0.11 <.001 
Disagreement with parents    
Sometimes 1.26 (1.05–1.52) 0.10 .015 
Often 1.88 (1.45–2.44) 0.13 <.001 
Parental Problems    
1 1.51 (1.20–1.90) 0.12 <.001 
2 2.22 (1.73–2.85) 0.13 <.001 
3 2.62 (1.88–3.67) 0.17 <.001 
Childhood Sexual Abuse 1.73 (1.30–2.30) 0.15 <.001 
Note. pseudo-R2 = .12, Wald χ2(12) = 415.61; *Bonferroni adjusted   
4.3.3.4 Predictors of CUD 
4.3.3.5 Full Model 
The full model with CUD as an outcome (see Table 18) also shows an approximately 
twofold increase in the odds of also meeting criteria for MDD (OR = 1.90, 95% CI = 
1.51 – 2.40). It explains approximately 15% of the variation in CUD and predictors 
significantly contribute to the model (Wald χ2(24) = 380.71, p = <.001). The average 
VIF was 3.65, mainly influenced by the large VIF for age (VIF = 27.00). No other 
variable exceeded a VIF of 10.   
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Table 18. Full multivariable regression model with odds ratios (95% confidence 
intervals) between selected predictors and Cannabis Use Disorder (CUD). 
CUD Odds Ratio (95% CI) Robust SE p-value*  
Major Depressive Disorder 1.90 (1.51–2.40) 0.12 <.001 
Age 0.94 (0.91–0.98) 0.02 .001 
Sex 0.37 (0.29–0.46) 0.12 <.001 
Family SES    
Average 0.99 (0.74–1.33) 0.15 .969 
Worse off 0.69 (0.47–1.03) 0.20 .069 
Nicotine Dependence 2.47 (1.97–3.10) 0.12 <.001 
Alcohol Dependence 0.72 (0.56–0.94) 0.13 .016 
Illicit Drug Dependence 1.91 (1.01–3.62) 0.33 .046 
Conduct Disorder 3.36 (2.47–4.58) 0.16 <.001 
Panic Disorder 0.97 (0.45–2.08) 0.39 .930 
Social Phobia 0.90 (0.66–1.24) 0.16 .524 
Raised by both parents 0.64 (0.48–0.84) 0.14 .002 
Excessive drinking parents 0.97 (0.73–1.29) 0.14 .852 
Childhood Sexual Abuse 1.78 (1.24–2.57) 0.19 .002 
Death of parent 0.57 (0.36–0.92) 0.24 .022 
Disagreement with parents    
Rarely 1.34 (0.81–2.22) 0.26 .252 
Sometimes 1.84 (1.11–3.07) 0.26 .018 
Often 2.09 (1.19–3.69) 0.29 .011 
Parental Problems    
1 1.25 (0.95–1.66) 0.14 .112 
2 1.21 (0.89–1.65) 0.16 .227 
3 1.30 (0.82–2.04) 0.23 .258 
School Safety    
Pretty safe 1.09 (0.87–1.35) 0.11 .453 
Very/somewhat unsafe 1.19 (0.81–1.75) 0.20 .379 
Peer drug use 2.18 (1.47–3.23) 0.20 <.001 
Note. pseudo-R2= .15, Wald χ2(24) = 380.71; *Bonferroni adjusted  
4.3.3.6 Significant Predictors of Cannabis Use Disorder 
The reduced model after backward selection included 14 predictors of CUD. It 
explained around 15% of the variance in CUD and was an adequate model (Wald 
χ2(12) = 370.06, p = <.001). The variance in CUD explained by the reduced model 
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was not smaller than that in the full model. The mean VIF for this model was 3.13, 
again largely due to the large VIF of age (VIF = 14.67). Somewhat higher VIFs were 
also found for peer drug use (VIF = 6.86) and being raised by both parents (VIF = 
6.39). Standard errors for these variables are likely to be inflated due to correlations 
with other predictors.  
All predictors in the reduced model are significant at a Bonferroni-corrected threshold 
of 0.05. Demographic, family and other drug use variables are particularly strong 
predictors of CUD, as are conduct disorder and childhood sexual abuse. Individuals 
with CUD are also less likely to report the death of a parent.  
Table 19. Odds ratios (95% confidence intervals) for significant predictors of 
Cannabis Use Disorder (CUD) after backward regression. 
CUD Odds Ratio (95% CI) Robust SE p-value*  
Major Depressive Disorder 1.92 (1.53–2.41) 0.12 <.001 
Age 0.94 (0.91–0.97) 0.02 .001 
Sex 0.37 (0.29–0.46) 0.12 <.001 
Family SES    
Worse off 0.70 (0.51–0.96) 0.16 .025 
Nicotine Dependence 2.50 (2.00–3.12) 0.11 <.001 
Alcohol Dependence 0.73 (0.56–0.94) 0.13 .016 
Illicit Drug Dependence 1.89 (1.01–3.56) 0.32 .048 
Conduct Disorder 3.44 (2.52–4.69) 0.16 <.001 
Raised by both parents 0.62 (0.47–0.82) 0.14 .001 
Disagreement with parents    
Sometimes 1.48 (1.19–1.86) 0.11 .001 
Often 1.72 (1.24–2.38) 0.17 .001 
Peer drug use 2.19 (1.48–3.24) 0.20 <.001 
Death of parent 0.57 (0.36–0.92) 0.24 .021 
Childhood Sexual Abuse 1.79 (1.24–2.60) 0.19 .002 




4.4.1 Association between CUD and MDD 
This chapter aimed to establish the co-morbidity between MDD and CUD in a 
sample of 3824 Australian twins and siblings, and to elucidate the role covariates 
play in this relationship. There are two principal findings that emerged from these 
analyses: 
1. When controlling for age and sex only, meeting criteria for one of the 
disorders increased the odds of the other by 2.23 times. 
2. These odds were not significantly diminished, indicated by overlapping 
confidence intervals of the adjusted and unadjusted associations, when a 
multitude of covariates predicting either phenotype were controlled for. After 
backward selection, the OR between CUD and MDD was 1.96 (with MDD as 
outcome) and 1.92 (with CUD as outcome). 
Overall, these results suggest that the CUD and MDD remain robustly associated in 
a large sample, despite controlling for an extensive range of covariates identified 
from previous literature.  
4.4.1.1 Shared covariates 
Although none of the covariates significantly attenuated the association between 
MDD and CUD, the somewhat attenuated OR may be due to several common 
covariates influencing the phenotypes of interest. After backward selection, 
disagreements with parents, having experienced childhood sexual abuse and 
meeting the criteria for conduct disorder significantly increased the likelihood of 
reporting both MDD and CUD. Sex and family SES also influenced both phenotypes 
significantly, however in opposite directions: males were more likely to report CUD, 
while females were more likely to report MDD. Additionally, individuals from families 
which were ‘worse off’ financially had significantly higher odds of reporting MDD, but 
were significantly less likely to meet criteria for CUD.  
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Controlling for these covariates may be necessary to obtain an accurate association 
between MDD and CUD, and the lack of controlling for them may explain the 
differences in ORs reported in previous cross-sectional and longitudinal studies. 
4.4.1.2 Unique covariates  
The analyses also highlighted a number of variables which uniquely influenced each 
phenotype. CUD was uniquely influenced by drug-related factors: nicotine, alcohol 
and illicit drug dependence, as well as peer drug use. Additionally, individuals with 
CUD were younger and less likely to be raised by both parents. Finally, CUD was 
less likely among individuals who had experienced the death of a parent. Meanwhile, 
individuals with MDD experienced significantly higher levels of parental problems, 
and were more likely to meet the criteria for social phobia and panic disorder. 
4.4.2 Integration of findings with previous literature and implications 
These results, tentatively, add evidence to the idea of a unique aetiological pathway 
between CUD and MDD, which cannot be fully explained by covariates. This 
conclusion is further supported by results from previous research that has employed 
a discordant twin approach in MZ twins, since all genetic (A and D) and shared 
environmental (C) factors are inherently controlled for. A discordant twin study of 
1874 MZ males found that twins with DSM-III-TR Major Depressive Disorder had 4.4 
(95% CI = 2.7–7.0) times higher odds of reporting DSM-III-TR cannabis 
abuse/dependence than their co-twins without MDD (Lin et al., 1996). A recent 
discordant twin study, including the current sample in addition to two other Australian 
twin cohorts, has found a significantly increased risk (OR = 1.72, 95% CI = 1.05–
2.82) of MDD in male and female twins who engaged in frequent cannabis use, 
compared to their co-twins who did not (Agrawal et al., 2017). A previous study by 
Lynskey et al. (2004) has not found a significant association between cannabis 
dependence and MDD in MZ twins. However, the analysed cohort in this previous 
study was also included in the larger discordant twin study, and the authors suggest 
that the absence of a significant OR may have been due to sample size issues. This 
is likely given that analyses can only be conducted on twin pairs discordant for both 
phenotypes, which will be a small sub-sample of twins. 
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As mentioned in Chapter 1, placing the current findings in the context of previous 
cross-sectional and longitudinal research is complicated by the heterogeneity of that 
literature. Studies have measured cannabis involvement and depression in various 
ways, controlled for different confounding variables and few studies having 
specifically examined CUD and MDD. Additionally, samples were taken from varying 
regions, ethnic makeups and age ranges. Variations in results therefore need to be 
interpreted bearing in mind these differences. These caveats aside, the current study 
results are compatible with several studies which were reviewed in Chapter 1 and 
have examined the association between clinical definitions of cannabis involvement 
and depression.  
Several cross-sectional and longitudinal studies found a significant association 
between clinical levels of cannabis involvement and depression which did not 
diminish with adjustment for covariates. Martins and Gorelick (2011) found that 
individuals with a lifetime history of a DSM-IV mood disorder (MDD, dysthymia, 
mania, hypomania) were 3.9 (aOR, 95% CI = 2.8–5.3, N = 43093) times more likely 
to meet criteria for lifetime DSM-IV cannabis abuse/dependence. Pacek et al. (2013) 
examined the bi-directional longitudinal association between MDD and CUD, where 
participants meeting the criteria for baseline CUD were significantly more likely to 
develop MDD in the following three years (OR = 2.02, 95% CI = 1.35–3.04, N = 
43093). This OR was reduced to 1.78 (95% CI = 1.17–2.71) when adjusted for 
demographic variables and family history of depression, but remained significant. 
Participants with baseline MDD showed similarly higher odds of developing CUD 
within three years (OR = 2.01, 95% CI = 1.09–3.68; aOR = 2.28, 95% CI = 1.28–
4.05). Bovasso (2001) reported a fourfold (aOR = 4.00, 95% CI = 1.23–12.97) 
increase in the odds of developing DSM-III-R depressive symptoms in individuals 
who reported DSM-III cannabis abuse approximately 15 years prior. Finally, 
Marmorstein and Iacono, (2011) reported an aOR of 2.54 (95% CI = 1.40–4.60) 
between DSM-III-R-based CUD at age 17 and DSM-III-R MDD within a 7-year 
follow-up period.  
However, several studies did not report significant co-morbidity in the first place, or 
found that it became non-significant after adjustment. To name some examples 
among the studies which have been reviewed in Chapter 1, a longitudinal study on 
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an adolescent sample did not find a significant relationship between DSM-IV 
Cannabis Abuse or Dependence and Major Depressive Disorder (Harder et al., 
2008), and Degenhardt et al. (2013) found no significant association between DSM-
IV Cannabis Dependence at ages 20 or 24 with MDD at age 29. Degenhardt et al. 
(2001) report an unadjusted OR of 2.88 (95% CI = 1.61–5.17, N = 10641) between 
DSM-IV Cannabis Abuse and DSM-IV Affective disorders (MDD, dysthymia, bipolar I 
and II), and of 2.85 (95% CI = 1.86–4.35) between Cannabis Dependence and 
Affective disorders, but these associations became non-significant when 
demographics and other drug use were adjusted for in the model.  
Overall, the current study results fall within the range of results found in previous 
twin, longitudinal and cross-sectional studies, and are compatible with the 
interpretation that there is a unique link between CUD and MDD which cannot fully 
be accounted for by covariates.  
Additionally, a cluster of childhood factors has been identified in the analyses, which 
could be the target of early interventions for the co-morbidity between MDD and 
CUD. Children who met criteria for conduct disorder, reported childhood sexual 
abuse and disagreed with their parents sometimes or often were more likely to meet 
the criteria for both disorders. These factors have been linked to both depression 
and cannabis involvement in the previous literature (see Table 2; Fergusson & 
Horwood, 1997; Hornor, 2009). Furthermore, both conduct disorder (Furlong et al., 
2013; Ogden & Hagen, 2008) and childhood sexual abuse (Fergusson, Lynskey, & 
Horwood, 1996; Putnam, 2018) may be linked to problematic parental behaviour. A 
recent Cochrane review has concluded that parent training has been shown to 
significantly reduce conduct problems in children (Furlong et al., 2013). Although 
parent-centred interventions to help prevent childhood sexual abuse have not yet 
been widely implemented, they are a promising area for research and practice 
(Mendelson & Letourneau, 2015). Providing parent training is not only beneficial for 
children, but also improves parental mental health (Furlong et al., 2013). 
Consequently, previous literature and findings from this thesis add evidence to 
support parenting interventions as a preventative measure for later mental health 
problems in general, and depression and cannabis-related problems in particular.  
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4.4.3 Strengths and limitations 
Data collection for the cohort of Australian twins was tailored around cannabis and 
cannabis-related variables, which allowed a comprehensive investigation of 
covariates in the current analyses. Although the data were retrospective (this and 
other strengths and limitations which apply to all analyses in this thesis will be 
discussed in Section 7.3), the age of onset was collected for many relevant 
covariates, allowing to mitigate the risk of controlling for variables which may have 
been the result of CUD or MDD.  
Nevertheless, epidemiological analyses on twin samples may need to be interpreted 
with some caution. Twins may differ from the general population in a number of 
ways. One example is an increased risk of obstetric complications (Kendler, Martin, 
Heath, & Eaves, 1995). However, studies on various measures of psychopathology, 
including depression, have not found significant differences in the rates of the 
examined disorders between twins and non-twins (Kendler, Martin, et al., 1995; 
Kendler, Pedersen, Farahmand, & Persson, 1996; Rutter & Redshaw, 1991). 
Additionally, the association reported in the current study is compatible with findings 
in non-twin populations. Therefore, the external validity of the conclusions in this 
chapter is not likely to be limited due to analysing twin data.  
An additional limitation in the analyses has resulted from the difficulty of matching 
variables in the dataset with some categories of variables – identified from previous 
literature – which were found to be related to cannabis involvement and depression. 
Matches with ages of onset before both CUD and MDD have been found for the 
majority of categories, but not all. Specifically, no variable related to ‘romantic 
relationships’, ‘educational/work factors’, ‘personality/intelligence’ or ‘general health 
and life satisfaction’ were included in the analyses. Although the dataset contained 
measures related to all these categories, divorces or having occupational difficulties, 
to mention two examples, were on average more likely to occur later than symptoms 
of CUD or MDD. The decision to exclude these additional variables may explain why 
the regression models, whether predicting CUD or MDD, explained a small portion of 
variance in the phenotype. This indicates that a more extensive inclusion of 
covariates would be important. However, the current sample required a trade-off 
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between including covariates comprehensively and including covariates that were 
likely to have occurred before the onset of either phenotype of interest.  A more 
accurate control for covariates would have been possible with a longitudinal sample. 
4.4.4 Conclusions and further analyses 
Results from the presented epidemiological analyses suggest that MDD and CUD 
are robustly associated in this cohort. More specifically, having one of the disorders 
increases the odds of having the other approximately twofold. Covariates which were 
most likely to reduce the unadjusted association were those which were significantly 
associated with both MDD and CUD. However, no covariates significantly attenuated 
the OR between the two disorders. 
A large section of the thesis is dedicated to twin model analyses, which decompose 
the covariance between CUD and MDD into genetic and environmental factors, and 
thereby inform the aetiology of this co-morbidity. However, twin models can only be 
fitted when it is established that the phenotypes of interest do significantly co-vary, 
which the current analyses have confirmed for this sample. Consequently, twin 
model analyses will be presented in the following chapters to examine the aetiology 
of the co-variance between the two phenotypes of interest.  
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5 Bivariate Twin Models of CUD and MDD  
5.1 Introduction 
Chapter 4 has established that the co-occurrence of Cannabis Use Disorder (CUD) 
and Major Depressive Disorder (MDD) was statistically significant in the current 
cohort of Australian twins, with an adjusted odds ratio of 1.92 (1.53–2.41; CUD as 
outcome) and 1.96 (1.57–2.45; MDD as outcome). This is in line with evidence from 
several twin, cross-sectional and longitudinal studies reviewed in Chapter 1. Despite 
consistent evidence of significant co-morbidity between MDD and CUD, there is 
limited understanding of the aetiological mechanisms underlying this relationship. 
Previous twin studies have not focused on the bivariate relationship between clinical 
levels of cannabis involvement and depression in general, and between MDD and 
CUD in particular. The twin model analyses presented in this chapter thoroughly 
examine the co-morbidity by focusing on genetic and environmental factors that 
might influence it.  
As described in Chapter 3, twin models decompose the variance within a phenotype 
and the covariance between phenotypes into genetic and environmental factors: 
additive genetic (A), dominant genetic (D), shared environmental (C) and non-shared 
environmental (E) factors. As discussed in Chapter 1 (see Table 3), previous 
research has suggested that variance of both MDD and CUD are influenced by 
genetic and environmental factors. Pinpointing the sources of covariance is an 
important step toward understanding the aetiology of the co-morbidity, and targeting 
prevention or intervention efforts efficiently.   
A bivariate correlated liabilities model was fitted to address two main aims: firstly, to 
ascertain which variance components influence CUD and MDD individually. The 
analyses examine whether the respective variances of both phenotypes are 
influenced by heritable factors in this cohort. This step is essential for establishing a 
link with previous literature and confirming that a behavioural genetic approach is 
appropriate to study the relationship between the phenotypes. The second aim is to 
examine how to what extent the covariance between the phenotypes can be 
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decomposed into genetic versus environmental factors. This will provide insight into 
the aetiological sources of their co-morbidity.  
To fit the appropriate model, several steps had to precede the final model fitting. One 
prerequisite of bivariate twin model analysis is the presence of sufficient covariance 
between two phenotypes. Therefore, the first step was confirming that CUD and 
MDD were significantly correlated. Based on the results in Chapter 4, within-twin 
correlations between the phenotypes were expected to be significant. The second 
step was to correctly specify the model parameters: it needed to be decided which 
variance components would be estimated and how sex differences would be 
accounted for in the model. The likely importance of variance components was 
determined from between-twin correlations. Since previous literature has reported 
sex differences for the prevalence of both MDD and clinical levels of cannabis 
involvement (Kessler et al., 2005, 1994), sex differences were assessed using sex 
limitation models. These models examine whether any quantitative or qualitative sex 
differences need to be considered in the model. If quantitative sex differences are 
present, the twin model needs to specify that the same latent factors influence both 
sexes, but to different degrees. In the case of qualitative sex differences, the twin 
model should specify that different genetic and environmental factors influence 
males and females.  Further details will be found in the methodology section. 
In addition to bivariate twin analyses, discordant twin analyses were conducted. Any 
genetic or environmental correlation found in bivariate twin analyses provides 
information on the source of co-morbidity, i.e. genetic or environmental factors, but 
remains agnostic about the process. As outlined in Chapter 1, discordant twin 
analyses can disprove causality as a potential process underlying the co-morbidity 
between CUD and MDD. Therefore, a conditional logistic regression of MZ twins 
discordant for CUD and MDD was conducted. A significant association between 
CUD and MDD in MZ twins would suggest that causal influences between CUD and 
MDD are possible and can be investigated in further twin model analyses. These 
analyses will also be the first discordant twin analyses on CUD and MDD in males 
and females, using DSM-5 definitions (although excluding craving for CUD) from a 
general population twin sample.  
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In summary, this chapter will: 
a) Test whether the covariance between CUD and MDD is significant, using 
phenotypic correlations within individuals;  
b) Choose the appropriate twin model by examining: 
a. Correlations between individuals as indicators of variance components 
which need to be included in the model (A,C,D,E); 
b. Sex limitation models as indicators of quantitative and qualitative sex 
differences which need to be included in the model. 
Once a significant covariance has been established and the appropriate twin model 
has been chosen, the main aims of this chapter are to: 
c. Determine which types of variance components significantly influence 
the variance and covariance of the phenotypes using nested sub-
models;  
d. Estimate the heritability of CUD and MDD 
e. Estimate the genetic and environmental correlations between the 
phenotypes; 
f. Examine the possibility of causal influences between MDD and CUD 





5.2 Methods  
5.2.1 Sample 
From a sample of 4131 twin pairs included in the Australian Twin Registry, 3824 
twins and non-twin siblings born between 1972 and 1979 were interviewed on 
cannabis use, related drug use and other psychopathology. For full details of the 
sample see Chapter 2 and Lynskey et al. (2012).  
After removing non-twin siblings and individuals of unknown zygosity, the analysis 
sample for the bivariate twin models comprised 3326 individuals: 976 monozygotic 
female (MZf), 490 monozygotic male (MZm), 741 dizygotic female (DZf), 373 
dizygotic male (DZm) and 746 dizygotic opposite-sex (DZos) twins. The analyses 
sample for discordant twin analyses comprised 63 MZ pairs who were discordant for 
both CUD and MDD. The mean age of the sample was 32 years. Informed consent 
was obtained from all individual participants included in the study. 
5.2.2 Measures  
MDD and CUD were assessed using DSM-IV criteria, and recoded into DSM-5 
variables as far as the available information allowed. Further details have been 
described in Chapter 2. In the analysis sample, 15.4% (11.9% of females, 22.6% of 
males) met the criteria for lifetime CUD and 26.1% (29.5% of females, 19.2% of 
males) met the criteria for lifetime MDD.  
5.2.3 Statistical analyses 
Data analysis for the bivariate correlated liabilities model was conducted using 
OpenMx (Neale et al., 2016) for R statistical software (R Core Team, 2014). 
Discordant twin analyses were performed in STATA (StataCorp, 2015).  
5.2.3.1 The bivariate correlated liabilities model  
This model has previous been introduced in Chapter 3 and will be described in 
further detail here. To estimate the heritability of both phenotypes and the genetic 
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and environmental correlations between them, a bivariate correlated liabilities model 
was fitted. The model contains separate latent genetic and environmental factors 
influencing each phenotype (see Figure 11). The heritability for CUD and MDD are 
estimated by the latent factor A, which is calculated by squaring the ‘a’ regression 
paths for each phenotype (‘a2’). The influence of other variance components is 
calculated by squaring their respective regression paths.  
The genetic and environmental covariance components (between phenotypes) are 
calculated as a product of all factor-specific paths connecting the phenotypes. As an 
example, the covariance due to A is found by the following calculation: a x rA x a. 
Here, rA is the correlation between genetic factors influencing CUD and those 
influencing MDD. 
 
Figure 11. Example of bivariate correlated liabilities model for CUD and MDD. No 
quantitative or qualitative sex differences are taken into account. 
Note.  Upper case latter (A,C/D,E)  = Latent additive genetic (A), shared environmental (C), 
dominance (D) and non-shared environmental (E) variance components 
Lower case letter (a,c/d,e)  = regression paths from latent variance component  to    
observed phenotype (CUD or MDD) 
 
 124 
5.2.3.2 Testing significance of covariance – tetrachoric correlations within 
individuals  
Twin models can only be fitted when there is sufficient covariance between 
phenotypes, which can then be decomposed into genetic and environmental factors. 
It is also necessary to establish the magnitude of this covariance, to calculate the 
proportion which is explained by A, C/D and E. Therefore, the phenotypic tetrachoric 
correlation between MDD and CUD was computed. Since the OR between MDD and 
CUD was significant even after adjusting for confounding factors (see Chapter 4) , it 
was expected that the tetrachoric correlation between the phenotypes would be 
significant. This correlation is computed between phenotypes within individuals. It 
was not expected that this within-person correlation would vary by zygosity, but a 
variation by sex was possible and would be an indicator of sex differences. 
5.2.3.3 Choosing the appropriate twin model 
Given a significant phenotypic within-person correlation in males and females, 
several parameters need to be specified before fitting the final model. Primarily, it 
was important to decide whether a) the covariance between traits was likely to be 
influenced by heritable factors, b) sex differences needed to be accounted for and c) 
C (shared environment) or D (dominance) should be estimated in the model.  
Prior to model fitting, the presence of sex differences and importance of variance 
components can be ascertained from between-person twin correlations. This 
informal initial assessment can be used to guide the selection of formal tests. Twin 
models informed by tetrachoric correlations are specified and then sub-models are 
tested formally to determine which sex differences and variance components should 
be included in the model most appropriate for the data.   
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5.2.3.4 Informal assessment of likely variance components and sex differences – 
Tetrachoric correlations between individuals   
Firstly, between-individual correlations indicate how likely a trait is to be heritable. If 
MZ correlations are higher than DZ correlations, the variance in a trait or covariance 
between traits is likely to be influenced by genetic factors.  
Secondly, these correlations provide evidence for the likely presence of sex 
differences. If male and female correlations differ or DZ opposite-sex twin 
correlations are lower than DZ same-sex correlations, this can indicate that sex 
differences are present in the sample and need to be examined. If there are 
differences in correlations between male and female same-sex twins, this suggests 
the presence of quantitative sex differences (Neale et al., 2006). If DZ opposite-sex 
correlations are lower than the correlations for DZ same-sex twins, males and 
females may be influenced by different factors and consequently display qualitative 
sex differences (Neale et al., 2006).   
Thirdly, tetrachoric correlations between individuals indicate whether C or D should 
be estimated in the model. As explained in Chapter 3, the limited availability of 
parameters for the model-fitting process only allows three variance components to 
be estimated at any time. This leads to the choice between C and D in the model. 
This choice is made by comparing MZ to DZ correlations. Should MZ correlations be 
more than twice the size of DZ correlations, this can only be accounted for by the 
influence of dominance genetic factors. Therefore, C is often omitted from the model 
to estimate D.  
Tetrachoric correlations within and between phenotypes for all zygosity groups were 
computed and all MZ and DZ correlations were compared to provide information on 
the issues above.  
5.2.3.5 Formally examining sex differences  
Formal tests of sex differences were examined based on the approach specified by 
Neale et al. (2006) and statistical details about the approach can be found in their 
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paper. Overall, it was examined whether two types of sex differences were present: 
quantitative and qualitative. Sex difference models were nested and compared to 
one another in terms of model fit. Further details were outlined in Chapter 3.  
5.2.3.6 Formally testing the significance of variance components 
The significance of variance components was tested formally by comparing model fit 
when each variance component was included in the model, to having a variance 
component fixed to zero. If model fit does not significantly deteriorate, the variance 
component fixed to zero is not thought to have a significant impact on the variance 
and/or covariance and was omitted from the model in the interest of parsimony. 
5.2.3.7 Discordant twin analyses 
As described in Chapter 2, discordant twin analyses were conducted using a 
conditional logistic regression. This regression is a form of logistic regression which 
allows for the matching of twins within a family. Consequently, the outcome of a 
conditional logistic regression is an OR between MDD and CUD within discordant 
twin pairs. The analyses only involved MZ twin pairs discordant for both MDD and 
CUD. Although MDD was analysed as the outcome and CUD as the predictor, any 
ordering of outcome or predictor would lead to the same result. Contrary to the 
bivariate twin models, sex and age did not need to be included as covariates, since 
they do not differ within twin pairs. 
5.3 Results 
5.3.1 The bivariate correlated liabilities model 
5.3.1.1 Tetrachoric correlations within individuals – confirming significance of 
covariance 
Tetrachoric correlations between MDD and CUD were examined within each 
individual, separately for males and females, in order to assess the magnitude of the 
relationship between the phenotypes, and to determine whether there are any sex 
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differences. These phenotypic correlations were r = .30 (95% CI = .21–.38) for 
females and r = .32 (95% CI = .21–.41) for males. These results indicated that there 
was sufficient covariance to decompose into genetic and environmental factors. The 
overlapping confidence intervals indicated that there were no sex differences in 
terms of the correlation between MDD and CUD within individuals.  
5.3.1.2 Tetrachoric correlations between individuals – choosing the most 
appropriate model 
In order to get an initial indication of the importance of different genetic and 
environmental factors, the importance of sex differences, and hence the appropriate 
twin model, within- and cross-trait tetrachoric correlations between twins of different 
zygosities were computed. 
Table 20. Tetrachoric correlations between CUD and MDD by zygosity. 
Zygosity CUD - CUD MDD - MDD CUD - MDD  
MZf .84 (.71–.91) .46 (.31–.60) .24 (.12–.37) 
DZf .50 (.26–.69) .08 (.04–.27) .15 (-.02–.31) 
MZm .70 (.48–.84) .43 (.12–.67) .15 (-.04–.33) 
DZm .42 (.11–.67) .24 (-.15–.57) .15 (-.10–.39) 
DZos .17 (-.07–.39) .22 (-.00–.43) .17 (.01–.20) 
Note.  CUD-CUD: correlation between twin 1 and twin 2 CUD 
 MDD-MDD: correlation between twin 1 and twin 2 MDD 
 CUD-MDD: cross-twin cross-trait correlation 
 
Table 20 shows the within-trait and cross-trait correlations between twins for MDD 
and CUD, by zygosity. The results in this table indicate: 
1.  For CUD, the differences in within-trait correlations between MZ and DZ twins 
suggest that A may explain a substantial portion of the variance in males (around 
58%) and females (around 68%). An ACE, rather than ADE model is likely to be 
most adequate, since neither MZf nor MZm correlations were over twice as large as 
the respective DZ correlations. The correlation between opposite sex DZ twins was 
 128 
somewhat, but not substantially, lower than the DZ same-sex correlation. This may 
be an indicator of qualitative sex differences in CUD.  
2. For MDD, A also seems to play an important role for males and females, possibly 
explaining around 38% and 76% of the variance, respectively. As the MZf within-trait 
correlation is substantially larger than two times the DZf correlation, an ADE model 
may be the more appropriate model for MDD. The correlations of DZ opposite sex 
twins were not significantly lower than those of same-sex twins, which indicated that 
qualitative sex differences may not play an important role with respect to MDD.  
3. The cross-twin cross-trait correlations for MDD and CUD indicate that additive 
genetic factors may influence the relationship between MDD and CUD in females, 
but not in males. The MZm and DZm correlations are equal. In females, A is not 
likely to play a substantial role, because confidence intervals between MZf and DZf 
twins are overlapping and the estimated portion of covariance explained by A would 
be 18%. 
Overall, an ACE model was fitted. Although the difference between MZf and DZf twin 
correlations for MDD was larger than two, all other correlations were suggestive of 
an ACE model. Furthermore, the results were indicative of possible sex differences, 
which were tested in the next step. 
5.3.1.3 Sex differences – formal tests  
Several sex limitation models were fitted, all of which were bivariate correlated 
liabilities models.  
Five different models were used to comprehensively examine quantitative and 
qualitative sex differences. Model 1 assumed quantitative sex differences for all 
variance components and qualitative sex differences for A. Model 2 estimated 
quantitative sex differences for all variance components and qualitative sex 
differences for C. Under model 3, only quantitative sex differences were estimated. 
Model 4 assumed no quantitative sex differences, i.e. all regression paths from the 
variance components to the phenotypes, and correlation paths between variance 
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components were equated across sexes. Model 5 tested whether thresholds could 
be equated for males and females. Model fit comparisons are summarised in Table 
21. 
Table 21. Model fit comparison between sex limitation models for CUD and MDD. 
Base Comparison EP Likelihood DF AIC P 
Model 1  30 6405.63 6564 -6722.37 - 
Model 1 Model 3 26 6405.96 6568 -6730.05 .988 
Model 2  30 6405.67 6564 -6722.33 - 
Model 2 Model 3 26 6405.96 6568 -6722.33 .991 
Model 3  26 6405.96 6568 -6730.05 - 
Model 3 Model 4 17 6414.30 6577 -6739.70 .499 
Model 4  17 6414.30 6577 -6739.70 - 
Model 4 Model 5 13 6511.85 6581 -6650.15 <.001 
The best fitting and most parsimonious model was model 4, which assumed 
differences in thresholds (i.e. prevalence), but no quantitative or qualitative sex 
differences.  
5.3.1.4 Variance components – formal tests   
Since estimates for shared environmental influences were low in model 4, an AE 
model was fitted to the data. Removing C from the model did not significantly 
deteriorate model fit (see Table 22).  
Table 22. Model comparison results between bivariate correlated liability models, 
with and without shared environmental factors (C). 
Base Comparison EP Likelihood DF AIC p 
ACE  17 6415.08 6577 -6738.92  
ACE AE 14 6415.08 6580 -6744.92 1 
In fact, the estimates of C were so small in the ACE model that the likelihoods of the 
ACE and AE model are identical. The resulting model is summarised in Figure 12. In 




Figure 12. Bivariate AE correlated liabilities model for CUD and MDD with 
regression coefficients and confidence intervals 
In the final model, genetic factors explained 77% (95% CI = 67%–85%) of the total 
variance in CUD, and non-shared environmental factors the remaining 23% (95% CI 
= 16%–27%). For MDD, genetic factors explained 42% (95% CI = 30%–54%) and 
non-shared environmental factors 58% (95% CI = 46%–69%) of the total variance. 
The genetic correlation between the two phenotypes was rg = .41 (95% CI = .24–.60) 
and the non-shared environmental correlation re = .19 (95% CI = -.05–.42). Genetic 
factors explained around 77% of the total phenotypic correlation.  
5.3.2 Discordant twin analyses 
A conditional logistic regression of MZ twin pairs discordant for CUD showed that MZ 
twins with CUD had significantly elevated rates of MDD (46.0%) relative to their co-
twins who did not have CUD (28.12%; OR = 2.83, 95% CI = 1.12–7.19; N = 63 MZ 












5.4.1 The bivariate correlated liabilities model 
The first aim of this chapter was to establish whether A, C/D or E  influence the 
variance of CUD and MDD. In the current cohort, heritability was estimated at 0.77 
for CUD and 0.42 for MDD. Aside from additive genetic factors (A), non-shared 
environmental (E), but not shared environmental (C) factors influenced the 
phenotype-specific variance. These results are in line with previous research for 
MDD (Kendler, Gatz, et al., 2006; Sullivan et al., 2000), and within the range of 
estimates obtained for Cannabis Abuse and Dependence (Kendler, Aggen, Tambs, 
& Reichborn-Kjennerud, 2006; Verweij et al., 2010).  
Establishing the genetic and environmental correlations between the phenotypes 
was the second aim, and these correlations were estimated to be 0.41 for the 
genetic factors and 0.19 for the non-shared environmental factors. In the most 
parsimonious model, shared environmental factors were not included. While the 
genetic correlation was statistically significant, the shared environmental correlation 
was not. The genetic correlation also explained most of the phenotypic correlation 
(77%), which suggests that the co-morbidity between CUD and MDD may be driven 
mostly by shared genetic factors. 
Additionally, in the current study no significant quantitative or qualitative sex 
differences emerged. The only sex differences found in the current analyses were 
with respect to prevalence of both MDD and CUD, which is consistent with previous 
literature (Kessler et al., 2005, 1994)  
Since this is the first study to examine a bivariate correlated liabilities model in CUD 
(with the exception of craving) and MDD, and report correlations for all genetic and 
environmental factors, there is limited twin literature with which these results can be 
compared. Fu et al. (2002) do not report the magnitude of the genetic correlation 
between MDD and cannabis dependence in their sample.  For lifetime cannabis 
dependence and MDD, Lynskey et al. (2004) report a genetic correlation of 0.44 
(95% CI = 0.17–1.00) for males and 0.69 (95% CI = 0.30–1.00) for females. The 
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current results are within the confidence interval for both. However, the current study 
looked at lifetime CUD, not cannabis dependence and is therefore not entirely 
comparable. To the best of the author’s knowledge, there are currently no other twin 
studies which have provided comparable twin estimates.  
It would be a valuable to compare the magnitude of the genetic correlation estimates 
from the bivariate twin study in this thesis with those estimated using molecular 
genetic data. Molecular genetic studies also suggest that there is significant genetic 
overlap between MDD and CUD (Carey et al., 2016; Demontis et al., 2018; Sherva 
et al., 2016), although they do not report on the magnitude of this association, only 
that it is significantly non-zero. While Hodgson et al. (2016) do report a genetic 
correlation (ρg = 0.42, p = .036, SE = 0.20), they looked at the relationship between 
lifetime cannabis use and MDD, not CUD and MDD. Given that large-scale 
genomewide association studies (GWAS) have been conducted for CUD and MDD 
already, a simple approach for estimating the magnitude of SNP-based genetic 
correlation would be to use a GWAS summary statistic based method such as LD-
Score Regression (Bulik-Sullivan, Finucane, et al., 2015; Bulik-Sullivan, Loh, et al., 
2015). Alternatively, with individual-level genetic and phenotypical data, the genetic 
correlation could be estimated using the GREML (genomic-relatedness-based 
restricted maximum-likelihood) method implemented in the software GCTA (genome-
wide complex trait analysis; Yang et al., 2010). Nonetheless, these previous 
genotype-based studies in combination with the findings in this thesis provide 
substantial evidence for a significant genetic correlation between CUD and MDD.  
Overall, the bivariate twin analyses suggest that CUD and MDD share overlapping 
genetic factors, which is a plausible explanation for their-co-morbidity: although the 
specific site is unknown, studies on humans and animals point toward the 
endocannabinoid system as a possible site of overlapping genetic vulnerability. As 
mentioned in Chapter 1, this is not only the primary site of the neurochemical effects 
of cannabis but is also thought to be involved in mood regulation (Ashton & Moore, 
2011). Several studies have linked the CB1 receptor, and its encoding gene CNR1, 
to both THC and mood regulation, (see Agrawal and Lynskey, 2014 for a review), 
making it a likely candidate for shared genetic vulnerabilities between CUD and 
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MDD. Additionally, overlapping genetic factors may be due to a genetically 
influenced covariates. 
5.4.1.1 Strengths and limitations 
The primary advantage of fitting a correlated liabilities model is its power to 
investigate the source of covariance between two phenotypes without presupposing 
a process underlying co-morbidity or any direction of effect. Different models, such 
as Cholesky decompositions used in one study on MDD and cannabis dependence 
(Fu et al., 2002) make assumptions about both sources and processes, because 
they require specifying a variable order (i.e. CUD before MDD or MDD before CUD). 
The estimates and interpretations of the model change depending on this variable 
order. In contrast, correlated liabilities model allow remaining agnostic about variable 
order and therefore the direction of any causal or non-causal effects.  
However, this means that correlated liabilities models cannot inform about the likely 
process of co-morbidity. Discordant twin models and analyses in Chapter 6, have 
been carried out to overcome this limitation. 
5.4.2 Discordant twin analyses 
Discordant twin analyses showed that causal processes could not be excluded as an 
explanation for the correlation between MDD and CUD, because MZ twins with CUD 
were significantly more likely to display symptoms of MDD than their co-twins without 
CUD. Therefore, there is sufficient reason to continue exploring causality in further 
analyses. The results are in contrast to study results in Lynskey et al. (2004) and in 
line with those in Lin et al. (1996), but overall they are not entirely comparable to 
either due to differences in variable definitions and samples. 
Discordant twin results are difficult to interpret due to the small number of MZ twin 
pairs discordant for both CUD and MDD. The sample size is characteristic of 
analyses on single cohorts, because – even in large cohorts – twin pairs discordant 
for both phenotypes are rare. For example, Lynskey et al.'s (2004) analysis sample 
comprised 87 twin pairs when they examined the association between MDD before 
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age 17 on later onset cannabis dependence. The vast reduction from total to 
analysis sample occurs because twins need to be discordant for both phenotypes.  
To conclusively examine whether causal processes can be excluded using the 
discordant twin method, larger sample sizes would be particularly critical with this 
type of analysis. A recent study by Agrawal et al. (2017) has been conducted on a 
large sample of twins, but the results cannot be compared as the current cohort was 
included in their analyses and they investigated frequent cannabis use (more than 
100 times used) rather than clinical definitions. For the purposes of the current study, 
the main intention was establishing that causal processes could not be ruled out 
within the current data set. 
5.4.3 Conclusion and further analyses 
In conclusion, overlapping genetic risk factors between CUD and MDD are both a 
plausible explanation of co-morbidity and have been found in the current study, as 
well as others. The correlated liabilities model fitted in the presented analyses is a 
model which is agnostic toward the specific process by which genetic factors 
contribute to the co-morbidity. Overlapping risk factors may mean that these risk 
factors simultaneously give rise to both CUD and MDD, but there are various other 
possible mechanisms. Discordant twin analyses suggested that causal mechanisms 
may be among them. Thirteen of those aetiological mechanisms, including but not 









6 Co-morbidity models of CUD and MDD 
6.1 Introduction 
The previous results chapters have demonstrated that Major Depressive Disorder 
(MDD) and Cannabis Use Disorder (CUD) are significantly co-morbid in this sample 
(OR = 2.23, 95% CI = 1.84–2.70), may be causally related and their covariance is 
primarily explained by overlapping genetic factors (r = .41, 95% CI = .24–.60). 
However, the aetiological processes by which these factors influence the co-morbidity 
remain unclear. This chapter aims to comprehensively investigate competing models 
of co-morbidity and will fit Neale and Kendler’s (NK; 1995) 13 co-morbidity models, 
which were based on the work of Klein and Riso (1993). Each model and each class 
of models makes different assumptions about the aetiological mechanisms that lead to 
co-morbidity. Four broad classes are examined: single liability, independent liability, 
multiformity and correlated liabilities. No other twin model approach examines such a 
large variety of model classes.  
If the co-morbid form arises from a single liability shared by CUD and MDD, the 
diagnostic boundary between MDD and CUD may have been artificially drawn, and 
they could be alternate forms of the same disorder. This model is not likely to explain 
the co-morbidity between MDD and CUD well, because it assumes a full overlap 
between the disorders. If this was the case, one would expect a much higher rate of 
co-morbidity found in this and other samples, and a significantly stronger genetic 
correlation between the disorders in the bivariate twin model (Chapter 5).  
Alternatively, the liability of the co-morbid form may be entirely independent, and ‘co-
morbid CUD and MDD’ could be a third disorder, unrelated to the pure forms of MDD 
and CUD. This model may not be a likely explanation for the observed co-morbidity 
either, since it assumes that the liabilities of MDD and CUD, in their pure form, are 
entirely unrelated. Given the likely overlap in neurobiology responsible for mood 
regulation and the psychoactive effects of cannabis (see Chapter 1) , this model is 
unlikely to be supported by the data. 
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Multiformity models suggest that the risk factors for CUD and MDD are unrelated, but 
once certain thresholds on the liability of one disorder are crossed, the risk of 
symptoms of the other disorder increases sharply. In other words, MDD and CUD 
influence each other in a discontinuous way, only once certain levels of risk are 
reached. This sudden increase in co-morbidity at high levels of risk is compatible with 
findings from longitudinal studies, which produce mixed results when examining non-
clinical definitions of cannabis involvement and depression, but report the highest 
associations between clinical levels of both (Bovasso, 2001; Lev-Ran et al., 2014; 
Marmorstein & Iacono, 2011; Pacek et al., 2013). Multiformity models are therefore 
plausible for CUD and MDD. 
Correlated liabilities models assume that liabilities between two disorders are related 
continuously, and aetiological factors overlap. Any change in risk for one disorder is 
accompanied by a change in risk for the other disorder, whether this is due to shared 
risk factors or causality. Correlated liabilities models without the assumption of 
causality are likely to fit the data well, since they are similar to those fit in Chapter 5. 
Since discordant twin analyses suggest that causal influences between CUD and 
MDD are possible, causal models may also fit the observed data well.  
In addition, the models test whether the co-morbidity observed in the population has 
occurred by chance.  
The NK co-morbidity models have been used to examine the co-morbidity  between a 
range of other substance-use and psychiatric phenotypes (Agrawal et al., 2007, 2004, 
2010). To mention one applied example of these twin models, Agrawal et al. (2007) 
investigated the ‘gateway hypothesis’, according to which cannabis use precedes and 
increases the risk of other illicit drug use (Kandel, Yamaguchi, & Chen, 1992). After 
fitting all 13 models to a sample of 4152 Australian twins, the correlated liabilities 
model provided the best fit to the data, with both genetic and environmental factors 
being highly correlated between cannabis and illicit drug use. This result suggests that 
cannabis and other illicit drug use co-occur due to shared risk factors influencing both. 
However, both the reciprocal causation and unidirectional causation (cannabis use 
causes other illicit drug use) models fit the data well. Consequently, some causal 
influence could not be excluded, and there was evidence for the gateway hypothesis 
(i.e. cannabis use causing other illicit drug use). This conclusion is supported by the 
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finding that high-risk female users of cannabis were at an increased likelihood to use 
other illicit drugs, irrespective of their individual liability to use other illicit drugs 
(extreme multiformity of cannabis use). In summary, this study has highlighted sex 
differences and strongly narrowed down the range of possible forms of co-morbidity 
between cannabis and other illicit drug involvement. Further genetic models can be 
applied to differentiate between the highlighted models.  
Previous literature suggests that twin models of co-morbidity would also be a useful 
tool to study the relationship between cannabis involvement and depression (Agrawal 
& Lynskey, 2014), since both MDD (e.g. Sullivan et al. 2000; Kendler et al. 2006) and 
cannabis dependence (Lynskey et al., 2002; Verweij et al., 2010) are influenced by 
genetic factors. Chapter 5 has demonstrated that this holds true for MDD and CUD in 
this sample as well.  
To date, no study has examined all 13 models with respect to MDD and CUD, 
although previous longitudinal and twin studies have produced conflicting findings 
regarding the relationship between these phenotypes. Therefore, analyses in the 
current chapter aimed to fit all 13 NK co-morbidity models to examine the relationship 
between CUD and MDD.  
6.2 Methods 
6.2.1 Participants 
The sample has been described in detail in Chapter 2. The analyses presented in this 
chapter were conducted on twins only and required complete data from each twin pair 
for both phenotypes. The sample size is therefore somewhat different from that of 
previous chapters: 2410 individual twins were included in the analysis sample, 565 
(396 female, 169 male) complete MZ pairs and 640 (298 female-female, 118 male-
male and 224 female-male) complete DZ twin pairs.  
6.2.2 Measures 
MDD and CUD were assessed using DSM-IV criteria, and recoded into DSM-5 
variables as far as the available information allowed: the definition of CUD included all 
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DSM-5 criteria except for craving. Further details have been described in Chapter 2. In 
the analysis sample, 14.75% individuals met the criteria for lifetime CUD and 25.55% 
met the criteria for lifetime MDD.  
6.2.3 Statistical models 
A summary of all models can be found in Table 23. Each model makes different 
assumptions about the way in which co-morbid cases arise. A detailed statistical 
discussion of the models can be found in Chapter 3,  as well as in Neale and Kendler 
(1995) and Rhee et al. (2004). This chapter aims to provide an explanation specifically 




Table 23. Summary and interpretation of Neale and Kendler (1995) models of co-
morbidity. 








Single liability: after crossing a common threshold, some develop 









The pure forms are unrelated disorders. There are three independent 
liabilities for CUD, MDD and co-morbid CUD with MDD.  
 
 Multiformity   
The liabilities for CUD and MDD are unrelated. CUD discontinuously 
increases the risk of MDD symptoms, and vice versa when 
thresholds are crossed. Random multiformity assumes one, extreme 















Assumes a single threshold within one disorder (e.g. CUD), above 
which the risk to develop symptoms of the other disorder (e.g. MDD) 
suddenly increases. This model allows for both disorders to increase 
the risk of symptoms of the other.  
  
4   RM of MDD   
Being above the threshold for MDD risk leads to a sudden increase 
in risk for symptoms of CUD, even when below the threshold for 
CUD.  
5   RM of CUD  
Being above the threshold for CUD risk leads to a sudden increase 







There are two distinct thresholds for both disorders. Crossing the first 
threshold leads to the pure form of a disorder. The second threshold 
allows for individuals with high amounts of risk factors. Individuals will 
be at increased risk for symptoms if they are above the second 




EM of MDD 
  
Being above the first threshold for MDD risk only leads to MDD. A 
proportion of high-risk individuals with MDD (above the second 
threshold) develop CUD symptoms, even when below the first 




EM of CUD 
  
Being above the first threshold for CUD risk only leads to CUD. A 
proportion of high-risk individuals with CUD (above the second 
threshold) have MDD symptoms, even when below the first threshold 
for MDD risk.  
9 Correlated liabilities  
Correlation between latent genetic and environmental influences on 
CUD and MDD gives rise to co-morbidity. 
10   Reciprocal Causation  
The liability for CUD has causal influence on the liability for MDD, and 
vice versa. 




The liability for MDD has a causal influence on the liability for CUD.  
12 
  
  Unidirectional: CUD to MDD  
The liability for CUD has causal influence on the liability for MDD. 
  
13   Chance  Co-morbid CUD and MDD occur due to chance alone.  
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Because both phenotypes were coded as binary variables, the foundation of each co-
morbidity model was a normal liability threshold model, similar to that in Chapter 5. 
Similar to widely used liability threshold models, all models estimate genetic (A), 
shared (C) and non-shared environmental (E) factors. D was not estimated in the 
current sample, because the difference between MZ and DZ correlations indicated an 
ACE model. The rationale for this decision was based on between-person correlations, 
and explained in Chapter 3. Despite these similarities, there are several important 
differences between models:  
1. The models differ in the number of liability distributions they assume. For 
instance, the alternate forms model assumes that both phenotypes arise from 
one distribution of liability.  In contrast, the three independent disorders model 
assumes that there are three underlying liability distributions. Two of those give 
rise to the pure forms of the phenotypes, and one gives rise to the co-morbid 
form.  
2. The models differ in the way in which the above-mentioned liabilities produce 
the phenotype. For example, in the alternate forms model, an individual 
develops co-morbid CUD and MDD by crossing the threshold on the shared 
liability distribution. However, in the three independent disorders model, an 
individual can develop CUD and MDD if they cross the threshold on the CUD-
specific and MDD-specific distribution at the same time, or if they do so on the 
liability distribution for the co-morbid form.  
3. The extreme multiformity model also differs from all others in the number of 
thresholds it assumes. Under the assumptions of this model, each liability 
distribution has two thresholds. If an individual crosses the first threshold, they 
only develop the pure form of the disorder. Crossing the second threshold 
means that the individual develops the co-morbid form. Consequently, co-
morbidity arises if an individual crosses the first threshold on both liability 
distributions, the second threshold on one liability distribution (e.g. CUD), 
and/or the other distribution (e.g. MDD).  
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6.2.4 Data analysis 
Data analysis was conducted using OpenMx (Neale et al., 2016) for R statistical 
software (R Core Team, 2014). The input to each model was a frequency table, which 
summarised the number of twin pairs fitting into 10 MDD-CUD co-morbidity categories 
(see Table 24). Each twin pair member was assigned to one of four disease state 
categories: MDD but no CUD (i.e. 1 0), no MDD, but CUD (i.e. 0 1), both MDD and 
CUD (i.e. 1 1), and neither (i.e. 0 0). Thereafter, the twin disease states were 
combined (i.e. 0 0 0 1). Although there are 16 different combinations of co-twin 
disease states, information about twin order was disregarded to avoid low cell counts. 
For instance, ‘0 0 1 0’ (see Table 24) is a category that contains cases where twin 1 
only (i.e. 1 0 0 0) or twin 2 only (i.e. 0 0 1 0) was affected by MDD. Subsuming all 
replicating disease states resulted in 10 categories.  
Table 24. Numbers of twin pairs in co-morbidity status categories. Used as input for all 
co-morbidity models. 
            Twin 1         Twin 2 MZ DZ 
        MDD CUD    MDD CUD   
1.      0a       0         0       0  298 277 
2.        0        0         0       1b 28 73 
3.        0        0         1       0 114 145 
4.        0        0         1       1 17 35 
5.        0        1         0       1 16 10 
6.        0        1         1       0 6 21 
7.        0        1         1       1 16 23 
8.        1        0         1       0 47 33 
9.        1        0         1       1 12 18 
10.      1        1         1       1 11 5 
Total  565 640 
a 0 = unaffected  
b 1 = affected  
For every model, the number of twin pairs expected in each of the 10 categories was 
based on the assumptions of the model. Maximum likelihood estimation was used to 
minimise the difference between the observed number of cases in each co-morbidity 
category and the expected number according to the model. A chi-squared goodness-
of-fit (χ2) test compared these observed and expected values and indicated model fit. 
The p-value of the χ2 test was used to reject models whose predicted data was 
significantly different from the observed data. The best fitting and most parsimonious 
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model was chosen based on the Akaike Information Criterion (AIC; Akaike 1987). 
According to Burnham and Anderson (2002), an AIC difference of three or greater 
indicates that the model with the lower AIC has substantially more support.   
6.3 Results 
The model-fitting results are summarised in Table 25. In addition to the 13 co-
morbidity models, a saturated model (model containing an equal number of 
parameters and data points) based on twin correlations was included for comparison. 
Five models can be rejected due to the large, statistically significant differences 
between the observed cell counts within the co-morbidity categories (see Table 24) 
and the cell counts expected under the chance, alternate forms, three independent 
disorders, RM of MDD, and EM of MDD models. 
Table 25. Co-morbidity model fit statistics, indicating fit of each model and differences 
between cell counts predicted under the model and observed call counts 
The only models that do not have substantially less support than the saturated model 
(i.e. an AIC difference larger than 3) are the RM of CUD model (model 5) and the CUD 
causes MDD model (model 12; see Figure 13a and b), with AIC differences of 2.30 
and 2.34 respectively. Both models have substantially more support than the 
correlated liabilities model. 
 
Model χ2  Df p AIC 
Saturated Model 13.16 11 .283 -8.84 
1.   Alternate Forms 96.31 14 <.001 68.31 
2. Three Indep. Disorders 32.90 8 <.001 16.90 
3.   Random Multiformity 15.10 10 .129 -4.90 
4.       RM of MDD 27.04 11 .004 5.04 
5.       RM of CUD 15.46 11 .162 -6.54 
6.   Extreme Multiformity 16.32 10 .091 -3.68 
7.       EM of MDD 28.23 11 .003 6.23 
8.       EM of CUD 19.50 11 .053 -2.50 
9.   Correlated Liabilities 15.21 9 .085 -2.79 
10.    Reciprocal Causation 15.23 10 .124 -4.77 
11.    MDD causes CUD 17.86 11 .085 -4.14 
12.    CUD causes MDD 15.50 11 .161 -6.50 
13.    Chance 59.46 12 <.001 35.46 
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1a. Random Multiformity of CUD      1b. Causation – CUD causes MDD 
   
Figure 13a and b. Parameter estimates from best fitting co-morbidity models: 
Random Multiformity of CUD and CUD causes MDD. 
Note.  r = probability of MDD phenotype if above threshold on CUD liability 
        iCUD = regression coefficient 
            * = significant at the 0.05 level 
These two best fitting models are, however, not substantially different from some of 
the models within their class. The RM of CUD model is not substantially different from 
the Random Multiformity model. The CUD causes MDD model is not substantially 
different from the MDD causes CUD and Reciprocal Causation model. Additionally, 
both models do not substantially differ from the Extreme Multiformity model.  
In the best fitting models both CUD and MDD are influenced by genetic and non-
shared environmental factors. In the case of CUD, 79–80% of the total variance is 
estimated to be explained by genetic factors and 20–21% by non-shared 
environmental factors. For MDD, 43–48% of the total variance is explained by genetic 
factors, and 52–57% by non-shared environmental factors. Model fit did not 
significantly deteriorate when C was dropped from both models. The parameter 




Table 26. Parameter estimates of all co-morbidity models for MDD and CUD. 
 Model 
 1 2 3 4 5 6 7 
a2MDD - .46 (.23 - .56) .48 (.20 - .60) .46 (.23 - .57) .48 (.19 - .60) .48 (.17 - .59) .46 (.23 - .56) 
c2MDD - .00 (.00 - .17) .00 (.00 - .22) .00 (.00 - .17) .00 (.00 - .23) .00 (.00 – .35) .00 (.00 - .45) 
e2MDD - .54 (.44 - .66) .52 (.40 - .65) .54 (.43 - .66) .52 (.40 - .64) .52 (.41 - .65) .54 (.44 - .66) 
a2CUD - .76 (.45 - .87) .82 (.52 - .90) .86 (.53 - .94) .80 (.50 - .87) .74 (.41 - .83) .76 (.45 - .87) 
c2CUD - .03 (.00 - .29) .00 (.00 - .24) .03 (.00 - .31) .00 (.00 - .24) .01 (.00 - .28) .03 (.00 - .29) 
e2CUD - .21 (.13 - .31) .18 (.10 - .29) .12 (.06 - .21) .20 (.13 - .31) .25 (.17 - .36) .21 (.13 - .31) 
a2shared .66 (.66 - .66) .53 (.00 - 1.00) - - - - - 
c2shared .34 (.34 - .34) .02 (.00 - 1.00) - - - - - 
e2shared .00 (.00 - .00) .45 (.00 - 1.00) - - - - - 
pa .44 (.44 - .44) - .02 (.02 - .08) .10 (.06 - .14) - - - 
rb .27 (.27 - .27) - .20 (.09 - .27) - .22 (.15 - .29) - - 
iMDDc - - - - - - - 
iCUDd - - - - - - - 
tMDDe - 0.63 0.71 0.64 0.72 0.69; 2.21 0.64; 1.92 
tCUDf - 0.96 1.01 1.06 0.99 1.04; 1.98 1.07 
tshared -0.31 1.13 - - - - - 
 





 8 9 10 11 12 13 
a2MDD .48 (.17 - .59) .45 (.18 - .56) .44 (.19 - .55) .47 (.22 - .57) .43 (.18 - .54) .46 (.23 - .56) 
c2MDD .00 (.00 - .08) .01 (.00 - .21) .00 (.00 - .14) .00 (.00 - .19) .00 (.00 - .18) .00 (.00 - .18) 
e2MDD .52 (.41 - .65) .56 (.44 - .67) .56 (.45 - .70) .53 (.43 - .65) .57 (.46 - .70) .54 (.44 - .66) 
a2CUD .74 (.41 - .83) .79 (.48 - .87) .80 (.48 - .88) .81 (.52 - .88) .79 (.79 - .87) .76 (.45 - .87) 
c2CUD .01 (.00 - .28) .01 (.00 - .26) .00 (.00 - .03) .00 (.00 - .23) .00 (.00 - .26) .03 (.00 - .29) 
e2CUD .25 (.17 - .36) .20 (.13 - .31) .20 (.12 - .30) .19 (.12 - .30) .21 (.13 - .32) .21 (.13 - .31) 
a2shared - .19 (-.03 - .31) - - - - 
c2shared - .01 (-.07 - .17) - - - - 
e2shared - .08 (-.01 - .17) - - - - 
pa - - - - - - 
rb - - - - - - 
iMDDc - - .07 (-.19 - .32) .26 (.18 - .35) - - 
iCUDd - - .21(-.05 - .52)  .28 (.20 - .38)  
tMDDe 0.72 0.64 0.66 0.64 0.66 0.63 
tCUDf 1.00; 1.81 0.99 1.01 1.03 .0.99 0.96 
tshared - - - - - - 
Note. Model numbers refer to the co-morbidity models outlined in Table 23. Shared a2, c2 and e2 refer to the single shared liability in model 1, third 
independent liability in model 2, or Cholesky paths from MDD to CUD in model 9.  
a p = probability of CUD if above threshold on the MDD liability (models 3 -5), or above threshold on the shared liability (model 1) 
b r = probability of MDD if above threshold on the CUD liability (models 3 -5), or above threshold on the shared liability (model 1) 
c iCUD = regression coefficient from CUD to MDD,  
d iMDD = regression coefficient from MDD to CUD 
e tMDD = threshold for MDD 




To the author’s knowledge, this study is the first to fit the 13 co-morbidity models 
proposed by Neale and Kendler (1995) to Cannabis Use Disorder and Major 
Depressive Disorder. The two best-fitting models were the Random Multiformity of 
CUD and CUD causes MDD models. Both models fit substantially better than the 
Correlated Liabilities model, and not substantially worse than the Saturated Model. In 
addition, five models could be statistically rejected: the Alternate Forms, Chance, 
Three Independent Disorders, RM of MDD and EM of MDD models. The heritability 
estimates in the best fitting models range from 79%–80% for CUD and 43–49% for 
MDD. 
6.4.1 Model-fitting 
These model-fitting results suggest that the direction of effect goes from CUD to 
MDD. Firstly, both the RM of MDD and EM of MDD models can be statistically 
rejected. It seems plausible, therefore, that the fit of the bi-directional random 
multiformity and extreme multiformity models is driven by the paths they have in 
common with the RM of CUD and EM of CUD models, respectively. Secondly, the 
CUD causes MDD model fits better than the MDD causes CUD model. Although this 
difference is not substantial, the fit of the MDD causes CUD model may reflect that 
direction of causation models are difficult to distinguish when modes of inheritance of 
the disorders are similar (Heath et al., 1993). In the current study, this may be 
because both disorders are mainly influenced by A and E, rather than by different 
aetiological factors (e.g. A C E vs. A E). Lastly, the MDD causes CUD model, along 
with all other models with a direction of effect from MDD to CUD, was a substantially 
poorer fit than the saturated model.  
It is unclear, however, which of the two best-fitting models is more likely. The CUD 
causes MDD model assumes that the liability to develop MDD symptoms increases 
continuously as the risk of CUD increases. The threshold in this model does not 
equal a sudden increase in risk, which means that even sub-threshold increases in 
liability to CUD have a causal influence on the liability to develop MDD (Rhee et al., 
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2004). On the other hand, the RM of CUD model assumes that the risk of MDD 
symptoms increases discontinuously, once the threshold on the CUD liability has 
been passed (i.e. an individual has reached a liability high enough to develop the 
disorder). An additional difference between the models is their assumption about 
aetiological processes. The causal model assumes that any causal processes occur 
at the level of the liability (Rhee et al., 2004), while the RM models remain agnostic 
about the way in which one disorder leads to symptoms of the other (i.e. via risk 
factors or at the phenotypic level).  
Despite some differences, the RM of CUD and CUD causes MDD models are not 
incompatible. Causality may play a role, and the good fit of the RM of CUD model 
may indicate that the causal influences on the risk of MDD only occur at higher levels 
of CUD risk (i.e. post-threshold). Additionally, it is likely that there are shared 
aetiological factors between CUD and MDD. Evidence from twin (Fu et al., 2002; 
Lynskey et al., 2004) and molecular genetic studies (Bobadilla, Vaske, & Asberg, 
2013; Hodgson et al., 2016; Sherva et al., 2016) suggests that there are genetic 
factors influencing both cannabis involvement and MDD. There is also a plethora of 
environmental factors that act as risk factors for both (see Chapter 4, e.g. Fergusson 
and Horwood 1997 and Feingold et al. 2014). Overall, the almost identical fit of both 
models may indicate that there are threshold-dependent causal links between CUD 
to MDD which occur at the level of liability.  
This interpretation is compatible with several findings. Risk factors for CUD, such as 
heavy cannabis use, are likely to exert an environmental and genetic effect on MDD. 
Heavy cannabis use can alter various domains of cognitive functioning, such as 
attention and memory (Solowij, 2002), and thereby affect daily functioning and 
potentially create circumstances in which individuals are more likely to develop MDD. 
For instance, cannabis use impacts educational attainment negatively (Lynskey & 
Hall, 2000), which in turn may affect emotional wellbeing. Environmental effects may 
also manifest themselves through changes in brain structure and function. Heavy 
cannabis users show a decrease in amygdala volumes (Yucel et al., 2008), which is 
also the case in unmedicated patients with MDD (Hamilton, Siemer, & Gotlib, 2008). 
Furthermore, cannabis intake influences the secretion of cortisol in the HPA axis and 
may lead to the dysregulation of such secretion over time (see Patel et al. 2014 for a 
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review). HPA dysregulation and an increase in cortisol levels, is also thought to play 
a critical role in the aetiology of MDD (Holsboer, 2000). Genes may modulate these 
environmental influences. Lastly, the conclusion that causal processes may be at 
work in individuals at high risk for CUD (e.g. high levels of cannabis use), also fits 
well with longitudinal studies which show that high levels of cannabis use are more 
strongly associated with MDD than lower levels.  
6.4.2 Heritability estimates 
These estimates are in line with estimates from previous analyses in this thesis 
(Chapter 5), similar to other twin studies for MDD (Kendler, Gatz, et al., 2006; 
Sullivan et al., 2000), and to studies on Cannabis Abuse and Dependence that 
included similar samples. Kendler et al. (2006a) report a heritability estimate of 77% 
(95% CI = 46%–93%) for DSM-IV Cannabis Abuse and Dependence in a sample of 
same-sex and opposite-sex twins with a mean age of 28.2. While a meta-analysis on 
twin studies reporting at least 1 symptom of Abuse or Dependence, presents lower 
heritability estimates (males: 54.4% (95% CI = 37.9%–64.9%), females: 58.5 (95% 
CI = 44.2%–72.9%), Verweij et al. 2010), the higher estimate obtained in the current 
study may be related to differences in sampling or the definition of problematic 
cannabis use.  
6.4.3 Strengths and limitations 
The primary strength of the current analysis is the comprehensive comparison 
between different models of co-morbidity. Many of these models are not commonly 
reported in twin studies. The best fitting model in the current analyses, the Random 
Multiformity model, is not a model which is usually tested in the twin literature, 
although it is particularly relevant to the investigation of drug use and use disorders. 
As an example, this model, when compared to the causal model, can test whether 
the likelihood of a co-morbid condition (e.g. MDD) increases at any or only at high 
levels of use. This is a relevant question to investigate for public health and policy. 
However, difficulty in differentiating between models was a known limitation, based 
on previous studies. Rhee et al. (2004) demonstrated that the NK approach to 
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discriminating between different models of co-morbidity is valid, but they did so with 
a large simulated sample and still noted several challenges. They highlighted that it 
is particularly difficult to discriminate between the multiformity and the Correlated 
Liabilities model classes, which was also the case in the current sample. 
Additionally, Rhee et al. (2004) pointed out that discrimination within subclasses of 
models (e.g. RM vs. RM of CUD) is also problematic. In the current analyses, the 
difference within subclasses was often not more than 3 AIC. It may be beneficial to 
replicate the study with larger samples or use meta-analysis to examine whether 
differences between models become more distinct. Replication of the results in this 
chapter would be useful to explore whether the results are cohort-specific or 
generalise across cohorts, but this is outside the scope of the current thesis.  
One limitation of the current study is that sex differences have not been taken into 
account. The prevalence of MDD and CUD did differ between males and females in 
the analysis sample, but currently all co-morbidity models can only be fitted on 
contingency tables, in which it was not possible to specify separate thresholds for 
males and females. The alternative approach of fitting separate models for males 
and females was not feasible due to reduction in sample size and associated loss of 
power. However, there are currently no grounds to assume that different co-
morbidity models would explain co-morbid cases in males and females. For instance, 
Agrawal et al. (2009) examined the co-morbidity between cannabis and tobacco use, 
and fitted separate models for male and female twins. They found that model fits 
were very similar for both sexes. It may be an interesting avenue for future research 
to explore sex differences in larger samples or using meta-analysis.  
Given that one of the best-fitting models makes assumptions about causality, it is 
also an important limitation that the data are retrospective and age of onset was not 
considered in the analyses. Using retrospective data has several disadvantages (see 
Section 7.3 and e.g. Coughlin 1990), but for the current analyses the most pertinent 
drawback is that longitudinal data would be better suited to test the direction of 
causation. Beyond twin models, recent molecular genetic methods also offer an 




Overall, the model fitting approach was helpful in indicating the likely relationship 
between CUD and MDD. While it was not possible to statistically differentiate 
between the two best fitting models, the RM of CUD and CUD causes MDD models, 
they both indicate that the direction of influence goes from CUD to MDD. Combined, 
the models suggest that CUD risk factors (liability) may cause MDD symptoms, but 
only in higher risk individuals. In addition, several models can be statistically 
excluded: CUD and MDD are not likely to be co-morbid by chance, arise from the 
same risk factors, or be due to a liability separate from the pure form of the 
disorders. The fact that a random multiformity model is the best fitting model is 
remarkable, because this model is not widely reported. Replications on larger 
































This thesis set out to test the presence of a co-morbidity between Cannabis Use 
Disorder (CUD) and Major Depressive Disorder (MDD) using epidemiological 
analyses, estimate the influence of genetic and environmental factors on these 
phenotypes and their covariance in bivariate twin model analyses, investigate a 
possible causal association and 13 different models of co-morbidity using the Neale 
and Kendler (1995) approach. The epidemiological analyses found that MDD and 
CUD were significantly co-morbid in this sample of 3824 Australian twins and their 
non-twin siblings (OR = 2.23, 95% CI = 1.84–2.70), and that this co-morbidity could 
not be fully attributed to various psychiatric, trauma-related, parental, peer and 
demographic covariates. Bivariate twin analyses found that – when separated into 
additive genetic, shared environmental and non-shared environmental correlations – 
the only significant correlation between MDD and CUD was genetic (r =.41, 95% CI 
= .24–.60). A possible causal relationship could not be excluded, because MDD and 
CUD were significantly associated (OR = 2.83, 95% CI = 1.12–7.19) in MZ twins 
discordant for both disorders. The Neale and Kendler (1995) co-morbidity analyses 
indicated that the direction of influence was from CUD to MDD, and that CUD risk 
factors may cause MDD symptoms, particularly in individuals at high risk of CUD.  
This chapter briefly summarises key findings, and then discusses: a) how the 
findings fit into the wider theoretical framework, b) how they fit into a biological 
framework, c) how the findings may direct further research within and across 
methodologies, and d) how they could inform policy, treatment and prevention. 
General methodological strengths and limitations will also be discussed.  
7.1 Epidemiological analyses 
Epidemiological analyses involved running multivariable logistic regressions between 
MDD, CUD and associated covariates on the full sample of 3824 twins and non-twin 
siblings. The analyses had two main aims: a) to establish whether and to what extent 
CUD and MDD were co-morbid in this sample, and b) whether and to what extent 
covariates influenced this association. Covariates were chosen from an extensive 
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range of available cannabis-related measures and selected based on previous 
cross-sectional and longitudinal studies examining clinical levels of cannabis 
involvement and depression (see Table 2). 
The main finding from these analyses was that the odds of meeting the criteria for 
one disorder increased significantly when an individual met the diagnostic criteria for 
the other (OR = 2.23, 95% CI = 1.84 – 2.70). This association remained significant 
when multiple covariates, including other drug dependence and psychopathology, 
were included in the regression analyses (aOR (MDD as outcome) = 1.96, 95% CI = 
1.57–2.45; aOR (CUD as outcome) = 1.92, 95% CI = 1.53–2.41). No covariate 
significantly attenuated the association, although several factors were significant 
predictors of both MDD and CUD. These findings suggested that there may be a 
unique aetiological link between CUD and MDD which cannot be fully explained by 
covariates. However, this interpretation is tentative, as a cohort study cannot control 
for all possible covariates.  
The epidemiological findings in this study fall within the range of results found in 
cross-sectional (see e.g. Degenhardt, Hall, Lynskey, Cofey, & Patton, 2012), 
longitudinal (e.g. Pacek, Martins, & Crum, 2013) and twin studies (Agrawal et al., 
2017), which have been reviewed in Chapter 1. The previous literature had rarely 
examined the relationship between MDD and CUD specifically. In addition, 
longitudinal studies which did report an association between MDD and CUD also 
controlled for a small number of covariates. The epidemiological results are a 
valuable addition to previous literature because they demonstrate a relationship 
between MDD and CUD despite having controlled for a large number of covariates 
found to be associated with both phenotypes in previous studies.   
The analyses also highlight the range of covariates which should be included in any 
further analyses of the association between the two main phenotypes. Of particular 
importance is the inclusion of conduct disorder (aORMDD = 1.55, 95 % CI = 1.13–
2.12; aORCUD = 3.44, 95 % CI = 2.52–4.69), childhood sexual abuse (aORMDD = 1.73, 
95 % CI = 1.30–2.30; aORCUD = 1.79, 95 % CI = 1.24–2.60) and parent-child 
disagreements (aORMDD = 1.88, 95 % CI = 1.45–2.44; aORCUD = 1.72, 95 % CI = 
1.24–2.38). These covariates significantly increased the risk of both MDD and CUD 
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after the inclusion of all other covariates, and may be indicators for possible 
preventative measures for the co-morbidity (see Sections Error! Reference source 
not found. below, and 4.4.2 in Chapter 4).  
Additionally, CUD showed significant positive associations with nicotine (aOR = 2.50, 
95 % CI = 2.00–3.12) and illicit drug dependence (aOR = 1.89, 95 % CI = 1.01–
3.56), as well as peer drug use (aOR = 2.19, 95 % CI = 1.48–3.24). Positive 
associations with MDD were found for low family SES (aOR = 1.44, 95 % CI = 1.15–
1.80), panic disorder (aOR = 3.12, 95 % CI = 1.71–5.67), social phobia (aOR = 2.87, 
95 % CI = 2.32–3.54) and parental problems (aOR = 2.62, 95 % CI = 1.88–3.67). 
These variables should also likely be included in any analysis of the co-morbidity of 
CUD and MDD.  
7.2 Twin model findings 
7.2.1 Heritability of, and correlation between, CUD and MDD  
Since the co-morbidity between CUD and MDD was demonstrated to be significant 
in this sample, bivariate correlated liabilities models were fitted to assess the relative 
importance of A, C/D and E in explaining the variance of and covariance between 
CUD and MDD. The models were fitted using a sample of 3326 twins, and potential 
quantitative and qualitative sex differences were tested. 
Findings from these analyses replicated those of previous studies in finding a 
significant heritably component of CUD (h2 = .77, 95% CI = .67–.85) and MDD (h2 = 
.42, 95% CI = .30–.54), as well as a significant genetic correlation between the 
phenotypes (rg = .41, 95% CI = .24–.60). Sex differences were only found to affect 
disorder prevalence, i.e. the thresholds on the liability distributions. The heritability 
estimates (Sullivan et al., 2000; Verweij et al., 2010), genetic correlation (Lynskey et 
al., 2004), and sex differences in prevalence (Kessler et al., 2005, 1994) were 
compatible with previous studies. 
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The primary finding of interest is the genetic correlation, since it points to the most 
likely source of co-morbidity between CUD and MDD, which, according to the current 
findings, is genetic, since there were no other significant environmental correlations. 
Although only one previous twin study has estimated a similar genetic correlation 
between these phenotypes (Lynskey et al., 2004), the current findings are also 
congruent with recent molecular genetic studies analysing common genetic variation. 
Among non-twin methods, genetic correlation estimates from molecular genetic 
studies are the closest comparison to those of twin studies.  
Large scale studies have demonstrated that common genetic variation can explain a 
small, but significant proportion of variance in MDD (Wray & Sullivan, 2017) and 
CUD (Demontis et al., 2018), and that there is a significant common genetic overlap 
between these disorders (Carey et al., 2016; Demontis et al., 2018; Sherva et al., 
2016). Two independent studies have reported a significant association between 
MDD and CUD polygenic risk scores (Carey et al., 2016; Demontis et al., 2018). 
Another study found significant pleiotropy between cannabis dependence and MDD 
by comparing genome-wide association study (GWAS) summary statistics for the 
two outcomes (Sherva et al., 2016), i.e. the same single nucleotide polymorphisms 
(SNPs) have been associated with both disorders. Significant pleiotropy has also 
been found for MDD and cannabis use (Hodgson et al., 2016).  
The overall implication of the current finding is that research into the aetiology of this 
co-morbidity should include the consideration of genetically influenced factors. A 
recent EMCDDA report on the co-morbidity of substance abuse and other psychiatric 
disorders concludes that further research is necessary to identify individuals at high 
risk of developing co-morbidities between substance use and other psychiatric 
disorders in order to administer early interventions. The current results suggest that 
these risk factors are likely to be genetically influenced.  
This may suggest that genetically influenced covariates, such as conduct disorder, 
which occur before the onset of either CUD or MDD should be targeted for 
preventative measures. Additionally, - since both CUD and MDD are polygenic traits 
(see Chapter 3) - molecular genetic studies may be useful in identifying early genetic 
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risk. These will likely need to identify a large number of loci, which will depend on 
power and consequently large sample sizes. Since familial factors play a significant 
role in the co-morbidity, the current results also support the use of family history in 
predicting patient prognosis, which was previously suggested by Milne et al. (2009). 
Funding research which enables genomic consortia to conduct large-scale molecular 
studies into the genetic risks of CUD and MDD and identifies genetically influenced 
early risk factors is likely to contribute toward the EMCDDA’s goal of identifying high 
risk individuals more efficiently.  
7.2.2 Causality and Neale and Kendler (1995) models of CUD and MDD co-
morbidity 
Although the thesis results and studies mentioned above have reported a genetic 
overlap between CUD and MDD, correlated liabilities may not be the best or only 
model of the aetiological mechanisms linking CUD and MDD. As demonstrated by 
discordant twin analyses, causality could not be discounted as an explanation for the 
co-morbidity, and 13 different models of co-morbidity (Neale & Kendler, 1995) were 
fitted to a sample of 565 complete MZ and 640 complete DZ twin pairs.  
The key finding of these analyses was that there may be a causal effect of CUD on 
MDD. This finding is suggested because the CUD causes MDD model was one of 
the best fitting co-morbidity models and all significant models suggested a direction 
of effect from CUD to MDD. In combination with the second model demonstrating the 
best-fit to the data, the random multiformity of CUD model, the co-morbidity model 
findings suggest that CUD risk factors may cause MDD symptoms, but only in higher 
risk individuals.  
Another finding which supports a possible causal relationship is the conducted 
discordant twin analysis. MZ twins who met the criteria for CUD were significantly 
more likely to meet the criteria for MDD than their co-twin discordant for CUD (OR = 
2.83, 95% CI = 1.12–7.19). While this does not prove a causal relationship, 
discordant twin analyses control for a large number of possible confounding 
influences since twins are genetically identical and have grown up in partially 
overlapping environments. A lack of association between CUD and MDD in MZ twins 
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could be interpreted as indicating that any previously found association was due to 
confounding genetic or environmental variables.    
These findings are in agreement with a systematic review of several longitudinal 
studies, which has found a significant effect of heavy (high-risk), but not light (low-
risk) cannabis use on later symptoms of depression (Lev-Ran et al., 2014). Other 
methods of validation are currently lacking and will be suggested in the following 
sections. 
Although the results presented in this study cannot definitively answer whether the 
link between CUD and MDD is causal, it provides critical evidence in favour of a 
causal association, and demonstrates that genetic designs can be an important tool 
in distinguishing between different types of possible co-morbidities. This should 
prompt further investigation, which goes beyond longitudinal research designs and 
capitalises on the benefits of genetically informed designs.  
It is unclear why longitudinal studies have found mixed evidence for the causal link 
between CUD and MDD while a causal model provides the best fit in the current twin 
design. One possibility is that there may be multiple forms in which CUD and MDD 
can co-occur. Having found different, equally fitting models may be either due to 
power constraints, or it may be an important finding in its own right. The different 
models which provide a similarly good fit to the data in the Neale and Kendler (1995) 
approach may do so because of multiple aetiological pathways to the co-morbidity of 
these disorders.  
Additionally, the current findings suggest that in trying to identify risk factors for the 
co-morbidity between CUD and MDD, researchers may want to focus on genetic risk 
factors primarily associated with CUD. The good fit of the random multiformity of 
CUD model supports the idea that research should focus on high-risk individuals, 
because the model suggests that only individuals at high risk of developing CUD will 
develop MDD. Since CUD was found to be primarily influenced by genetic factors, as 




7.3 General methodological strengths and limitations 
7.3.1 Strengths 
A primary strength of this thesis is the application of multiple methodologies to 
address different core questions around the covariates, source and process 
underlying the co-morbidity between MDD and CUD. Epidemiological analyses 
capitalised on analysing the full sample, including 476 non-twin siblings, and tested 
the influence of a multitude of covariates. Bivariate correlated twin models were 
applied to decompose the covariance between MDD and CUD into genetic and 
environmental factors to get a clear understanding of the source of co-morbidity, 
while discordant and co-morbidity model analyses investigated the processes which 
might underlie co-morbidity. Answering questions of epidemiological and behavioural 
genetic nature is a unique advantage of twin samples and of the analyses in this 
thesis.  
Twin studies are currently the most comprehensive method to compare between a 
large number of different co-morbidity models at the same time. They are also a 
powerful method to estimate genetic correlations between traits, and currently 
cannot be replaced by molecular genetic studies due to the issue of missing 
heritability (Manolio et al., 2009). Presently it is still not possible for molecular genetic 
studies to account for all the genetic effects that can be detected in twin studies 
(Nolte et al., 2017).   
A further strength of the studies presented here lies in the size and nature of the 
sample analysed. Data collection was tailored to the aim of analysing cannabis and 
related variables (Lynskey et al., 2012). Consequently, the sample contains a large 
number of cannabis-related measures and covariates, which is an advantage 
compared to other cohort studies, which may analyse cannabis-related variables in 
datasets originally intended for a different purpose. For instance, the NESARC 
(National Epidemiologic Survey on Alcohol and Related Conditions) is an 
epidemiological survey centred around alcohol use and related problems, although 
many longitudinal studies (Blanco et al., 2016; Cougle et al., 2015; Feingold et al., 
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2015; Pacek et al., 2013) on cannabis-related issues have been published using this 
data. 
The number and quality of measurement of available covariates has been of critical 
benefit to the epidemiological analyses, which were able to include a wide variety of 
covariates compared to some other cohort studies examining the relationship 
between CUD and MDD (see Table 2). Since there is some inconsistency in the 
literature about the strength and significance of the associations found between CUD 
and MDD or other clinical levels of cannabis involvement and depressive symptoms, 
adequate control for covariates is crucial.  
This sample also maximises available power given its size. It contains relatively 
small numbers of missing data, since computer-assisted telephone interviews were 
used. Additionally, a large proportion of individuals met criteria for CUD (similar to 
cannabis dependence estimates in a previous Australian cohort; Lynskey et al., 
2004), which increased the power of the analyses. Twin studies with phenotypes 
which have low population prevalence suffer from power issues (Neale, Eaves, & 
Kendler, 1994) and difficulties distinguishing between sources of variation (Neale & 
Maes, 2004). 
7.3.2 Limitations 
General limitations of twin studies have been discussed in Section 3.7 (Chapter 3). 
Findings from twin studies may be affected by a violation of the Equal Environments 
Assumption, assortative mating and gene-environment or gene-gene interplay. As 
reviewed in Section 3.7, violations of the Equal Environments Assumption have not 
previously been found for MDD or cannabis dependence (Kendler et al., 1993, 1994; 
Lynskey et al., 2002; Xian et al., 2000). Additionally, assortative mating is unlikely to 
bias twin models fit to psychiatric phenotypes. (Maes et al., 1998). The biasing effect 
of gene-environment and gene-gene interplay on A, C and E estimates is less clear. 
Since the dataset does not contain molecular genetic information, they were not 
modelled and are beyond the scope of this thesis.  
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Data collection relied on retrospective self-report measures, which is a further 
potential limitation. Since cannabis is an illegal substance in Australia, individuals 
may not accurately self-report patterns of drug use and use disorders. However, the 
relatively high prevalence of cannabis use (68.52%) suggests that under-reporting of 
drug use is unlikely to be problematic in this sample. Additionally, specific 
experiences (e.g. age of first symptom onset) are unlikely to be directly observed, so 
there is no viable alternative to self-reports (Wagner & Anthony, 2002). The 
retrospective nature of reporting and consequent recall bias is a concern for 
epidemiological analyses in particular, because these relied on age of onset reports 
on a number of variables. One could argue that cannabis-related behaviours may not 
be remembered correctly due to effects on memory (Hall, 2015), but studies suggest 
that cannabis-related experiences are recalled reliably (Johnson & Mott, 2001). 
Despite potential biases, self-report retrospective studies have been used widely to 
examine both depression and cannabis involvement (see studies reviewed in 
Chapter 1) and are considered a valid method of data collection in general and in 
drug users (Anglin, Hser, & Chou, 1993; Sartor et al., 2011).  
Additionally, the current data does not permit the examination of whether the 
association between CUD and MDD varies by type or potency of cannabis used. 
Since cannabis potency may influence the likelihood of developing cannabis 
dependence (Freeman & Winstock, 2015), as well as other psychiatric disorders, 
information on type of cannabis used would have clarified, for instance, whether the 
causal link suggested in the co-morbidity models may have been driven by a sub-
population of high potency cannabis users. Although at time of writing the author is 
not aware of any studies that have examined the effect of cannabis type or potency 
on MDD, some research suggests that the likelihood of schizophrenia following 
cannabis use depends on the amount of THC and relative proportion of THC and 
cannabidiol (CBD), two phytocannabinoids, in the cannabis smoked. For example, 
one study found that cannabis with high levels of THC and an large ratio of THC to 
CBD was three to five times more frequent in individuals with first episode psychosis 
(Di Forti et al., 2015). The lack of potency and cannabis type information is a 
limitation of the current study and an interesting avenue for future research.  
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7.4 Synthesised analysis of thesis findings  
A synthesised view of the findings might suggest that CUD and MDD are significantly 
co-morbid, and that this co-morbidity is likely to be explained through a causal effect 
of CUD on MDD which may be influenced by genetic factors. The following section 
will attempt to form a coherent picture from the findings that: a) CUD and MDD are 
significantly co-morbid, b) the only significant correlation between CUD and MDD 
was found to be genetic, c) the direction of effect in the co-morbidity models is from 
CUD to MDD, and d) that MZ twins who met criteria for CUD were significantly more 
likely to meet criteria for MDD than their co-twins who did not meet the criteria for 
CUD. This will be done by fitting them into a theoretical and biological framework. 
7.4.1 Integration of findings into a theoretical framework 
In an overview article Agrawal and Lynskey (2014) have suggested several potential 
mechanisms by which CUD-related factors may influence the development of MDD 
(see Figure 14). The findings in this thesis most support the models in Figure 14b 
and Figure 14e. Due to the significant genetic correlation in Chapter 5, with no 
significant shared or non-shared environmental correlation, the current findings add 
evidence to the suggestion that any aetiological mechanism is mediated through 
genetically-influenced factors. Due to the significantly better fit of models suggesting 
that the direction of effect goes from CUD to MDD, the current findings suggest that 
a causal model may be a more suitable aetiological framework than a model which 
implies correlated liabilities only. A causal genetically-mediated model may take two 
forms according to Agrawal and Lynskey (2014). CUD use may impact genetically-
influenced biological structures, such as limbic brain areas and the hypothalamic–
pituitary-adrenal axis, and the susceptibility to its effect on MDD may be genetically 
influenced (Figure 14b). Alternatively, smoking large quantities of cannabis due to 
CUD may lead to an activation of diathesis, i.e. an activation of genetic factors which 
increase the likelihood of developing MDD (Figure 14e). If it were the case that 
shared genes simultaneously influence CUD and MDD, one would have expected 
the correlated liabilities model (Figure 14d) to be the best fit in the Neale and Kendler 
(1995) models. However, it was a significantly worse fit than models suggesting a 




Figure 14. Possible aetiological relationships between CUD and MDD, adapted from 
Agrawal and Lynskey (2014). 
Evidence in favour of the activation of diathesis (e) model comes not only from the 
suggestion of causal genetic influences, but also from a significantly elevated rate of 
MDD among MZ twins who had CUD compared to their discordant co-twins without 
CUD. Both MZ twins have the same genetic material, but the exposure of one twin to 
high levels of cannabis may activate genes that increase the likelihood of MDD. This 
may explain why a causal mechanism cannot be excluded based on discordant twin 
analyses, but an environmental link between CUD and MDD is not evident in the 
bivariate twin analyses. The discordant twin results could also be consistent with 
model (b), since the genetic mechanisms impacting biological structures altered by 
cannabis use and producing MDD may only become relevant when high levels of 
cannabis use are present.  
For either model, the section below aims to give a thorough overview of potential 
biological ‘bridges’ between CUD and MDD which may be the location of any genetic 
effects. 
7.4.2 Integration of findings into a biological framework 
The most likely biological bridge between CUD and MDD involves the 
endocannabinoid system, and its influence on the limbic system, as well as the 
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hypothalamic–pituitary–adrenal axis. High levels of cannabis use are likely to modify 
signalling in both systems, which in turn may lead to symptoms of depression.  
7.4.2.1 Endocannabinoid influence on the limbic system and HPA axis 
The limbic system is crucially involved in emotional processing, contains moderate to 
high amounts of endocannabinoid receptors (Hill et al., 2008), and functional 
disturbances of the limbic system are linked to symptoms of MDD (Herman, 
Ostrander, Mueller, & Figueiredo, 2005). In a comprehensive summary on the link 
between the endocannabinoid system and depression, Hill et al. (2008) review 
evidence showing that levels of endogenous cannabinoids are altered in individuals 
with MDD, as is the expression of CB1 receptors. Endocannabinoid receptor 
signalling is also altered in the course of various treatments for MDD.  
Critical evidence suggesting a relationship between endocannabinoid functioning 
and MDD comes from human trials on the anti-obesity drug rimonabant, which is a 
partial CB1 receptor agonist. A meta-analysis of randomised controlled trials 
concluded that that the drug likely caused MDD, depressive mood and depressive 
symptoms (Christensen, Kristensen, Bartels, Bliddal, & Astrup, 2007). A plausible 
interpretation of these results is that MDD may have been brought on by the reduced 
ability of endocannabinoids to bind to CB1 receptors. Since CB1 receptors were 
found to be down-regulated in cannabis users until they were abstinent for a month 
(Hirvonen et al., 2012), the effect of cannabis use on CB1 receptors is a plausible 
neurochemical explanation for the association between CUD and MDD.  
In addition, specific functions of the endocannabinoid systems within the limbic 
system can be linked to specific symptoms of MDD. Hill et al. (2008) examined 
changes in endocannabinoid levels and CB1 receptor density in response to chronic 
unpredictable stress in rats – an animal model of depression. They found that CB1 
receptor density was altered in most regions of the limbic system and that levels of 
anandamide were significantly reduced in all regions. The endocannabinoid system 
helps to maintain reward salience via its activity in the limbic brain regions (Parsons 
& Hurd, 2015). Anhedonia is a main symptom of MDD and is characterised by a lack 
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of response to things and activities previously perceived as rewarding. This may be 
due to abnormalities in endocannabinoid signalling. 
However, the key influence of the endocannabinoid system on depression may 
extend beyond the limbic regions, via the hypothalamic–pituitary–adrenal (HPA) axis. 
The human stress response is regulated by a cascade of chemical changes involving 
the hypothalamus, pituitary gland and adrenal cortex. When people are subjected to 
a stressor, the hypothalamus secretes vasopressin and adrenocorticotropic 
hormone-releasing factor, which triggers the release of adrenocorticotropic hormone 
in the pituitary. When the latter hormone reaches the adrenal cortex, it causes the 
release of adrenal steroids, such as glucocorticoids, which help generate an 
appropriate stress response. Glucocorticoids suppress the immune system and 
activate the metabolism, preparing the body to address the stressor.  
Glucocorticoids also directly impact the brain. Particularly relevant for depression, 
glucocorticoids affect the functioning of limbic regions, such as the hippocampus and 
amygdala, and interact with monoamines, serotonin and noradrenaline. Excess 
amounts of glucocorticoids make hippocampus cells more susceptible to damage 
and decrease their proliferation (Herbert et al., 2006). Furthermore, glucocorticoids 
interact with noradrenaline in the amygdala to enhance memory formation in 
response to emotionally arousing stimuli (Herbert et al., 2006). Glucocorticoids are 
likely to play an important role in adaptive memory formation to improve an 
individual’s response to aversive events, but may also play a role in the development 
of depression by increasing attention or memory toward negative events (Kukolja et 
al., 2008). Glucocorticoids also regulate tryptophan hydroxylase, an enzyme required 
for the synthesis of serotonin, as well as the expression of serotonin receptors 
(Herbert et al., 2006), and serotonin dysregulation is crucially involved in the 
pathophysiology of depression (Ressler & Nemeroff, 2000).  
It is not surprising that  one of the most consistent biological correlates of MDD is a 
hyperactivity of the HPA axis (Pariante, 2017; Pariante & Lightman, 2008). 
Individuals with MDD have increased adrenal and pituitary gland activity, and higher 
levels of cortisol in various bodily fluids (Pariante & Lightman, 2008). Additionally, 
individuals treated with synthetic glucocorticoids are at increased risk of developing 
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depressive symptoms (Brown & Suppes, 1998). HPA hyperactivity is thought to be a 
cause, rather than consequence of MDD, and result from impaired negative 
feedback of glucocorticoids on the stress response cascade (Pariante & Lightman, 
2008).   
Since endocannabinoid levels change when people are subjected to stress (Hill, 
Miller, Carrier, Gorzalka, & Hillard, 2009), endocannabinoids may be involved in the 
modulation of the HPA axis. Several studies on mice suggest that endocannabinoids 
serve to inhibit HPA axis activation (Gorzalka et al., 2008). Endocannabinoids are 
also thought to play a role in stress adaptation, as their increase during chronic 
stress dampens the stress response (Gorzalka et al., 2008). This is a crucial 
function, as steroid release is useful for combating stressors in the short term, but 
causes harm in the case of overexposure, as reviewed above.  
However, cannabis intake influences the secretion of cortisol in the HPA axis and 
may lead to the dysregulation of such secretion over time (see Patel et al. 2014 for a 
review). If endocannabinoids fail to successfully dampen the stress response, this 
may modulate the effect of stress on depression. One molecular genetic study has 
shown that polymorphisms in the CNR1 gene, which encodes the CB1 receptor, 
moderated the influence of childhood physical abuse on anhedonia (Agrawal et al., 
2012). In other words, genetic factors primarily associated with CUD may contribute 
to the development of MDD through their effect on the stress response.  
The evidence reviewed above points to a link between the endocannabinoid system, 
CUD and MDD. Genetic factors may influence neurobiological structure and function 
predisposing an individual to both MDD and CUD or providing a link for causal 
influences.  
7.5 Implications for future research 
7.5.1 Multivariable twin models 
Since epidemiological analyses found a number of covariates which may have 
attenuated the association between CUD and MDD, albeit not significantly, and 
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bivariate twin modelling found a significant genetic correlation between the two 
phenotypes, it would be a valuable next step to examine the influence of these 
covariates on the genetic correlation. 
For instance, one could examine whether the genetic correlation between CUD and 
MDD – which was observed in Chapter 5 – is cannabis-specific, or shared between 
different substances. Studies from a range of fields have observed that liability is 
likely to be shared between different drug phenotypes to a significant extent (Moss, 
Chen, & Yi, 2014; Palmer et al., 2015, 2012; Schwantes-An et al., 2016; Vanyukov et 
al., 2012). A significant attenuation of the genetic correlation between CUD and MDD 
after the inclusion of a third substance would suggest that the genetic correlation 
between CUD and MDD is not cannabis-specific. Since poly drug use occurs 
frequently (Moss et al., 2014) and significant genetic links between MDD and other 
substance use have been found in the literature (Carey et al., 2016; Edwards & 
Kendler, 2012; Kendler, Neale, MacLean, et al., 1993), the specificity of the 
correlation to cannabis should be examined before any health or policy decisions are 
made on the basis of the link between CUD and MDD.  
Additionally, it may be valuable to examine whether the genetic correlation is MDD-
specific or shared with multiple forms of non-substance psychopathology. A 
molecular genetic study employing polygenic risk score analyses found that there 
was a significant association between polygenic risk scores for a substance-
involvement cluster (representing a general liability to alcohol, cannabis, cocaine, 
nicotine, and opioid involvement) and a psychiatric disorder cluster (MDD, ADHD, 
autism spectrum disorder, bipolar disorder and schizophrenia), suggesting that 
multiple forms of psychopathology share genetic influences (Carey et al., 2016). This 
finding has been supported by polygenic risk score association analyses of the  
Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) for the 
aforementioned five psychiatric disorders.   
To ascertain the specificity of the genetic link found in Chapter 5, multivariate 
analyses could be conducted using twin models or molecular genetic methods. 
However, both would depend on sample constraints and multivariate twin models 
may prove difficult to fit with clinical phenotypes, as binary or ordinal multivariate 
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data often causes multi-parameter optimisation problems in OpenMx (Neale et al., 
2016). The current sample may therefore not be suitable and larger samples would 
be best placed to examine this question. 
7.5.2 Alternative causal models 
Although a large number of aetiological models can be compared using cross-
sectional twin data, they are not the gold-standard test of causality. A randomised 
controlled trial would be unethical, but there are several other ways to improve on 
the design of the current study to estimate causality.  
7.5.2.1 Longitudinal twin research  
Firstly, it could be advantageous to examine the co-morbidity models in a 
longitudinal twin sample. Both MDD and CUD would have to be measured at 
baseline and at follow-up, allowing a comparison between co-morbidity models 
which make predictions in both directions of causality. This may also improve the 
degree to which co-morbidity models can be differentiated from each other. To the 
best of the author’s knowledge, no longitudinal twin study has examined co-morbidity 
at the time of writing. 
7.5.2.2 Mendelian randomisation  
Secondly, there are novel molecular genetic methods that may be able to circumvent 
the ethical problems associated with randomised controlled trials. Mendelian 
randomisation is one approach that could validate the possibly of causal genetic 
relationships between CUD and MDD reported in this thesis. Instead of grouping 
participants into individuals who do and do not consume large amounts of cannabis, 
individuals at genetic risk of developing CUD are treated as the ‘affected’ and 
individuals at low risk as the ‘control’ group (Lawlor, Harbord, Sterne, Timpson, & 
Davey Smith, 2008). Genetic risk can be operationalised as a polygenic risk score 
for CUD for each individual. It can then be analysed whether individuals at genetic 
risk for CUD are significantly more likely to have MDD. This type of analysis does not 
depend on longitudinal data, because any measured genetic risk would precede the 
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development of a disorder (Davey Smith & Hemani, 2014). Furthermore, Mendelian 
Randomisation can now be combined with twin models to circumvent problems 
involving pleiotropy (Minica, Dolan, Boomsma, de Geus, & Neale, 2017).  
However, this method is dependent on having strong genetic predictors of the 
outcomes in question (Burgess & Thompson, 2011), and although large-scale 
GWAS of CUD and MDD have been performed, the proportion of variance that can 
be explained by identified associated loci is low. Nonetheless, this would be an 
interesting area to explore as genetic loci explaining a larger proportion of variance 
in CUD and MDD are discovered.  
7.5.2.3 Genetic pathway analysis 
Thirdly, given the likely biological pathways of overlap between CUD and MDD and 
the fact that their relationship was suggested to be primarily genetic in bivariate 
analyses, an analysis of specific genes and pathways underlying the genetic 
correlation between these outcomes could aid in elucidating the causal relationship 
between CUD and MDD. The current study cannot provide information on the 
specific sources (e.g. single genes) of their genetic correlation or causation.  
One approach for this is the systematic comparison of known gene or pathway-
associations for each outcome. One of the candidate genes which may be 
associated with both CUD and MDD is CNR1, as mentioned above (Agrawal et al., 
2012). Additionally, a recent study has tested the association between substance 
use, depression and genetic variants with four candidate genes: the serotonin 
transporter (5-HTTLPR) gene, the neuropeptide Y (NPY) gene, the brain-derived 
neurotropic factor (BNDF) gene and the corticotrophin-releasing hormone-binding 
protein (CRHBP) gene (Trucco, Villafuerte, Hussong, Burmeister, & Zucker, 2018). 
The three latter genetic variants are all associated with the human stress response. 
Trucco et al. (2018) examined a sample of 426 adolescents and analysed whether 
variants of the aforementioned genes were linked to adolescent substance use and 
mediated by childhood depressive symptoms. Although none of the associations 
examined in this study were significant after covariates were controlled for, perhaps 
due to the small sample size and the fact that variables were measured in 
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adolescence and included substance use, rather than substance use disorders, their 
approach is promising in establishing biologically-informed pathways involving 
internalising psychopathology, such as MDD, and substance use disorders, such as 
CUD.  
An alternative approach for elucidating the genetic overlap between CUD and MDD 
is the hypothesis-free comparison of GWAS summary statistics for both phenotypes. 
This could be achieved by looking for concordance in loci showing suggestive (1x10-
5) or genome-wide (5x10-8) significance between outcomes or comparing gene- or 
pathway-based association results. A similar but perhaps more automated approach 
to highlight genes or pathways underlying the genetic correlation between CUD and 
MDD is through the estimation of partitioned genetic correlation, whereby the genetic 
correlation is estimated using subsets of genetic variation (Ni, Moser, Wray, & Lee, 
2017).  
7.5.2.4 Ecological Momentary Assessment 
Additionally, causality between CUD and MDD may occur over shorter time windows 
than those that are usually investigated in longitudinal studies. Twin, longitudinal and 
cross-sectional studies often rely on the reporting accuracy over long periods of time, 
which may be inconsistent, and explain the mixed results with respect to the 
association between CUD and MDD. To address both issues, studies utilising 
ecological momentary assessment (EMA), measure drug use and mood fluctuations 
in real time and might provide insight into moment-to-moment causality. EMA is a 
research design which is used to collect real-time data about participants’ behaviour 
(e.g. cannabis use and mood fluctuations) in their natural environment (Shiffman, 
2009). Several studies have looked at the association between cannabis use and 
mood (Buckner, Crosby, Silgado, Wonderlich, & Schmidt, 2012; Buckner, Crosby, 
Wonderlich, & Schmidt, 2012; Buckner et al., 2015), but none have done so in 
individuals who have been diagnosed with MDD and CUD.  
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7.6 Clinical and policy implications 
7.6.1 Clinical implications 
7.6.1.1 Clinical research 
Although the current findings may have only limited direct clinical implications, as 
they are based on analyses of a general population sample, they can suggest 
testable hypotheses for clinical research. In particular, finding that the Random 
Multiformity of CUD model fit best in the co-morbidity model analyses suggests that 
the effect of cannabis involvement on depression should be investigated further in 
clinical studies. The most suitable study design to delineate whether cannabis 
involvement causes depressive symptoms would be a Randomised Controlled Trial. 
As mentioned previously, such a trial would not be ethical to conduct, although 
cannabis users themselves report using cannabis to treat depression (Hakkarainen 
et al., 2015).  
Two trials conducted in the 1970s did examine a potential medicinal effect of THC on 
MDD, one did not report an improvement and one reported a worsening of 
symptoms (Turna, Patterson, & Van Ameringen, 2017). Since recent evidence 
suggests that cannabis products which include THC may increase the likelihood of 
depressive symptoms (see Chapter 1), it is clear why more recent trials have not 
been conducted. However, symptoms of depression could be measured as part of 
ongoing and future trials which measure the potential medicinal effect of cannabis on 
other physical and mental health disorders, for which beneficial effects can be 
expected, and ethical clearance can be obtained.   
The hypothesis, based on findings from this thesis, would be that medicinal cannabis 
which contains THC may lead to an increase in depressive symptoms, whichever 
other disorder it is being used to treat. Trial results are expected to vary depending 
on the type of cannabis used, and trials of interest are those that include cannabis 
with THC. Many trials examine the effect of cannabidiol alone or the effect of 
synthetic pharmaceutical drugs (e.g. dronabinol) mimicking some properties of 
phytocannabinoids. However, pharmaceutical cannabinoids, cannabidiol or any 
170 
 
cannabis without THC are not the cannabis smoked recreationally by the general 
population. Consequently, results of such trials are not entirely comparable to results 
of population surveys examining cannabis use (and reporting an increased OR 
between cannabis involvement and depression), including the sample utilised in this 
thesis. Therefore, it is unclear whether an effect of pharmaceutical or CBD-based 
cannabinoids on depressive symptoms should be expected. However, the literature 
reviewed in Chapter 1 suggests that cannabis including THC may increase risk of 
depression after frequent administration.  
According to a review and meta-analysis of RCTs by Whiting et al. (2015) the effect 
of medicinal cannabinoids, with or without THC, has been tested on nausea and 
vomiting, psychosis, sleep disorders, appetite stimulation in AIDS/HIV, intraocular 
pressure in glaucoma, spasticity due to multiple sclerosis or paraplegia, Tourette 
syndrome and anxiety disorders. For a variety of reasons most of these trials were 
assessed to be at substantial risk of bias. Interestingly, the main reason was that 
trials had high withdrawal rates, which were not adequately accounted for. While 
beyond the scope of this thesis, it would be worth investigating whether withdrawal 
rates may have been due to any effects cannabis may have exerted on mood.  
Out of 505 studies which were assessed in the meta-analysis (Whiting et al., 2015), 
only five studies included a depression outcome measure in their trials, but none met 
criteria for inclusion in the meta-analysis. Out of the five studies, Whiting et al. (2015) 
report that one found negative effects of a high dose of nabiximol (containing both 
THC and CBD) spray on depression scores, when compared to placebo. However, 
the original paper does not report these results (Portenoy et al., 2012) and states 
that there were no significant effects of nabiximol on depression scores. None of the 
five studies reported results at follow-up. Another recent meta-analysis of both RCT 
and non-RCT studies (Goldenberg, Reid, IsHak, & Danovitch, 2017)  found that 
three studies reported positive effects of cannabis on depressive symptoms, but only 
one of these was an RCT, it had a very small sample size (N = 23) and measured 
depression scores only during the time cannabis was administered (Ware et al., 
2010), when a positive effect on mood may be expected. For a useful estimate of the 
effect of cannabis on depression, a follow-up measure would be necessary.   
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Overall, there may be considerable scope to investigate the effect of cannabis-based 
medicines on depression outcomes in such RCTs, because the quality of evidence is 
in need for improvement. It would be important to utilise a reliable and valid 
depression measure, preferably measuring DSM or ICD clinical symptoms, which 
was not used in any of the trials reviewed above. It would also be important to 
measure depression after a follow-up period, because the short-term effects of 
cannabis on mood, whether they are euphoria (Whiting et al., 2015) or depressive 
symptoms (e.g. Tramèr et al., 2001) cannot differentiate between temporary states 
and persistent disorders. A causal relationship between cannabis involvement and 
MDD would therefore need to be demonstrated at longer term follow-up.   
As an alternative study design, a measure of depressive symptoms could be 
included as part of clinical trials which measure the efficacy of CUD treatments, to 
test whether the treatment of cannabis-related problems also decreases the 
likelihood of depressive symptoms (given that untreated CUD may lead to MDD). 
The complication is that clinical trials usually aim to recruit individuals with “pure” 
disorders and consequently any co-morbid symptoms of depression may be 
screened out at the start of a trial (e.g. Hoch et al., 2014). However, if one assumes 
that a portion of the individuals with CUD had “not yet” met criteria for depression but 
were at risk to do so in the future, it would still be informative to assess whether 
those who had been treated for CUD would also be less likely to later on develop 
depressive symptoms than those who did not.  
Research into treatments for CUD and other cannabis related problems is ongoing, 
with no currently approved pharmacotherapies (Copeland, Pokorski, & Gibson, 
2017). Among psychosocial therapies, a recent Cochrane review concluded that 
most support exists for a combination of Motivational Enhancement Therapy and 
Cognitive Behavioural Therapy (Gates, Sabioni, Copeland, Le Foll, & Gowing, 2016). 
Although these therapies are promising, several drawbacks have been identified. 
Crucially, trials lack an adequate assessment of other aspects of participant mental 
health (Copeland et al., 2017), which have, for instance, been implemented in 
studies on the efficacy of methamphetamine treatment (Mcketin et al., 2013). 
Addressing this drawback may provide a crucial opportunity to include reliable 
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measures of depressive symptoms to be used as outcomes during follow-ups of 
RCTs assessing therapies for CUD and other cannabis-related problems. 
7.6.2 Prevention 
With budget cuts to the UK’s National Health Service addiction services 
(Mohammadi, 2014) and calls for researchers to reduce waste and increase value 
(e.g. Macleod et al., 2014), there is a continuous pressure to focus resources where 
they are needed most.  
Economic analyses weighing the costs and benefits of investment into depression 
treatment and prevention suggest that the economic benefits will far outweigh the 
costs (Chisholm et al., 2016). Since prevention is preferable to treatment and 
treatment for co-morbid cases is known to be more challenging than for non-
comorbid mental health issues (Torrens et al., 2015), it is helpful to identify high-risk 
groups before they develop clinical symptoms of MDD. All results in this thesis, 
especially co-morbidity model findings, suggest that individuals with CUD qualify as 
such a group. As mentioned previously, the number of  European first-time treatment 
seekers for cannabis problems has almost doubled in the past decade (EMCDDA, 
2017). These treatment seekers may be a critical target population for MDD selected 
preventive interventions. The goal would be to reduce the incidence of new co-
morbid cases through early intervention in high risk groups, which aligns with the 
recommendations of the EMCDDA (Torrens et al., 2015). The most effective 
preventive interventions for MDD are CBT-based and interpersonal psychotherapy-
based interventions (Muñoz, Cuijpers, Smit, Barrera, & Leykin, 2010). It may be 
crucial to aim such interventions at young individuals since the vast majority of 
mental health problems begin before the age of 18 (Wykes et al., 2015) 
In fact, epidemiological analyses have highlighted a cluster of childhood variables - 
conduct disorder, childhood sexual abuse and disagreements with parents - which 
significantly increase the odds of both CUD and MDD. This finding may point 
towards the importance of childhood interventions to prevent later onset mental 
health co-morbidity. As previously outlined in Chapter 4, dysfunctional parenting in 
childhood is related to childhood sexual abuse (Fergusson et al., 1996; Putnam, 
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2018), conduct disorder (Furlong et al., 2013; Ogden & Hagen, 2008), as well as 
CUD and MDD in the current analyses. Dysfunctional parenting may therefore be a 
nexus worth targeting with parental training interventions in order to prevent co-
morbid mental health conditions later in life.  
7.6.3 Policy 
Results from this thesis primarily have future research and clinical implications, 
because studies have not directly measured the impact of cannabis-related policy on 
cannabis use prevalence, CUD prevalence or cannabis-related harms. Therefore, 
any extrapolations from the current thesis findings to policy are tentative.  
Debate around the legalisation of cannabis is ongoing and controversial, with further 
research needed to assess the impact of legalisation on public health (Wilkinson, 
Yarnell, Radhakrishnan, Ball, & D’Souza, 2016). Firstly, it has been noted in previous 
research that the extent of cannabis use is related to individual (Bachman, Johnston, 
& O’Malley, 1998) and social (Keyes et al., 2011) beliefs about its risks. In the United 
States, attitudes about the harmfulness of cannabis increased in some states after 
legalisation, but not in others (Cerdá et al., 2017). Educating the public on the 
possible harms of cannabis, whether legal or illegal, may be a crucial step in 
mitigating cannabis-related harms. 
Epidemiological findings in this thesis, which are similar to findings from many 
previous cross-sectional studies, suggest that CUD is associated with an almost 
twofold increase in the likelihood of MDD., and discordant as well as co-morbidity 
twin analyses suggest that there may be a causal link from CUD to MDD. Given the 
high baseline prevalence of MDD  and its disabling effects (Ferrari et al., 2013), CUD 
should be regarded as an important potential risk factor for MDD, since it may double 
an already high risk of the disorder. Although there is no conclusive proof of a causal 
association, the consistent evidence of a significant co-morbidity in this and other 
studies may suggest that educational programs in schools, medical advice to 
patients known to consume cannabis, and buying information in areas where 
cannabis is legal, should include information about this possible link and hopefully 
reinforce the belief that the consumption of cannabis has significant associated risks. 
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Although the well-researched link between cannabis use and schizophrenia could 
also act as strong deterrent against heavy cannabis use, schizophrenia has a 
lifetime prevalence of less than 1% in most populations (McGrath, Saha, Chant, & 
Welham, 2008). Individuals deciding whether to smoke cannabis may be more 
deterred by a highly prevalent disorder such as MDD, since they are more likely to 
know affected individuals, and a twofold increase in the risk of a prevalent disorder 
may inspire more caution. 
Results from the co-morbidity model analyses suggest that the increased risk for 
MDD may occur discontinuously and only set in once high levels of CUD risk are 
reached. These high levels of risk may be due to high levels of cannabis use. This 
finding is consistent with a meta-analysis of longitudinal studies’ findings that only 
high levels of cannabis use show a significant association with MDD (Lev-Ran et al., 
2014). Given that the total prohibition of cannabis use may not be in the best public 
interest (MacCoun & Reuter, 2011), it will be important to advise individuals on safer 
levels of use and harms associated with high levels of use.  
It can be argued that the disadvantages of cannabis legalisation are likely to be an 
increase in drug use overall, while the likely advantage would be decreased harm 
per use (MacCoun & Reuter, 2011). Recent trends in cannabis consumption in the 
US support this idea: a large scale epidemiological study has found that cannabis 
use, within a decade of increasing legalisation, has increased between 2001–2002 
and 2012–2013, while the proportion of individuals with cannabis use disorder has 
decreased (Hasin et al., 2015). Given the high likelihood of an increased availability 
of cannabis in the future, and therefore its increased consumption, the results of this 
study aim to contribute to decreasing harm in users, particularly those who may be 
concerned about risks of developing co-occurring mental health disorders such as 
MDD. 
7.7 Final remarks 
Epidemiological and twin analyses in this thesis have provided insight into 
covariates, sources and processes behind the co-morbidity of MDD and CUD. While 
direct implications of these findings are primarily focused on future research, they 
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also add to the body of evidence informing decisions on policy, treatment and 
prevention. In summary, findings from this thesis suggest that CUD and MDD are 
significantly co-morbid, and associated with several childhood risk factors. The co-
morbidity can be primarily attributed to genetically influenced factors and causal 
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